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ABSTRACT
Set Valued Dynamic Treatment Regimes
by
Tianshuang Wu
Chair: Susan Murphy
Dynamic Treatment Regimes (DTR)s are composed of sequences of decision rules, one
per stage of treatment. Each decision rule inputs patient information and outputs a
single recommended treatment. While the majority of present studies are focused on
finding the optimal DTR, we take another approach. Instead of trying to determine
the true best DTR, we aim to construct a set of DTRs such that the true best DTR
is contained in this set with a desired probability. The reasons are as follows: (1)
Usually we do not have enough data to identify the best DTR and (2) we want to give
patients and clinicians more options. To discuss the second reason in more detail,
patients and clinicians might have treatment preferences related to cost, side effects or
convenience, etc. Thus, our goal is to provide a recommended set of DTRs, such that
the DTRs contained in the set are those we cannot distinguish from the best, while the
DTRs we exclude are those that are certain to be inferior with high confidence. This
idea comes from decision support: we do not tell patients and clinicians what to do;
we do not offer treatments known to be inferior. Rather we offer a set of treatments
that excludes inferior treatments. In this thesis we develop a set valued DTR in which
the decision rules at each stage can output a set of treatments. Second we develop
x
an approach for constructing a recommended set of DTRs. In the appendix we prove
the relevant theorems.
xi
CHAPTER I
Introduction
Comparisons of treatments is always crucial when we have more than one available
candidate at hand at a certain situation, e.g., at a certain time point for a certain kind
of patients. For the comparison of two populations, there are a lot of well developed
methods from parametric methods like t-test to non-parametric methods like U -test.
However, in practice, we often face the situation when more than two treatments are
available at hand and we would like to compare them together. One naive way is
to compare them pairwise and produce
(
N
2
)
confidence intervals of the difference s of
the effects between all pair of treatments. Naturally this approach fails to consider
the Family-Wise Error Rate (FWER) (see Shaffer (1995) for more details). Rescues
have been made by different approaches, like the Bonferroni correction proposed by
Bonferroni (1936) and developed by Dunn (1959, 1961),the Sidak correction which
is credited to Sˇida´k (1967) by Seidler et al. (2000). If there is one “standard effect”
that serves as a control and we want to compare the effect of each treatment with
this control, a simultaneous comparison method called Multiple Comparison with the
Control (MCC) (Dunnett , 1955) can be applied. If we are only interested in whether
all effects of the treatments are equal, ANOVA (Box et al., 1954a,b) could be applied.
But if we want further know the relationship between the effects of the treatments, the
Multiple Comparisons with the Best (MCB) method proposed by Gupta (1965) and
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developed by Hsu (1996) can be applied. This method is the main technique of many
procedures in this thesis and will be introduced in more details in the corresponding
sections.
Besides the effect of treatments, sometimes we are also interested in comparing two
or more sequences of decision rules that provide sequences of treatments over time. A
sequence of decision rules that adapts over time, which take patients characteristics at
each time point as input and output a recommended treatment, have different names
in different fields, like Dynamic Treatment Regimes (DTRs) (Robins , 1986, 1989,
1993, 1997, 2004), adaptive treatment strategies (Lavori and Dawson, 2000, 2008)
(Murphy , 2005a) (Thall et al., 2000, 2011), treatment policies (Lunceford et al., 2002)
(Wahed and Tsiatis , 2004, 2006) or adaptive interventions (Almirall et al., 2014). Lei
et al. (2012) provided a detailed introduction of DTRs. There are a lot of scientific
questions that can be asked, like finding the best DTR among several given DTRs, the
comparison of DTRs with the same or different initial treatments etc. Murphy (2005a)
proposed a clinical design named Sequential Multi-Assignments Randomized Trials
(SMART) that can obtain data and answer these questions efficiently. To analyze
the data from a SMART, Q-learning technique (Watkins and Dayan, 1992; Murphy ,
2005b) can be applied. There are a lot of variation of this technique, examples can
be found in (Murphy , 2003; Robins , 2004; Blatt et al., 2004; Moodie et al., 2007;
Henderson et al., 2010; Zhao et al., 2009). However, they all suffer from the same
issue called non-regularity, which will be discussed in detail in chapter III. A number
of papers have discussed this problem including (Robins , 2004; Moodie et al., 2007;
Henderson et al., 2010; Chakraborty et al., 2009; Moodie and Richardson, 2010; Laber
et al., 2010).
In practice, we will often encounter different scenarios that we need to make
recommendation among several treatments at a time point, or among several DTRs
at the beginning of a session. Traditionally, researchers used data from clinical trials to
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estimate the “effects” of each treatment or DTR, and recommend patients or clinicians
with the one with the highest estimated effect. We are trying to provide another
approach. As those treatments or DTRs that do not have the highest estimated
effects, hence abandoned, might have other advantages like lower burden of side effects
or financially, or better agreement with patients schedule. So we do not want to given
them up that easily since their having lower estimated effect than the chosen one might
be merely by chance. So following the idea of Horrace et al. (2000), we would like to
construct a recommended set of treatments of DTRs, such that those contained in
the set are those statistically we cannot distinguish from being the best, while those
we excluded from the set are those we are statistically certain to be inferior than
the best. Our work follows the idea of clinical decision support system in the sense
that we do not tell clinicians or patients what to do, because usually we do not have
enough statistical evidence to do so, but rather tell them what not to do.
The rest of this thesis are organized as follows. In chapter II we will focus on the
situation where there are several one-stage treatments and we would like to construct
a recommended set. In that chapter we will first review the existing methods and
then introduce two new methods that are more “efficient” than the popular MCB
method. In chapter III we will discuss the construction of treatments when we have
more than one stages. The key part is the new definition of the effect of a non-
final stage treatment and the technique of constructing the confidence interval of the
differences of the effects. Chapter IV will deal with the situation where we would like
to construct a set of DTRs. This is the joint work with some other researchers and
the result has been published in Biostatistics. The final discussion and future work
will be in chapter V. The proof as well as the graphs can be found in the Appendix.
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CHAPTER II
Comparison methods
2.1 Introduction
As has been mentioned in chapter I, when there are more than one treatment
available, instead of trying to find the treatment with the best “effect”, we would
like to construct a set of treatments such that the best one is contained with high
probability. But if this is our only goal, then naively including all the treatments in
a set will work. Thus we are seeking other properties of this set.
We would like to start with a simple setting, i,e., the estimators of the treatments
are independent and have the same variance. Let’s consider N populations indexed by
{1, 2, · · · , N}; corresponding to these N treatments we have observations {Xij} where
i = 1, · · · , N and j = 1, · · · , n and n is the common sample size of each population.
We assume that observations are independent to each other and observations from
the ith population follow N(θi, σ
2), where θi is the mean of the ith population .
Either the common variance σ2 is known or can be consistently estimated by σˆ2
(usually the pooled sample variance). Our goal is to find a set Sˆ, based on the data,
that contains the best ( i.e. with largest mean) index with probability more than
a given level 1 − α. Let θ(1) ≤, · · · ,≤ θ(N) be an ordered sequence, then we need
P ((N) ∈ Sˆ|θ1, · · · , θN) ≥ 1 − α ∀θ′is. Let θˆi = 1nΣnj=1Xij (i = 1, ..., N) be the
sample average of the ith indexed population and thus a natural estimator of θi,
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and θˆ = (θˆ1, ..., θˆN)
T . Let δi = (θi − θ1, θi − θ2, · · · , θi − θN) be an N-1 dimensional
vector denoting the differences between the ith mean and other means, let δˆi be the
corresponding estimator with θs replaced by θˆs.
Here, we are comparing several populations instead of two. One idea is to compare
each pair of them, and screen out those population who are ‘significantly worse’ than
some other populations. This means that we are constructing
(
N
2
)
confidence intervals
in total, each for a pair of true difference, and for each index i, it is excluded from
the set if and only if all the N − 1 confidence intervals that involve θi suggest that
θi is lower. As has been discussed by Hsu (1996), this approach suffers from the
common shortcoming of Bonferroni method: the lack of power. i.e., the probability
of excluding true inferior treatments is very low even if there is a moderate difference.
The second idea is that we consider all the means as one vector. This vector θ lies in
an N dimensional space which can be divided into N parts, each of which is the set
where one particular θi is larger than or equal to all other θjs. If we fail to reject that
θ lies in the space where θi is largest, we keep index i in our confidence set. Many
methods we introduce below follow this idea. Further more, as what we concern
is only the differences between them, not the exact value. So we can consider the
difference between one of the population and the others. Thus what we concern is an
N − 1 dimensional vector δ. In such a way we can reduce the dimension of the vector
of interest by one and obtain more power.
The rest of this chapter is organized as follows, section 2.2 will contain a review of
several existing comparison methods and their pros and cons. In section 2.3 we will
introduce two new methods as supplements of Multiple Comparisons with the Best
technique.
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2.2 Review of the comparison methods
The first two of the methods reviewed in this section use the technique of Hypoth-
esis testing, which can be inverted to the problem of constructing confidence sets. We
let index i into Sˆ if and only if we fail to reject the null hypothesis
H0 : θi ≥ θj ∀j ∈ {1, 2, · · · , N} (2.1)
The null space is that the difference vector δ lies in the place where the ith element
of θ is the largest. And the alternative space is the complement of H0
2.2.1 Union-intersection principle (UIP) method
Union-intersection principle (UIP) is introduced by Roy Roy (1953), the idea is
that we decompose the alternative as the union of {Hi}Ki=1, and for each H0 v.s Hi
we have a test, then we accept H0 iff we accept all the null of subtests. In other
words, we reject H0 iff we accept some Hi. The rationale of this decomposition is
that although the null space is convex, the alternative space is not. Thus if we directly
use likelihood ratio test (as we would introduce later), there will be problems. We
will talk about this in detail in that part. Now we decompose H1 into several parts
and it is easier to compare each of them against H0.
What Gupta uses here is a variation of UIP, which is mentioned by Sen (2007).
Here we write
H0 =
⋂
j∈F
H0j, H1 =
⋃
j∈F
H1j (2.2)
where F is a suitable index set, and for each j ∈ F , there exists a suitable test for
testing H0j against H1j. And again we accept H0 iff we accept all the H0j.
Gupta’s UIP method is introduced by Gupta (1956). Here F = {1, 2, · · · , N}
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and H0j = {θi ≥ θj},H1j = {θi < θj}. For each j the test statistic is ηˆij =
√
n(θˆi −
θˆj)/σij where σij is the standard deviation of Xi−Xj. If we don’t know it, we replace
it by the pooled sample standard error σˆij. So the test statistic for population i
is ηˆi = (
√
n(θˆi − θˆ1)/σi1,
√
n(θˆi − θˆ2)/σi2, · · · ,
√
n(θˆi − θˆN)/σiN). We accept H0j if
ηˆij ≥ −dij, where {dij}Nj=1,j 6=i is determined to guarantee the 1 − α size, i.e. for i
fixed,
P (ηˆij ≥ −dij ∀j |θi = θj ∀j) = 1− α (2.3)
As this is the worst case scenario. To explain, our ultimate goal is that
P (ηˆij ≥ −dij ∀j |θi ≥ θj ∀j) ≥ 1− α (2.4)
As enlarging θj (for j 6= i) will make ηˆij smaller, so the worse case, i.e. the smallest
value of the left hand side of (2.4) for fixed {dij} happens when θi = θj ∀j. i.e.
P (ηˆij ≥ −dij ∀j |θi = θj ∀j) ≥ 1− α (2.5)
But we can always enlarge the power (i.e. make all {dij} smaller, say, by timing
a number γ a little smaller than 1 to all {dij}, thus the left hand side of (2.5) will be
smaller but as normal distribution is continuous so by carefully choosing γ we can let
it be still no smaller than 1 − α) while still preserving size α. So the optimal set of
{dij} satisfies (2.3), in the sense that we cannot shrink any dij without enlarging at
least one of the other dij.
And thus the rule of forming Sˆ is that
Sˆ = { i | ηˆij ≥ −dij ∀j 6= i} (2.6)
Under the case that all means are the same, ηˆi (we drop the term ηˆii to make ηˆi N-1
dimension since ηˆii is always zero) is distributed as a multivariate normal (if we know
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the variances) or t (if we don’t know the variances) distribution with no unknown
parameter. Denote it as Z = (Z1, Z2, · · · , ZN) (Note that this is N-1 dimension as
we don’t have the term Zi) so (2.3) becomes
P (Zj ≥ −dij, ∀j 6= i) = 1− α (2.7)
In principle any {dij} satisfying (2.7) can form an Sˆ with desired coverage prob-
ability. Gupta chose the case that dij ≡ di.
Edwards and Hsu (1983) showed that following (2.6), not only we have 1 − α
probability of covering (N) := arg maxi=1,··· ,N θi, but also have an estimate of θ(N)−θi
for each i.i.e
P ((N) ∈ Sˆ, θ(N) − θi ≤ Ui) ≥ 1− α (2.8)
for some Ui determined by the data. And this can be done with the following knowl-
edge of variance matrix, either we completely know it or at least we know the structure
of it, i.e. we know that variance matrix Σ = σ2C where C is a known matrix and σ is
a (possibly unknown) scalar (This is called general MCB, comparing with standard
MCB, which is that θˆis are independent. Here MCB stands for multiple comparisons
with the best).
We can see this in another point of view, we are constructing a ‘one-sided confi-
dence interval’ of the true δ base on (2.6), and recall we are dividing RN−1 into N
subspaces such that each of them represents the area where a certain θi is the largest.
From (2.6) it’s equivalent that we let index i into the confidence set if and only if the
‘confidence interval’ has non-empty interception with the area where θi is the largest.
We will see another kind of ‘confidence interval’ in the section of likelihood ratio test.
If we estimate treatment effects using only the average of effects from samples,
then usually the estimators are independent, but if they are combined with some other
covariates with unknown coefficients, then we need to estimate both the treatment
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effects and those unknown coefficients, thus leads to dependency. Below are detailed
explanation. This example comes from Horrace et al. (2000).
We consider panel data regression model
yit = θi + x
′
itβ + it i = 1, · · · , N, t = 1, · · · , n (2.9)
Here yit is the tth observation of the ith population, θi is the effect of the ith
treatment, xit is some feature covariates of the tth person given the ith treatment
and it is the error. For simplicity, we assume that for each population there are
equally n observations and the error it are iid normal with mean 0 and variance σ
2.
If β were known, then we could write (yit − x′itβ) = θi + i, then this reduces
to standard MCB. If β is not known but we have a consistent estimator βˆ from the
regression in deviations from individual means (i.e. by regressing yit − y¯i on xit − x¯i)
and then define θˆi = y¯i − x¯iβˆ. This leads to the following expression for θˆi:
θˆi = θi + ¯i − x¯i(βˆ − β) (2.10)
θˆi can be used as an estimator for θi, it’s unbiased and consistent if βˆ is unbiased
and consistent for β. Let x˜ be the Nn×K matrix (K is the dimension of xit) of x’s
expressed in deviations from individual means, so that its typical row is of the form
xit − x¯i. Let x¯ be the N ×K matrix whose ith row is x¯i. Then the variance matrix
of βˆ is σ2(x˜′x˜)−1 and variance matrix of θˆ is σ2C where C = IN/n+ x¯(x˜′x˜)−1x¯′. This
leads to general MCB.
If we consider a more general case. In model (2.9), the ‘treatment effect’(θi) is
the same for all members taking the same treatment. We can generalize this to the
model that the treatment effect is also effected by characteristics of the individual.
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That is we are considering the model
yij = x
′
ijα + x
′
ijβi + ij i = 1, · · · , N, j = 1, · · · , n (2.11)
So here α is a fixed vector (with length K, suppose) which can be considered as
‘fix effect’ for person with characteristic xij. βi (with length K) is the characteristic
of treatment i. So x′ijβi will be the treatment effect for individual with xij and taking
the ith treatment.
Now let’s define Ak(i, j) (k=1,...N) as the indicator, it’s 1 if i = k and 0 otherwise.
It means whether the ijth person has taken treatment k.
Let x˜ij = (x
′
ij, A1(i, j)x
′
ij, · · · , AN(i, j)x′ij) be a 1 by (N + 1)K vector and X =
(x′11, · · · , x′Nn)′ be an Nn by (N + 1)K design matrix . Y ′ = (y11, · · · , yNn) ,
β = (α′, β′1, · · · , β′N)′ and  = (11, · · · , Nn)′ be outcome, total coefficient and er-
ror vectors, respectively. So we have the general linear regression model Y = Xβ+ .
So the OLS solution is βˆ = (XTX)−1XTY . For a (possibly new) person with
characteristic x0, the treatment effect for him from treatment i is x
′
0βi and the
corresponding estimate is θˆi = x
′
0βˆi. So the vector we are interested in is θˆ =
(θˆ1, · · · , θˆN) = (x′0βˆ1, · · · , x′0βˆN) = X0βˆ. Where X0 is an N by (N + 1)K matrix,
its ith row is constructed as follows, first a zero vector with length iK, follows by x0
and then another (N − i)K zeros. Thus we have (x′0βˆ1, · · · , x′0βˆN) = X0βˆ. (Recall
βˆ = (αˆ′, βˆ′1, · · · , βˆ′N)′).
Assuming ij ∼ iid N(0, σ2). We have θˆ = X0βˆ = X0(XTX)−1XTY , V ar(βˆ) =
σ2(XTX)−1 and V ar(θˆ) = V ar(X0βˆ) = σ2X0(XTX)−1XT0 . Now we finish the con-
struction of generalized MCB.
Gupta’s method is a special case of Seal (1955). To decide whether a population is
selected into the confidence set, instead of just from the difference between the target
sample average and the largest sample average (Gupta’s setting), Seal considered
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the difference between the target sample average with the weighted average of all
other sample averages. Below is the detailed construction: in his paper, he first
assumed that the sample size (denoted by n as usual, same for all populations) is so
large that we can treat the estimated variance as the true variance (he assumed that
all populations have the same variance and independent). Denote s as the common
standard deviation of N normal distributions, and xi be the sample average of the ith
population, and x(1) < · · · < x(N) be the ranked observation (as normal distribution
is continuous we assume no equal observations).
To find the ’critical number’, let yi (i = 0, 1, · · · , N − 1) be N observation from
N(0, s2) and let y(1) < · · · < y(N−1) be N−1 ranked observations among y1, · · · , yN−1.
The y(i)s will define another set of random variables Y(i) (i = 1, · · · , N − 1). Let
tα(c1, · · · , cN−1) denote the upper 100α% point in the probability density function of
t(c1, · · · , cN−1) =
∑N−1
i=1 ciY(i) − Y0
s
(2.12)
The class C of decision rulesD(c1, · · · , cN−1) with ci ≥ 0, i = 1, · · · , N−1,
∑N−1
i=1 ci =
1 is defined as follows: reject any observation x0 from the given observations xi, i =
0, 1, · · · , N − 1 if
N−1∑
i=1
cix(i) − x0 > stα(c1, · · · , cN−1) (2.13)
and accept otherwise. Note that if we let cN−1 = 1 and all other ci’s equal to 0, then
this is Gupta’s method. In his paper, Seal discussed another special case when all cis
are equal, i.e. c1 =, · · · , cN−1 = 1/(N−1), (he denoted the decision rule in this case as
D¯). First, he proved that this setting minimized the variance among all
∑N−1
i=1 ciY(i)
such that
∑N−1
i=1 ci = 1. In the case that all but one population have the equal mean,
i.e. θ1 = θ2 = · · · = θN−1 = θN + δ where δ can be positive or negative, naturally we
want to (a) maximize the probability of selecting the Nth population if δ > 0 and (b)
minimize the probability of selecting the Nth population if δ < 0. Seal proved that
11
D¯ can achieve both requirements (a) and (b) among the set of rules D(c1, · · · , cN−1),
the optimality means that under this rule, the the maximum probability of including
the best and excluding the worst is achieved, among the set of rules D(c1, · · · , cN−1).
The reason why Seal considered this scenarios is that he wanted a test that contains
the best and reject the worse at the same time, with high probability, while our goal
is just including the best.
If we again go back to confidence interval point of view, Seal’s confidence interval
generally has different shape comparing to Gupta’s. Gupta’s interval is a cube (in θ’s
RN space ) or a parallelogram (in δ’s RN−1 space ) and the surface of the interval is
parallel to the boundary of the areas ( recall that different areas represent spaces where
a certain θi is the largest). Generally Seal’s confidence interval is a parallelogram and
not parallel to the boundaries. Thus it is lack of power generally.
Comparing with Gupta’s method, we can see that Seal’s D¯ method gives more
chance (to be selected into the confidence set) to the true best population if it does
not perform the best (i.e. has the largest sample average), but at the same time of
course gives more chance to other populations as well. So generally Seal’s set size will
be larger than Gupta’s. And Seal’s method works only well in his special scenario
(all means but one are equal), which is not a common case. And it will perform very
bad if only one population has very low mean while the differences between others
are relatively small. Because in this case each population (except the one with lowest
mean) will be selected into the confidence set with high probability as its sample
average will be larger than the average of all other sample averages. Keep in mind
that our goal is that under the restriction of containing the best population with high
probability, try to get as small a set as possible ( here the measure of a set is how
many elements it contains).
Based on Seal’s work, Hsu (1985) considered another similar selection rule. In his
paper he considered the situation when we have different sample sizes ni for the ith
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population. Naturally instead of ci = 1/(N − 1) in Seal’s case, we have
ci =
ni∑
j 6=i nj
Also he considered the case that we don’t know the common variance, then the
s in (2.13) is replaced by the estimated standard deviation sˆ and the critical value
tα changes correspondingly to satisfy (2.12) with s replaced by sˆ. Similar to Seal’s
method, this rule maximizes the probability of including the best as well as excluding
the worst.
2.2.2 Likelihood Ratio Test (LRT)
LRT is always a popular technique. Perlman et al. (1999) favored it to the many
’Uniformly more powerful’ tests. In their paper, they listed several tests that carefully
enlarged the rejection region (while preserving the 1−α level) and hence trivially en-
larged the power. But these new rejection regions violated the intuition of hypothesis
testing. For example, in the problem about the mean of a normal distribution with
unknown variance, H0 : |µ| > 1 and Ha = Hc0. The rejection region is in figure 2.1,
where x is observed sample average and s the sample standard deviation. LRT uses
just the small triangular region A as the rejection region, while the new test adds the
region Q as well. Thus, if we observe x¯ = 0 and sˆ = 10100, then using this new test
this observation provides strong evidence against the null. Their reason is that with
such large deviation, no one can distinguish between µ = 1 and µ = −1, let along
between H0 and H1.
Another example can be found in the work of Berger (1989). He considered a
problem similar to our multiple comparisons. His H0 is that the mean vector δ lies
outside the region where all the component of it are positive. And H1 = H
c
0. (In our
setting, we let δ be the difference between ith mean and others’, then our H0 and
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Figure 2.1: The rejection regions of Perlman’s test.
H1 are Berger’s H1 and H0, respectively).He carefully enlarged the rejection region of
LRT while still preserving the level 1− α confidence level. Thus it trivially enlarged
the power uniformly. But Perlman criticized this method as its rejection region has
zero distance from the null space, i.e. we can have sample mean infinitely close to
the null space but still gets rejected. In his other new test, the rejection region even
contains some area of the null space. See figure 2.2, where the rejection region of
Berger’s type 1 test is R1
⋃
R2
⋃ · · ·⋃R5, of type 2 test is R1⋃R2⋃ · · ·⋃R9, and
of likelihood ratio test is just R1. So it might happen that you reject the null of not
all coordinates are positive when your observation averages are all negative.
Now we focus on index i, for simplicity we assume that we know the variance of the
populations (and they are equal, so without loss of generality, equal to 1). The null
hypothesis is the same as in (2.1) and the alternative is Hc0. Assume we have equal
samples from each population, and let Yj = (Yj1, · · · , YjN) = (Xji − Xj1, · · · , Xji −
XjN), j = 1, 2, · · · , n be the difference between the ith population and the others,
in the jth sample, note that Yj is N-1 dimensional. And Yj is again multivariate
normal with mean vector δ = (δ1, · · · , δN) = (θi − θ1, · · · , θi − θN) and the known
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Figure 2.2: The rejection regions of Berger’s two new tests.
variance matrix here denoted by Σj, the variance matrix of (Xi−X1, · · · , Xi−XN).
In general, if the variance matrix of X is ΣX then Σj = DjΣXDj where Dj has -1
in its jth column, and the remaining columns are the columns (in order) of −IN−1.
A special case is that our Xs are independent (ΣX = I) then Σj is a matrix with
diagonal elements 1 and other elements 1/2. So the likelihood function is proportional
to
exp(−1
2
n∑
j=1
(Yj − δ)TΣ−1(Yj − δ)) (2.14)
Under the null, the δ that maximize (2.14) is δ˜ = (δ˜1, δ˜2, · · · , δ˜N) = (δˆ11(δˆ1 ≥
0), δˆ21(δˆ2 ≥ 0), · · · , δˆN1(δˆN ≥ 0)).
Under the whole space, the δ that maximize (2.14) is δˆ, where δˆ = (δˆ1, · · · , δˆN) =
(θˆi − θˆ1, · · · , θˆi − θˆN).
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So do the division and finally we have the rule, is that we accept H0 if
f(Y ) =
n∑
j=1
{(Yj − δ˜)TΣ−1(Yj − δ˜)− (Yj − δˆ)TΣ−1(Yj − δˆ)} ≤ C (2.15)
where C is determined such that
P (f(Y ) ≤ C | θ1 = θ2 =, · · · ,= θN) = 1− α (2.16)
After the discussion below, we have the explicit form for f(Y ) = nY¯ TA ΣAY¯A, where
A = {i |Y¯i < 0}, and Y¯A is Y¯ with ith element remaining for i ∈ A and ΣA is Σ with
ith row and columns remaining for i ∈ A.
To find f(Y ), let A ⊆ {1, 2, · · · , N} be a subset of indices. And Y¯ j be the jth
average of Y (i.e. x¯i − x¯j). j = 1, 2, · · · , N . It can be calculated that for the
’quadrant’ that Y¯ j is smaller than 0 for j ∈ A and other average less or equal to 0,
f(Y ) in (2.15) becomes nY¯ TA ΣAY¯A. Where Y¯A is a vector with length |A| (cardinality
of A), and the elements are Y¯ j for j ∈ A. And ΣA is this sub-matrix of Σ with all jth
row and column remaining (still j ∈ A). So our test statistic is Y¯ = (Y¯ 1, · · · , Y¯ N),
keep in mind that these are differences between average of the ith population and
others, so it’s N − 1 dimension.
The accept region of likelihood ratio test is something between a cube (as in
Gupta’s case) and an ellipsoid. To illustrate, let’s now assume that we have N=3 and
we first test whether population 3 should be taken into Sˆ.
Let’s draw a 2-d Cartesian coordinate system, with horizontal axis denotes δˆ1 =
θˆ3 − θˆ1 and vertical axis δˆ2 = θˆ3 − θˆ2.
So the using Gupta’s rule, if a point lies above x = −d and to the right of y = −d
then we accept the null.
For the likelihood ratio test rule, if a point lies in the first quadrant it will be
accepted. If it’s in the second quadrant, the null is accepted if its first coordinate
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Figure 2.3: The acceptance regions from Gupta and LRT. Both regions are the top
right of the two curves.
is larger than −c, similarly if it’s in the fourth quadrant, the null is accepted if its
second coordinate is larger than −c. If it’s in the third quadrant, it’s accepted if it
lies to the upper right of the curve x2 − xy + y2 = c2. The picture is shown in figure
2.3
Here are a few remarks:
First they both have continuous boundaries, but both have non-differential points.
Gupta’s happens at the lower left corner, LRT happens at the intersection of boundary
and axes. Besides, this confidence set has non flat boundary comparing with Gupta’s
and Seal’s confidence set.
Second, as Gupta’s boundary contains point (−d,−d) and LRT’s contains (−c,−c).
If c = d then Gupta’s acceptance region will be contained in LRT’s. So we must have
d > c.( if d < c then Gupta’s acceptance region in the second, third and fourth quad-
rant will all be contained by that of LRT’s.) Note that here δˆ1 and δˆ2 are positively
correlated.
Also we would note that there is a deficiency for LRT that it’s not a monotone
test. A monotone test means if it accepts H0 for a sample with average (δˆ1, δˆ2), it
must accept H0 for all the samples with average (δ˜1, δ˜2) if δˆ1 ≤ δ˜1 and δˆ2 ≤ δ˜2. This
can be visually verified from the graph of acceptance regime above.
A second deficiency is that usually we don’t know the variance (which is the com-
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mon case). Then under the null the δ that maximizes (2.14) is still the same, but the
Σ that maximizes (2.14) will be very complicated. To be precise, consider the (i, j)th
element of Σˆ, this is the MLE of covariance of the ith and jth population, will be
1
n
∑n
k=1(Yik − δ˜i)(Yjk − δ˜j), where Yik is the kth observation of the ith population,
(similarly for Yjk), and δ˜i = δˆi1(δˆi ≥ 0) where δˆi is the sample average. So plugging
Σˆ into (2.15) we get a very complicated form to solve.
All we have discussed are methods that can get a confidence set Sˆ in one step.
Another idea is that we can screen out indices one by one until we cannot distinguish
them. The method below follows this idea.
For a hypothesis testing, if our null is simple, i.e. null space is a single point,
then we can use the p-value method. If the p-value, the probability of ‘more extreme‘
situation happens given the null is true, is below our confidence level α, then we
reject the null. One idea is that we sequentially test that the remaining population
are equally the best, and kick out a population that ‘performs’ the worst if the null
is rejected, and go on to the next test until we accept that the remaining populations
are equally good. This idea was proposed by Hansen et al. (2011). Although there are
concern that these sequential testings can ‘accumulate’ Type I errors with unfortunate
consequences, in their paper, the authors claimed that the Model Confidence Set
(MCS) does not suffer from this problem because the sequential testing is halted
when the first hypothesis is accepted. Below is the detailed procedure.
If our set of remaining populations is M = {i1, · · · , im}, and the null is that
H0,M : θi1 = · · · = θim with the alternative H1,M = Hc0,M . Recall our notation
δij = θi − θj and naturally δˆij = θˆi − θˆj, we define di· =
∑
j∈M δij/m and naturally
dˆi· =
∑
j∈M δˆij/m. From these statistics, we construct the t-statistics
tij =
dˆij√
V̂AR(dˆij)
and ti· =
dˆi·√
V̂AR(dˆi·)
(2.17)
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where V̂AR(dˆij) and V̂AR(dˆi·) denote estimates of VAR(dˆij) and VAR(dˆi·), respec-
tively. The t-statistics tij and ti· are associated with the null hypothesis that Hij :
δij = 0 and Hi· : δi· = 0 because we have
θi1 = · · · θim ⇔ δij = 0 for all i, j ∈M
⇔ δi· = 0 for all i ∈M
Moreover, the equivalence extends to {δi· ≤ 0 for all i ∈ M} as well as {|δij| ≤
0 for all i, j ∈ M}, and these two formulations of the null hypothesis map naturally
into the test statistics
Tmax,M = max
i∈M
ti· and TR,M = max
i,j∈M
|tij|
which are available to test the hypothesis H0,M . Both tests reject H0,M if the test
statistics are above a certain number. The asymptotic distributions of these test
statistics are nonstandard because they depend on nuisance parameters ( under the
null and the alternative). However the nuisance parameters pose few obstacles, as
the relevant distributions can be estimated with bootstrap methods that implicitly
deal with the nuisance parameter problems.
Once we reject a null H0,M , we need an elimination rule eM to delete one popula-
tion from M . For these two tests, the author proposed two natural elimination rules
emax,M = arg maxi∈M ti· and eR,M = arg maxi∈M supj∈M tij. They proved that these
two elimination rules equipped with the testing rules Tmax,M and TR,M satisfy the as-
sumption that under the alternative, as sample size n goes to infinity, the probability
of deleting (possibly one of) the best population goes to zero.
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2.2.3 Bayesian approach
Bayesian approach is another useful tool. Roth (1978) proposed a method
called fiducial procedure. By considering θs as random variables instead of fixed
unknown numbers, he calculated pi, the probability of the ith population being the
best based on the samples. Then his selection rule is: arrange {pi} in descent order
p(1) ≤ p(2) ≤ · · · ≤ p(N), then sequentially select (N), (N − 1) · · · until (i), into SˆF ,
where i is the largest number such that
∑N
j=i p(j) ≥ 1−α. In the calculation of pi, he
assumed that all θs are normally distributed with means equal to the corresponding
sample average and a common known variance. In his paper, he proved that first, for
any observation, his confidence set is a subset of that from Gupta’s rule. Second, if
there are more than two populations, then there is positive probability that fiducial
confidence set is a proper subset of Gupta’s. But smaller size must suffer from some
deficiency. In his paper he also showed that the fiducial procedure does not satisfy
the condition infθ P (θ(N) ∈ SˆF ) ≥ 1− α when there are more than two populations,
the worst case is just like Gupta’s, i.e. θ(1) = θ(2) = · · · = θ(N−1) = θ(N)− and → 0.
But as we are in the Bayesian world, maybe this frequentist’s P ∗ condition (i.e.,
contain the fixed “true” best index with a desired probability) is not appropriate for
a Bayesian method. Gupta and Yang (1985) extended Roth’s work. They proposed a
non-randomized method ψB and a randomized method ψB∗.(We will see the fiducial
procedure is a special case of ψB if we choose non-informative prior for the mean
vector). We introduce these two methods below:
Let Xij be the jth observation of the ith population. i = 1, · · · , N , j = 1, · · · , ni.
Let Xi = Ti(Xi1, · · · , Xini) be a suitable estimator of θi (usually the sample average).
A selection rule based on an observation X = (X1, · · · , XN) will be denoted by
ψ(x) = (ψ1(x), · · · , ψN(x)) where ψi(x) : RN → [0, 1] is the probability that i is
included in the confidence set when X = x = (x1, · · · , xN) is observed. A correct
selection (CS) is defined to be the selection of any subset that includes the best
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population. Suppose we have a prior distribution for θ and instead of satisfying the
frequentist’s P ∗ condition (defined last paragraph), they considered controling the
posterior probability of CS to be larger than P ∗ = 1− α, that is
P (CS|ψ,X = x) =
N∑
i=1
ψi(x)pi(x) ≥ P ∗ ∀x (2.18)
where pi = P (θi ≥ θj ∀j|X = x). If we assume that the posterior cdf of θ is continuous
then it’s clear that
∑N
i=1 pi(x) = 1 ∀x. Let p[1](x) ≤ · · · ≤ p[N ](x) be the ordered
pi(x)’s and let θ(i) be the population associated with p[i](x) (Note that here θ(i) no
longer denote the ith smallest population mean as now they are not fixed). Then a
subset selection procedure is completely specified by {ψ(1)(x), · · · , ψ(N)(x)} where
ψ(i)(x) = P ((i) is selected | ψ,X = x), i = 1, · · · , N (2.19)
The posterior-P ∗-condition (called PP ∗-condition) is defined to satisfy the in-
equality in (2.18) as well as ψ(N)(x) = 1 ∀x (means we always select the population
with highest probability being the best based on the observation). Let’s have a look at
(2.18), it means on average (w.r.t the posterior distribution), that this selection has
good behavior (in the sense of selecting the true best population with high probabil-
ity), which is weaker than the ’level 1−α’ requirement since this requires everywhere
good behavior.
Now define non-randomized rule ψB = (ψB(1)(x), · · · , ψB(N)(x)) by:
ψB(i)(x) =

1 if i ≥ j
0, if i < j
(2.20)
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and j is the largest integer between 1 and N such that
N∑
i=j
p[i](x) ≥ P ∗
So we can see this is very like the fiducial procedure’s idea. And if we allow
random selection, a similar rule ψB∗ = (ψB∗(1)(x), · · · , ψB∗(N)(x)) can be formed by setting
ψB∗(N)(x) = 1 and
ψB∗(i) (x) =

1 if
∑k
j=i p[j](x) ≤ P ∗, i 6= k,
ν if
∑k
j=i+1 p[j](x) < P
∗ and
∑k
j=i p[j](x) > P
∗
0 otherwise
(2.21)
where the constrain ν is determined such that
νp[i](x) +
k∑
j=i+1
p[j](x) = P
∗ 0 < ν < 1
In this paper, the authors again considered that given the θs, the observations of
population i has iid N(θi, σ
2
i ) distribution.
First they consider non-informative prior τ(θ) ∝ C with common known σ2 and
common sample size n, then
pi(x) =
∞∫
−∞
Π
j 6=i
Φ(t+
√
nσ−1(xi − xj))dΦ(t), i = 1, · · · , N
which coincides the fiducial procedure.
If they have unequal but known σ2i and unequal sample sizes ni, then
pi(x) =
∞∫
−∞
Π
j 6=i
Φ(tνi/νj + (xi − xj)/νj)dΦ(t), i = 1, · · · , N
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where νi = σi/
√
n.
If they have unequal and unknown σ2i and unequal sample sizes ni, they chose
prior τ(θi, σi) ∝ σ−1i for each population and
pi(x) =
∞∫
−∞
Π
j 6=i
Tνj
(
t
si/
√
ni
sj/
√
nj
+
xi − xj
sj/
√
nj
)
dTνj(t)
where νi = ni − 1, s2i =
∑ni
j=1(xij − xi)2/νi, i = 1, · · · , N , and Tν is the cdf of the
t-distribution with ν degrees of freedom. For large ν, it can be approximated by the
normal distribution.
They also considered two more cases, one is that θs have common distribution
N(µ0, σ
2
0) and given θi, Xi (sample average) has distribution N(θi, σ
2/n),then
pi(x) =
∞∫
−∞
Π
j 6=i
Φ(t+ bnσ−2(xi − xj))dΦ(t), i = 1, · · · , N
where b2 = (σ−20 + nσ
−2)−1.
The other one is θi have independent normal prior distribution N(µi, σ
2
0i). And
given θi, Xi has distribution N(θi, σ
2
1i/ni), let z(xi) = b
2
i (σ
−2
0i µi + niσ
−2
1i xi), b
2
i =
(σ−20i + σ
−2
1i ni)
−1, and
pi(x) =
∞∫
−∞
Π
j 6=i
Φ(tbi + (z(xi)− z(xj))/bj)dΦ(t), i = 1, · · · , N
Comparing with the frequentists’ methods, this Bayesian approach has some ad-
vantages. As listed in Gupta and Yang (1985):
a) It can be applied to any family of distributions, even their mixture, and does
not need equal sample sizes.
b) Good prior information will not be ignored. Even under non-informative situ-
ation they perform well.
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c) They are robust in terms of the loss function. We do not even need to specify or
to know the exact form of the loss function before we make a decision. As long as the
loss function has some ’regular’ property like transition invariant and non-increasing
in the size of confidence set.
d) The weight or contribution of each population in the confidence set is known.
e) It is robust if the true family of distributions for each population is symmetric.
2.2.4 Comparison of these methods
Evaluation of confidence set is closely related to the measure (in most cases
Lebesgue) of the confidence region of parameters (in our case, is the mean vector),
because it’s converted from a confidence region. Joshi (1969) and Hwang and Casella
(1982) considered the confidence region that minimizes the maximum Lebesgue mea-
sure. Basically their method is based on a ball confidence region {µ | ‖ X¯−µ ‖22≤ C},
and change X¯ to δ(X¯) to achieve the minimax property. Hooper (1982) considers a re-
gion based on a Neyman-Pearson type criterion to form confidence region (dependent
on the true mean vector), which minimizes the expected Lebesgue measure among in-
variant confidence sets.(A confidence region C(x) with data x generated from model
with parameter θ is invariant if the conditional frequency (given X = x) of C(x)
covering θ is the same as that of C(g(x)) covering g(θ) and g belongs to a invariant
group, usually the group of linear transformation).
Cohen et al. (1973) proposed a criterion of judging the behavior of a confidence
region. A confidence region is said to be admissible if there is no other confidence set
that has smaller Lebesgue measure and probability of covering the true parameter.
For one dimension confidence interval, Aitchison and Dunsmore (1968) and Win-
kler (1972) considered the loss function which is a linear combination of undershooting
(upperbound of confidence interval smaller than the estimated parameter) and over-
shooting (lower bound larger than the parameter) and the length of the interval. They
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showed that if the penalty for the length is too large then the confidence interval will
shrink to a point estimator. For multi-dimension, Casella and Hwang (1991) used
the loss function which is the linear combination of the Lebesgue measure of the con-
fidence set and the probability not covering the true parameter. They didn’t directly
constrain the probability of covering the true parameter, but it is connected with the
penalty of not covering it, i.e the penalty parameter of not covering the truth is a
one-to-one function of the constrain of the probability of covering the truth.
But smaller confidence region for the mean does not necessarily implies smaller
expected confidence set in our setting. (When we talk about the measure of a set
, we mean the number of indices it contains). We can see that Gupta’s confidence
region of means is ’one-sided’, i.e. have infinite Lebesgue measure, but contains fewer
indices comparing to the minimum confidence region (The ellipsoid).
Lehmann (1952) considered maximizing the minimum power. In this article he
proved (Thm 4.1) that in our setting, in three population case (which means every
test involves two-dimension parameter testing), the Gupta type acceptance region
maximizes the minimum power. The minimum power always happens where the true
(δ1, δ2) lies in either {0,∞} or {∞, 0}, this corresponds to the case that two of the
three population have very large means comparing to the third, while the difference
between these two large means is small. Intuitively this makes sense, as in this
scenario the question is actually the comparison of only two populations (since the
third one has such small mean), but the critical value d is unnecessarily enlarged and
thus has small power (we can see that d gets larger as the dimensionality gets larger
from the way d in constructed). But here we should know the variance among all the
monotone hypothesis.
One concern is that maximizing the minimum power might not be the best choice.
Since what we would like is the ’good’ behavior around the true parameters, not the
parameters far away (i.e. not likely to be true given the samples).
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Another kind of loss function is instead of the measure of the confidence region of
estimation of θ, we directly penalize the size of the confidence set. Bjørnstad (1986)
considered the following two kinds of loss functions
l(θ, Sˆ) = α(|Sˆ|)
∑
i∈Sˆ
l0(θ(N) − θi) l(θ, Sˆ) = α(|Sˆ|)
∑
i∈Sˆ
l0(θ(N)/θi − 1) (2.22)
Here |Sˆ| means the size of Sˆ. α, l0 are continuous, non-decreasing and l0(0) = 0
and l0(x) > 0 if x > 0.
To understand this, first the loss is positive related with the size of the confidence
set, then we penalize more if the true best mean is away from others. In his paper
the author discussed the asymptotic behavior of Gupta’s rule. He proved that as the
sample size n goes to infinity, if there is only one best population (treated as fixed,
i.e. not Bayesian view), then Gupta’s method will eventually select the only true
population, i.e. the false positive and false negative rate will both go to zero. Further
more, this convergence holds uniformly for a set of θ lies in a compact set K, i.e. if
we restrict θ ∈ K, then for any  > 0, there exists an N such that for any sample size
n > N we have the probability of including the best and not including others both
larger than 1− , regardless of where exactly θ lies, (as long as it belongs to K). This
seems too greedy since what we want is just covering the truth with probability 1−α.
But here if we use hypothesis testing point of view, our null hypothesis is that a vector
(differences between the mean of the ith population and that of the others) lies in a
set that has interior points. So in order to have good coverage for all points in the null
space, like the argument in deriving (2.3), it’s equivalent to cover the ‘sharp point’ (
the origin) when the true vector lies there. So if the truth is that the parameter lies
inside the null space, by law of large number the sample mean converges uniformly
to the true population mean, thus we have that the sample difference vector of the
largest population will eventually fall into the null space (thus selected into the con-
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fidence set) and sample difference vector of other population will converge to points
that are away from the null space, thus get excluded in the confidence set eventually.
If our main concern is just the expected size of our sample size Eθ(|Sˆψ|), (here
the subscript θ of E means the expected size depends on the true mean vector θ, and
the subscript ψ of Sˆ means the confidence set Sˆ follows the selection rule ψ) Berger
et al. (1979) considered minimizing the largest possible expected size, i.e. minimizing
maxθ Eθ(|Sˆψ|). In his paper, he proved that Gupta’s method achieved the lower
bound, which is (1−α)N , which happens at the case one of the population is slightly
larger than each of the rest.
Recall that Gupta’s test (in fact the whole UIP test) is monotone while likelihood
ratio test is not. Gupta and Huang (1980) showed that for any non-monotone test, we
can construct a better new test based on it, in terms of smaller maximum expected
set size (i.e. how many elements are there in a set), while still preserving the level
1− α.
But by just looking at the maximum, we sacrifice a lot. A method having a
smaller maximum size might perform relatively worse in general, comparing with a
method having a larger maximum size. What’s more, if we just consider the maximum
expected size, then Gupta’s method is only as good as the naive selection rule, which
selects any population with probability 1 − α and obviously satisfies selecting the
best population with probability no less than 1 − α for any true θ. And Eθ|Sˆ| =∑N
i=1 P (i ∈ Sˆ) =
∑N
i=1(1−α) = (1−α)N for any θ, so maxθ Eθ|Sˆ| = (1−α)N . Thus
this method also achieves the lower bound of maximum expected set size. Even if the
performances are the same for these two methods at the point where all populations
have the same mean ( in this case the best population is tagged to be any one of them),
Gupta’s method selects much fewer in many other cases. So instead of just looking at
the maximum expected size, maybe it’s a good idea to look at the general behavior,
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i.e. some sort of average expected size with respect to some prior distribution of θ,
or just
∫
Ω
Eθ(|Sˆψ|)dθ if we know θ ∈ Ω a compact subspace of RN .
Following the idea of Lehmann (1952), we want to find {dij} satisfying (2.7) and
have some good property. Another criterion is instead of maximizing the minimum
power, we try to maximize the average power, here average is taken w.r.t some dis-
tribution of the true parameter. We want to give more reward of enlarging the power
of those parameter around the point estimator of it since they are more likely to be
in that area given the data. So we can use the posterior distribution of the mean
vector (we can use non-informative improper prior). Thus, our test statistic will be
something other than the differences of sample average (plus estimator of variance if
it’s not known).
Next we consider loss functions in Bayes world.
The PP ∗ condition, which is defined after formula (2.19), is:
P (CS|ψ,X = x) ≥ P ∗ ∀x and ψ(N)(x) = 1 (2.23)
And for given a prior τ , let D = D(τ, P ∗)(D∗ = D∗(τ, P ∗)) be the class of all
non-randomized (randomized) selection procedures in which all procedures satisfy
the PP ∗ condition for any given observation X = x. We can see that D and D∗
contain many rules including some useless rules like psii(x) = 1 for all i and x (i.e.
select all population regardless of the observation). They all satisfy the PP ∗ condition
hence are valid candidates. Our next job is to select some rule from them to have
good properties in some sense.
Another definition is for a group G (usually permutation), for all g ∈ G,θ ∈ Θ
and confidence set s, a loss function L has property T if (1) L(θ, s) = L(gθ, gs), (2)
L(θ, s) is non-increasing in θi for i ∈ s and (3) L(θ, s) ≤ L(θ, s′) if s ⊆ s′. Basically
the first property requests the selection is invariant under permutation, second is we
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don’t penalize more if the true population mean get higher, when this population
index is in the confidence set, and the third means you always penalize more for a
larger confidence set. So if we define L(θ, s) = |s| where |s| is the size of s, then
this loss function has property T. Then Gupta and Yang (1985) proved the following
theorem:
Suppose the prior distribution τ is symmetric on Θ. Given θ ∈ Θ, X1, · · · , XN are
independently distributed and the pdf f(xi|θi) has monotone likelihood ratio prop-
erty. Then the selection procedure ψB(ψB∗) defined in (2.20) and (2.21) is monotone
and is a Bayes procedure in D(D∗) provided that the loss function has property
T. This theorem also holds if H(θ|x), the posterior cdf of θ, given X = x, is ab-
solutely continuous and have the generalized stochastic increasing property, that
is: (1) H(θ|x) = ΠNi=1Hi(θi|x), where Hi(·|x) is the posterior cdf of θi and (2)
Hi(t|x) ≥ Hj(t|x) for any t whenever xj ≤ xj. To understand (2), let’s assume
xi is the sample average of the ith population having N(θi, σ
2/n) and we use non-
informative prior, xis independent given θis, so Hi(t|x) = Hi(t|xi) = Ψ(t
√
n/σ − xi)
so it’s non-increasing in xi.
These two ψ methods are also the most efficient in D(D∗), i.e.eff(ψ) ≥ eff(ψ′) for
all ψ′ ∈ D(D∗). The efficiency is defined as
eff(ψ|x) = P (CS|ψ, x)/E(S|ψ, x)
where E(S|ψ, x) is the posterior expected size of the selected subset. The expectation
of eff(ψ|x) is the efficiency of procedure and is denoted by eff(ψ).
In summary, there are good properties we want a selection procedure to have. Be-
low, a procedure is denoted as ψ(θˆ1, · · · , θˆN , ΣˆN , n), where θˆi are consistent estimator
of the mean of each population (in most cases sample mean) and ΣˆN is a consistent
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estimator of the covariance matrix of the estimator of vector θ, (pooled sample covari-
ance matrix in general), and n the common sample size of each population. In other
words, as all the popular methods (Seal, Gupta, UIP, LRT, all the Bayesian methods)
concern only the sample averages ( actually only the differences of those averages if
sample sizes of each populations are the same.), and the estimated covariance matrix
(if unknown), so we only focus on selection rules that are function of only θˆ and ΣˆN .
This is due to the reduction to sufficient statistics for normal distribution.
Below are some good properties we would like a selection rule to have: (denote
that event that the selection rule selects the true best population as correct selection,
or CS, and the size of a set Sˆ which counts how many populations it contains by |Sˆ|,
a set followed a rule ψ is denoted as Sˆψ)
I Include the best population with high probability, regardless of where the true
mean vector lies (frequentists’ view), i.e. infθ P (CS|ψ) ≥ 1− α.
I’. Include the best population with high probability on average (Bayesian view),
i.e. EP (CS|ψ) ≥ 1−α, where expectation is taken with respected to some posterior
distribution of θ.
II. Small maximum expected set size, i.e. small maxθ Eθ|Sˆψ|, where expectation
is taken with the distribution of θˆ for fixed θ.
II’. Small average expected set size, i.e. small EτEθ|Sˆψ| where τ is some posterior
distribution of θ.
III. Monotonicity, meaning if population i is selected into Sˆ by some rule ψ based
on θˆ, then increasing θˆi while remains other θˆj the same will not exclude i, follow the
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same ψ. i.e. 1(i ∈ Sˆ|ψ(θˆ1, · · · , θˆi, · · · , θˆN) ≥ 1(i ∈ Sˆ|ψ(θˆ1, · · · , θˆ′i, · · · , θˆN), for any
θˆi ≥ θˆ′i.
IV. If we add a ’useless’ competitor, it shouldn’t effect the choice of Sψ, i.e.
limθˆN→−∞ Sψ(θˆ1,··· ,θˆN ,ΣˆN ,n) = Sψ(θˆ1,··· ,θˆN−1,ΣˆN−1,n), where ΣˆN−1 is the first N−1 columns
and rows of ΣˆN .
V. As the differences of {θˆi}s get smaller and smaller, we tend to select all of
them. i.e. let ∆ = maxi,j{|θˆi − θˆj|}, we want lim∆→0 Sˆψ = {1, 2, · · · , N}.
VI. If a population ’performs’ the best, it should always be selected into the con-
fidence set. i.e. θˆi ≥ θˆj ∀j ⇒ i ∈ Sˆψ.
Here are a few remarks:
0. Here we mainly compare three methods: Gupta’s, model confidence set (MCS)
and Bayesian ( which is Fiducial if we consider non-informative prior). We don’t
consider much of LTR method because in the situation we don’t know the variance
(which is almost all the cases), it’s very hard to get the form of the test.
1. I is much stronger than I ’ and can imply I ’. But as the ’inf’ always takes place
where all θis are equal. If the sample means are vary dispersed, then the truth being
all means are the same is vary small. Gupta’s method achieves I, but sacrifices a lot in
the sense of large set size. In order words, Gupta’s method always considers the worse
case, even if it seems very unlikely to be the case, and thus unnecessarily enlarges
the set size. For example, if our observations are (10, 9.9, 9.3, 9.3, 0, 0), with common
sample size n = 18, known standard deviation σ = 1 and significance level α = 0.05.
As here our total population is N = 6 so d = 2.234 and dσ
√
2/n = 0.745 so we should
include the first four populations into our Sˆ. But if we think that as the last two
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means are more than 10 standard errors away from the largest sample average, it’s
almost impossible for these two populations to be the best (p-value almost zero), so
there are ‘essentially ‘ just four populations competing, we use N = 4 hence d = 2.062
and dσ
√
2/n = 0.687, so we only select the first two populations into our Sˆ. This
idea will be applied in the nest section where we will introduce two new methods call
step-up and step-down methods.
2. Bayesian method doesn’t satisfy I when N > 2 but satisfies I’.
3. MCS satisfies more than I. To see this, first we consider that all populations
have equal means, then what we concern is the probability of including the first
population in our Sˆ. This probability is equal to the probability of accepting the null
which is all population means are equal ( in this situation our Sˆ includes all indices),
plus the probability of rejecting the null but finally didn’t kick out this population in
the following steps. The first probability is already 1 − α, and the second is strictly
positive ( for example only one other population’s sample mean is way below others,
we will kick this one out and terminate). So in summary the probability of having
the first index in Sˆ is larger than 1− α when all population means are equal. And if
it is not the case, the one with largest mean will be harder to kick out than the case
when all means are equal.
4. All three methods satisfy III (but LRT doesn’t).
5. Gupta’s method violates IV, because each new-comer will enlarge the ’selection
threshold’ d, which depends only on number of populations. But Bayesian method
satisfies this property. Because as an added population’s sample mean goes to negative
infinity, its probability of being the best will shrink to zero and won’t effect the
probability of others being the best. MCS also satisfies this. If we add a useless
competitor, it will be kicked out in the first step. More over, MCS does a better
job in the sense of avoiding the influence of bad population. Because as long as the
sample mean of a bad population is below a certain threshold, it will completely have
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no impact on the selection procedure. But for the other two, the influence of bad
population always exists ( becomes smaller and smaller as the sample mean of the
bad population gets lower).
6. Gupta’s method and MCS satisfy V, it’s very easy to see this from the rule.
Bayesian method doesn’t always satisfy this, but only when the population is large
(larger than 1/α). For example, if α = 0.1, then we only have a problem with V when
there are at least 10 populations.
7. All the methods introduced in this review satisfy VI.
So in summary, Gupta’s method satisfies I,III,V and VI, and Bayesian I’,III,IV,VI,
and MCS I,III,IV,V,VI. In the consideration of II and II’ Gupta’s method focus on
the worst case scenario, which is all the true means are equal, so it performs well when
this is the truth, or the differences between the true population means are small. But
it performs bad when the true differences of population means are large, in which case
Bayesian method performs better, because Gupta’s method’s lack of ability to get rid
of ’clearly’ bad interrupting population. And MCS performs worst, as it selects every
population with larger probability ( which is discussed in remark 3).
Gupta’s method performs better if the true means are close and Bayesian method
is better when true means are separated. So a natural question is that can we have
a method performs better for both cases, and satisfies as many above properties as
possible.
2.3 Step-up and step-down methods
2.3.1 Introduction
As has been discussed in the last section, Gupta’s method always considers the
worst case scenario, i.e., when all the population means are the same, even if there are
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strong evidence that some of the population means are not the best. By considering
the worst case, the “threshold” d is unnecessarily large and thus to not have enough
power to exclude true inferior indices. Following the sequential testing idea from MCS,
we propose two multi-stage procedure of constructing the confidence set Sˆ. Section
2.3.2 will contain the introduction of the two methods, followed by a numerical study
in section 2.3.3. In section 2.3.4 we will have a discussion on these two methods.
2.3.2 Form of the two methods
Before the introduction of the two methods, we first review the procedure of
Gupta’s method.
We have a critical number dN such that dN satisfies
P (Zi ≤ dN ∀i = 1, · · · , N − 1) = 1− α (2.24)
Where Z = (Z1, · · · , ZN−1) follows a multivariate normal distribution with mean zero,
its variance matrix has 1 on its diagonal and 0.5 elsewhere. So Gupta’s selection rule
is
i⇒ SˆG iff θˆi ≥ θˆ(N) −
√
2dNσ√
n
(2.25)
Where θˆ(N) is the value of the largest sample means.
Now we introduce the procedures of the two new methods. Note that one key
assumption is that they both need that the variance of each point estimators of the
population means are the same. For the introduction of the two procedures, we
assume for simplicity that we know this common variance and denote it as σ2. We
can also have a similar procedure by using σˆ2, the consistent estimator of σ2. Besides,
they also both required that these estimators are independent.
Step-up method:
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We have a sequence of critical values c1, · · · , cN , · · · . We sort the value of sample
means in ascending order: θˆ(1) < · · · < θˆ(N). (As we have continuous distribution so
the chance to tie is zero). And below is the selection rule of step-up method:
Step 0: Initialize an empty set denoted as SˆSU .
Step 1: (N) always in SˆSU .
Step 2: If θˆ(N−1) ≥ θˆ(N) − c2σ/
√
n then (N − 1) is selected into SˆSU and go to
step 3; Else, stop.
Step 3: If θˆ(N−2) ≥ θˆ(N) − c3σ/
√
n then (N − 2) is selected into SˆSU and go to
step 4; Else, stop.
· · · · · ·
Step N − 1: If θˆ(2) ≥ θˆ(N) − cN−1σ/
√
n then (2) is selected into SˆSU and go to
step N ; Else, stop.
Step N : If θˆ(1) ≥ θˆ(N) − cNσ/
√
n then (1) is selected into SˆSU . Stop.
This method can be thought as a sequence of hypothesis testing. First we test
whether the population with the second largest estimated mean has its population
mean no smaller than that of the population with the largest estimated mean, and
continue testing until we reject a test (the null will always be that the target popu-
lation’s mean is the largest) or we select all populations.
Now is the discussion of one approach to get the critical values.
For c2, we need that Pθ1=θ2(1 ∈ SˆSU) = 1 − α. After finding c2 we find c3 by
solving Pθ1=θ2=θ3(1 ∈ SˆSU) = 1− α (*) Here the only unknown number is c3, the left
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hand side of (*) is monotone with respect to c3 and is below and above 1−α when c3
is zero and infinity. So we can uniquely get c3. For greater N , cN will be find similarly.
Step-down method:
We have a sequence of critical values c1, · · · , cN , · · · (These are different from the
cs in step-up method. For comparison of the methods, we will denote the two vec-
tors of cs as csu and csd) . We sort the value of sample means in ascending order:
θˆ(1) < · · · < θˆ(N). (As we have continuous distribution so the chance to tie is zero).
And below is the selection rule of step-down method:
Step 1: Select all indices into a set denoted as SˆSD.
Step 2: If θˆ(1) ≤ θˆ(N) − cNσ/
√
n then (1) is removed from SˆSD and go to step 3;
Else, stop.
Step 3: If θˆ(2) ≤ θˆ(N) − cN−1σ/
√
n then (2) is removed from SˆSD and go to step
4; Else, stop.
· · · · · ·
Step N − 1: If θˆ(N−2) ≤ θˆ(N) − c3σ/
√
n then (N − 2) is removed from SˆSD and
go to step N ; Else, stop.
Step N : If θˆ(N−1) ≥ θˆ(N) − c2σ/
√
n then (N − 1) is removed from SˆSD. Stop.
This method can be thought as a sequence of hypothesis testing. First we test
whether the population with the smallest estimated mean has the largest population
mean, and continue testing until we accept a test (the null will always be the target
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population has the largest mean) or we removing all populations except the one with
the largest sample mean.
Now is the discussion of one approach to get the critical values.
For c2, we need that Pθ1=θ2(1 ∈ SˆSD) = 1 − α. After finding c2 we find c3 by
solving Pθ1=θ2=θ3(1 ∈ SˆSD) = 1− α (*) Here the only unknown number is c3, the left
hand side of (*) is monotone with respect to c3 and is below and above 1 − α when
c3 is zero and infinity. So we can uniquely get c3. For greater N , cN will be find
similarly.
2.3.3 Simulation Study
As currently we do not have any theoretical results of these two methods. We
would like to show their performance by numerical simulation. As only the differences
between population means are what we concern, without loss of generality we assume
that the mean of the third population is always zero. The mean of the first and
second population ranged from 0 to 4.5, common sample size n = 4 (As we already
know the common σ so we do not require a large sample size) and common known
variance σ2 = 1. For any point, we generate data 1000000 times and use the three
methods to get selected set. Figure 2.4 through 2.6 the difference in average set size
between the three methods.
We can see that these two methods both beat Gupta’s method, in the sense that
they both have smaller expected set sizes than Gupta’s. And the difference between
these two are not significant.
2.3.4 Discussion
The reason we do not further investigate these two methods is that although they
both beat Gupta’s method, in the sense that their expected set sizes are always smaller
than that of Gupta no matter what the true population mean θ is, the improvement
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Figure 2.4: The difference of expected set sizes between set from Gupta’s method and
the step-up method.
Figure 2.5: The difference of expected set sizes between set from Gupta’s method and
the step-down method.
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Figure 2.6: The difference of expected set sizes between set from the step-up method
and the step-down method.
is so small (at most 0.1 in three-population case) that it would be hard to convince
people to use it, considering so many more assumption they need.
Although I spent almost two years in this project and got no good result, it serves
a very big lesson for me. It teaches me the correct way of doing research: every
time we have a new method, first do some simulation to see if the improvement over
the existing method is big enough to worth further attention. If I conducted the
simulation at the beginning I would not have spent that two years trying to prove
the relevant theorems and the write-ups. Luckily I stopped in time to work on the
next project, which will be introduced in the next few chapters.
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CHAPTER III
Set valued DTR
3.1 Introduction
In practice, clinicians offer treatment according to their patients’ individual char-
acteristics at each decision point. Clinicians collect and measure the information from
the patient and recommend the category and dose of treatment correspondingly. Dy-
namic Treatment Regimes (DTRs) are sequences of decision rules that map from the
patient’s information to a recommended treatment. A DTR is analogous to a policy
in reinforcement learning and to a controller in control theory. The ideas behind
DTRs extend beyond medicine, appearing in education, marketing and economics,
among other fields.
Most of the current research on DTRs focuses on constructing decision rules that
take as input a patient’s information and output one recommended treatment. How-
ever this is at odds with clinical decision support systems in which the clinician
provides a set of treatments; this set excludes treatments known to be less effective
given the patient’s information. Examples include DXplain (Barnett et al., 1987),
Iliad (Warner Jr , 1989), RECONSIDER (Blois et al., 1981) and QMR (Miller and
Masarie Jr , 1989). Currently the set of treatments is informed by clinical expertise,
biological theory, and—in the case where sequential decisions regarding treatment are
required—only an indirect use of data (see (Fortney et al., 2010) and (Trivedi et al.,
40
2014) for example).
At the beginning of this chapter, we consider the simple setting where there are
just two decision points, and we assume that there are two (and just two) possible
treatments at each stage. In the last section we will discuss the case when there are
more than two treatment per stage This work borrows ideas from a variety of areas,
including the area of multiple comparisons with the best. Robins et al. (2014) recom-
mend that the first-stage treatment effect be a data-dependent parameter and work
from the field of computer science that advocates assuming that the least effective in
the set of treatments at the second stage may be selected. As will be both concep-
tually and mathematically explained in detail in section 3.2, this prospective has a
bearing on how we define the effect of a non-final stage treatment: instead of assum-
ing that patients will take the best corresponding future treatment, we assume that
they will take the true worst corresponding future treatment in the recommended set.
(The concept and construction of the recommended set will also be discussed in detail
in section 3.2.) As we will see, the recommended set is random (i.e., depends on the
data), and the parameters to be estimated are also random. Further discussion can
be found in section 3.2.
A set valued DTR is different from a traditional DTR in two respects. First, in
many cases we do not have enough evidence that the treatment recommended by the
DTR is better than the remaining treatments. A set-valued DTR, instead of always
recommending only one treatment at each decision point, will recommend a set of
treatments. The treatments in this set are those we do not have enough statistical
evidence on to distinguish from the best treatment. When one of the treatments is
significantly better than the rest, the set will contain only this treatment.
The second difference is that we evaluate a non-final stage treatment in a different
way. Traditional DTRs, using the dynamic programming idea, define the effect of a
non-final stage treatment as the expected final outcome a patient would have, if he or
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she took this treatment at the stage in question and took the best treatment at future
stages. Our way of evaluating a treatment differs because we cannot assume that the
patient will actually take the best treatment at all future stages. This assumption
becomes even more unrealistic if the recommended set of treatments at some future
stage contains several treatments. Thus, as will be discussed in section 3.2, we will
define the effect of a treatment to be the expected final outcome if the patient takes
this treatment at the current stage, and takes the worst from the set of recommended
treatments at each future stages. The goal of recommending a set of treatments is
therefore not to select the “best” treatment but rather to screen out treatments that
are believed to be bad.
According to Laber et al. (2014a), when we cannot distinguish between the effects
of several treatments, we should provide all such treatments to the clinician. However,
as detailed in the following section, because we are providing a set of treatments at
each stage, we do not know which one the patient will choose in the future. Therefore,
our definition of the effect of a non-final stage treatment is different from that in Laber
et al. (2010).
Other studies approach treatment regimes differently. Fard and Pineau (2009)
discuss the construction of sets of Markov Decision Processes (MDPs). Instead of
trying to identify the best policy (i.e., the function mapping a state to an action),
they form a set of polices. Each policy in the set has expected discounted reward no
less than 1−  times the largest expected discounted reward among all policies, where
 is a user-specified value.
Laber et al. (2014a) discuss set-valued DTRs from yet another point of view. In
their work, they assume that there are two outcomes of interest. Instead of considering
a linear combination of them as one single outcome, they construct the decision rule
at each stage so as to provide a set of recommended treatments. A treatment is chosen
for the recommended set if each of its interested outcomes is either better or not too
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much worse than for the other treatments. This procedure can deal with the case
where the two interested outcome have different units (e.g., the amount of reduction
in blood pressure on the one hand and in blood fat on the other). Note, however, that
giving a precise meaning to “not too much worse” requires a user specified threshold.
The main contribution of this work is twofold. First, we for the first time consider
set valued DTRs when the interested outcome is a scaler without any user-specified
threshold. To accommodate the set-valued DTRs we give a new definition of the
effect of a non-final stage treatment, which usually is a random quantity instead of a
fixed quantity. Second, we propose a new scientific goal of DTRs: instead of a DTR
attempting to pin down the true best treatment, it should screen out significantly
worse treatments for a given patient.
The rest of the chapter is organized as follows: in section 3.2 we introduce set
valued DTRs and argue the coherent issue. In section 3.3 we provide a method for
constructing the confidence intervals of the desired estimand and the corresponding
asymptotic properties. In section 3.4 we examine the finite sample performance of the
proposed confidence interval using simulated data. In section 3.5 we apply our method
to data from an ADHD study. Section 3.6 provides a discussion of the open problems
and future work. In the last section we will discuss the procedure of constructing
the recommended set when there are more than two treatments at each stage. In the
appendix we introduce traditional DTRs in detail and provide related proofs as well
as more simulations.
3.2 Set-valued DTRs and the construction of the recom-
mended sets
We suppose that at each stage there are two available treatments, denoted as
At ∈ {−1, 1} for t = 1, 2. We assume the data is from a sequentially randomized trial
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(?), also known as a sequential multiple assignment randomized trial (Murphy , 2005a).
For each patient, we observe a sequence (X1, A1, X2, A2, Y ). Here Xt (t = 1, 2) is the
patient’s covariate before the assignment of treatment At at stage t. The primary
outcome, Y , is a scalar, coded such that a higher value indicates a better result.
We let Ht denote the history before assigning treatment At, thus H1 = X1 and
H2 = (X1, A1, X2). At time t the clinician makes a decision based on Ht.
A traditional DTR in the two stage setting is composed of a pair of decision rules,
pitra = (pi1,tra, pi2,tra), where pit,tra is a map from the domain of Ht to the domain of
At, i.e., at each decision time point t, the output of pit,tra is a single treatment from
the domain of At.
A set-valued DTR differs from a traditional DTR in that the range of a set-
valued DTR is different. Specifically, a set-valued DTR is a pair of functions, piset =
(pi1,set, pi2,set), where pit,set is a map from the domain of Ht to Power(At), which is
the power set of the domain of At but with ∅ excluded. For example, if At can take
values in {−1, 1}, then Power(At) = {{1}, {−1}, {1,−1}}.
An optimal traditional DTR piopttra is such that Epi
opt
traY = suppitra E
pitraY . It is a
sequence of decision rules, which if implemented with the population of patients, will
have the largest expected outcome. In contrast, optimal in the contest of set-valued
DTRs may be defined in a variety of ways. We use a “worst-case” definition. Our
worst-case definition allows for the fact, that given a set of treatments to choose
between, the clinician/patient may select the worst-performing treatment in that set.
In order to explain this definition, first we need to analyze how we compare treatment
effects.
In order to compare treatments, we need a criterion: at each stage we compare
treatments based on the Q-function for that stage. The Q-function for stage 2 is just
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the conditional expectation
Q2(h2, a2) := E(Y |H2 = h2, A2 = a2) (3.1)
Thus, Q2(h2, a2) is the expected outcome for patients with H2 = h2 who are
provided A2 = a2 at the second stage. The parametric form of Q2 can be defined as
Q2(H2, A2; θ2) := H
T
2,0θ2,0 +H
T
2,1θ2,1A2 (3.2)
For each h2 we use an estimator of Q2(h2, a2) and ideas from literature on Multiple
Comparisons with the Best (Hsu, 1996) to construct a recommended set Sˆ2(h2) of
second-stage treatments. Each set contains the stage 2 treatments that can not be
differentiated from the best stage 2 treatment.
Before introducing the construction of Sˆ2(h2), we define the second-stage estimand
θ∗2 := arg min
θ2
P (Y −Q2(H2, A2; θ2))2 (3.3)
Here θ∗2 can be interpreted as the true second-stage regression coefficient. At stage
2 for a patient with H2 = h2, we are interested in h
T
2,1θ
∗
2,1, which is half the difference
between the effect of treatment A2 = 1 and the effect of treatment A2 = −1. The
estimator of θ∗2 is defined as θˆ2 := arg minθ2 Pn(Y2 − Q2(H2, A2; θ2))2. The limiting
distribution of
√
nhT2,1(θˆ2,1 − θ∗2,1) is always normal; a proof of this fact can be found
in the online supplementary materials.
To form Sˆ2(h2), we proceed as follows. First we construct two one-sided confidence
intervals for hT2,1θ
∗
2,1 of the form (−∞, u) and (l,+∞), respectively. If u > 0, mean-
ing we cannot reject the hypothesis hT2,1θ
∗
2,1 > 0, we include treatment 1 in Sˆ2(h2).
Similarly if l < 0, meaning we cannot reject hT2,1θ
∗
2,1 < 0, we include treatment -1 in
Sˆ2(h2).
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Note that another way of constructing Sˆ2(h2) is to consider one two-sided con-
fidence interval (say, (l˜, u˜)) for hT2,1θ
∗
2,1 instead of two one-sided confidence intervals.
In this variant, Sˆ2(h2) would contain both treatments if 0 ∈ (l˜, u˜) and would contain
only sign(l˜) otherwise (in this case sign(l˜) = sign(u˜)).
Although the Lebesgue measure of the two one-sided confidence intervals is larger
than that of the two-sided confidence interval (the former having infinite Lebesgue
measure), the recommended set constructed from one-sided confidence intervals is
less conservative than that constructed from two-sided confidence intervals, in the
sense that it will contain the true inferior treatment with smaller probability. Indeed,
although they both contain the true better treatment with probability no less than
the given value (see (Hsu, 1996)), the probability of each treatment being included
in the alternative Sˆ2(h2) constructed from a two-sided confidence interval will always
be no smaller than the corresponding probability for the Sˆ2(h2) constructed from
one-sided confidence intervals, since it is easy to show that we always have l˜ < l
and u˜ > u. In other words, the approach that uses one-sided confidence intervals to
construct Sˆ2(h2) has greater power, and that is the approach we take in this chapter.
As the limiting distribution of
√
n(θˆ2 − θ∗2) is always normal, we can use a one
sided t-test. Specifically, we consider the asymptotic pivot
√
n(hT2,1θˆ2,1 − hT2,1θ∗2,1)/
√
hT2,1Σˆ21,21h2,1 (3.4)
where Σˆ21,21 is the submatrix of (PnB2BT2 )−1PnB2BT2 (Y −BT2 θˆ2,1)2(PnB2BT2 )−1 corre-
sponding to the plug-in estimator of the asymptotic variance of Vn :=
√
n(θˆ2,1−θ∗2,1);
thus
√
hT2,1Σˆ21,21h2,1 is the estimated standard deviation of
√
n(hT2,1θˆ2,1 − hT2,1θ∗2,1).
Note that (3.4) asymptotically follows the standard normal distribution. Let z1−α be
the 1−α quantile of a standard normal distribution. Then we have two (1−α)-level
one-sided confidence interval for hT2,1θ
∗
2,1: (−∞, hT2,1θˆ2,1 + z1−α
√
hT2,1Σˆ21,21h2,1/
√
n)
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and (hT2,1θˆ2,1 − z1−α
√
hT2,1Σˆ21,21h2,1/
√
n,+∞). We construct Sˆ2 as follows: we in-
clude 1 in Sˆ2 if h
T
2,1θˆ2,1 > −z1−α
√
hT2,1Σˆ21,21h2,1/
√
n, and we include −1 in Sˆ2 if
hT2,1θˆ2,1 < z1−α
√
hT2,1Σˆ21,21h2,1/
√
n.
Note that Sˆ2(h2) contains both treatments if and only if
√
n|hT2,1θˆ2,1|/
√
hT2,1Σˆ21,21h2,1 ≤ z1−α.
Alternatively if we define T (h2,1,
√
nθˆ2,1, Σˆ21,21) = n(h
T
2,1θˆ2,1)
2/hT2,1Σˆ21,21h2,1 and
χ = χ(α) = z21−α, we see that Sˆ2(h2) contains only one treatment if and only if
T (h2,1,
√
nθˆ2,1, Σˆ21,21) > χ; it contains both treatments if and only if T ≤ χ. This is
useful for the decomposition of
√
ncT (θˆ1 − θˆ∗1).
Next we consider stage 1. To define the Q-function for this stage, let s2(·) be a
deterministic function that maps the domain of H2 to Power(A2). Define
Q1(h1, a1; s2) := E
[
min
a2∈s2(H2)
Q2(H2, a2)
∣∣∣H1 = h1, A1 = a1] (3.5)
Its parametric form can be defined by
Q1(H1, A1; θ1(s2), s2) := H
T
1,0θ1,0(s2) +H
T
1,1θ1,1(s2)A1 (3.6)
where θ1(s2) := (θ1,0(s2)
T , θ1,1(s2)
T )T .
We also define the predicted outcome
Yˆ ∗(s2) := min
a2∈s2
Q2(H2, a2; θ
∗
2) (3.7)
Finally, for any second stage treatment regime Sˆ2, we define our estimand
θˆ∗1 = θˆ
∗
1(Sˆ2) :=
{
arg min
θ1(s2)
P (Yˆ (s2)−Q1(H1, A1; θ1(s2), s2))2
} |
s2=Sˆ2
(3.8)
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where θ∗1(Sˆ2) := (θ
∗
1,0(Sˆ2)
T , θ∗1,1(Sˆ2)
T )T .
Remark III.1. In (3.7), Yˆ ∗ can be interpreted as the expected true final outcome for
a patient if he or she had taken the true worse treatment in s2 at the second stage.
Remark III.2. We can see in (3.8) that the estimand, θˆ∗1(Sˆ2) depends on Sˆ2, which is
a random quantity. This follows the idea of Robins et al. (2014). We need to consider
the case where patients choose the true worse treatment in the recommended set (if
the set contains more than one treatment), so we need to consider the randomness of
the recommended set. For notational convenience, we will denote θˆ∗1(Sˆ2) by θˆ
∗
1.
Remark III.3. We can interpret θˆ∗1 as the true first-stage regression coefficient if the
second-stage recommended set is Sˆ2. At stage 1 for a patient with H1 = h1, under
the assumption that the second-stage recommended set is Sˆ2, the patient’s expected
final outcome is hT1,0θˆ
∗
1,0 + h
T
1.1θˆ
∗
1,1A1. Thus we are interested in h
T
1,1θˆ
∗
1,1, which is half
the difference between the effects of the treatments A1 = 1 and A1 = −1.
Remark III.4. In stage 1 we construct two one-sided confidence intervals for hT1,1θˆ
∗
1,1
similarly to how we constructed, in stage 2, the confidence intervals for hT2,1θ
∗
2,1. The
estimator is defined as
θˆ1 := arg min
θ1
Pn(Y˜s − (HT1,0θ1,0 +HT1,1θ1,1A1))2
where Y˜s = mina2∈Sˆ2(H2) Q2(H2, a2; θˆ2), which is the estimator of
Yˆ ∗ =mina2∈Sˆ2(H2) Q2(H2, a2; θ
∗
2). The difficulty is that
√
nhT1,1(θˆ1,1 − θˆ∗1,1) might not
always converge to a normal distribution and might have different limiting distribu-
tion from its bootstrap analog
√
nhT1,1(θˆ
(b)
1,1 − θˆ1,1). Thus our confidence interval for
√
nhT1,1(θˆ1,1− θˆ∗1,1) from quantiles of
√
nhT1,1(θˆ
(b)
1,1− θˆ1,1) will have poor coverage in some
scenario. (Details of how this naive bootstrap method is carried out can be found at
the beginning of section 3.4, the simulation study).
An example of the poor coverage of the naive bootstrap approach can be seen in
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the simulation model discussed in Laber et al. (2010), Working under a generative
model, we can show that if the significance level is set at 95%—i.e., we want to
include the true better first-stage treatment in the first-stage recommended set with
probability no less than 95%—then the recommended set constructed from the naive
bootstrap method will include the true better treatment with probability around
only 87%. To deal with this problem, we use the notion of Adaptive Confidence
Interval (ACI), introduced by Laber et al. (2010), to construct a confidence interval
for
√
nhT1,1(θˆ1,1 − θˆ∗1,1). The downside to this procedure, as will be shown in section
3.5, is that the recommended set constructed by our method is conservative, in the
sense that it sometimes contains the true better treatment with probability larger
than the specified value. The procedure and properties of ACI will be provided in
the next section.
To summarize, our algorithm is as follows:
1. Calculate the second-stage regression: θˆ2 := arg minθ2 Pn(Y2 −Q2(H2, A2; θ2))2.
1.1 Construct the second-stage confidence set: Sˆ2(H2) = {−1, 1} if we can reject
neither that A2 = 1 is better than A2 = −1 nor that A2 = −1 is better than A2 = 1
, and Sˆ2(H2) = {sign(HT2,1θˆ2)} otherwise.
2. Predict the second-stage outcome: Y˜s = Y1 + mina2∈Sˆ2(H2) Q2(H2, a2; θˆ2).
3. Calculate the first-stage regression: θˆ1 := arg minθ1 Pn(Y˜s −Q1(H1, A1; θ1))2.
3.1 Constructing stage 1 confidence set: Sˆ1(H1) = {−1, 1} if we can reject neither
that A1 = 1 is better than A1 = −1 nor that A1 = −1 is better than A1 = 1 , and
Sˆ1(H1) = {sign(HT1,1θˆ1)} otherwise.
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3.3 Role of the ACI in the construction of the recommended
set
In this section we focus on the ACI in order to describe in greater detail how
to construct the recommended set of treatments. We continue to consider the case
where there are two stages and, at each stage, there are two available treatments,
denoted as -1 and 1.
Recall that at stage 2, for a patient with H2 = h2 = (h
T
2,0, h
T
2,1)
T , the true effect
of treatment A2 = 1 is h
T
2,0θ
∗
2,0 + h
T
2,1θ
∗
2,1, while the true effect of treatment A2 = −1
is hT2,0θ
∗
2,0 − hT2,1θ∗2,1. We are interested in the quantity hT2,1θ∗2,1, which is half of the
difference between effects of treatments 1 and −1. If we define c = (0T , hT2,1)T , where
0T is a zero vector with the same length as hT2,0, then we can write h
T
2,1θ
∗
2,1 = c
T θ∗2. If
we cannot reject cT θ∗2 ≥ 0, we include 1 in the recommended set; if we cannot reject
cT θ∗2 ≤ 0, we include −1 in the recommended set. Details of this hypothesis testing
were introduced in section 3.2.
All the difficulty lies in the construction of the first-stage confidence interval. For
a patient with H1 = h1, we would like to construct two one-sided confidence intervals
for hT1,1θˆ
∗
1,1 = c
T θˆ∗1, which is half the difference between the effects of A1 = 1 and
A1 = −1, where c = (0T , hT1,1)T . We want to construct confidence intervals based
on cT θˆ1. however, as we will see below,
√
n(θˆ
(b)
1 − θˆ1) and
√
n(θˆ1 − θˆ∗1) might have
different limiting distributions. Therefore, this naive bootstrap method will perform
poorly, as the simulation study in section 3.4 will show.
For t = 1, 2, we define Bt := (H
T
t,0, AtH
T
t,1)
T ,Σt,∞ := PBtBTt and Σˆt := PnBtBTt .
We assume Σˆt is invertible. Using standard methods it can be shown that Vn :=
√
n(θˆ2− θ∗2) is asymptotically normal with mean zero and variance-covariance matrix
Ω = (PB2B
T
2 )
−1PB2BT2 (Y −BT2 θ∗2)2(PB2BT2 )−1.
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Let Σ21,21 denote the submatrix of Ω corresponding the limiting asymptotic covariance
of
√
n(θˆ2,1 − θ∗2,1) and let Σˆ21,21 be the corresponding plug-in estimator. Then θˆ1 =
Σˆ−11 PnB1Y˜s. We can decompose
√
n(θˆ1 − θˆ∗1) as
Sn + Σˆ−11 PnB1(Un +On) (3.9)
where
Sn = Σˆ−11
√
nPnB1[Y1 +HT2,0θ∗2,0 − |HT2,1θ∗2,1|1(T (H2,1,
√
nθˆ2,1, Σˆ21,21) ≤ χ)
+HT2,1θ
∗
2,1sign(H
T
2,1θˆ2,1)1(T (H2,1,
√
nθˆ2,1, Σˆ21,21) > χ)
−BT1 θˆ∗1 +HT2,0(θˆ2,0 − θ∗2,0)] (3.10)
Un =
√
n(|HT2,1θˆ2,1| − |HT2,1θ∗2,1|)(21(T (H2,1,
√
nθˆ2,1, Σˆ21,21) > χ)− 1) (3.11)
On =
√
n(|HT2,1θ∗2,1| −HT2,1θ∗2,1sign(HT2,1θˆ2,1))1(T (H2,1,
√
nθˆ2,1, Σˆ21,21) > χ) (3.12)
with 1(X) equals to 1 if X holds and 0 otherwise.
The term Sn is asymptotically normal, but Un is non-smooth in θˆ2,1. Therefore,
following the idea of Laber et al. (2010), we divide the data into two parts: those for
which we can not distinguish the two second-stage effects, and those for which we
can. For the second group, we just perform the usual bootstrap, while for the first
group, we let θ∗2,1 vary in its domain and take the supremum (or infimum) to be the
upper (resp. lower) bound.
The term On is asymptotically zero but only if P is fixed; under some local
alternative Pn it might not converge to zero. So we do the similar trick to On as well.
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To be specific, the upper bound on cT
√
n(θˆ1 − θˆ∗1) is given by
U(c)
= cTSn + cT Σˆ−11 PnB1
√
n(|HT2,1θˆ2,1| − |HT2,1θ∗2,1|)1(T (H2,1,
√
nθˆ2,1, Σˆ21,21) > λn)
+cT Σˆ−11 PnB1
√
n(|HT2,1θ∗2,1| −HT2,1θ∗2,1sign(HT2,1θˆ2,1))1(T (H2,1,
√
nθˆ2,1, Σˆ21,21) > λn)
+ sup
γ∈Rdim(θ
∗
2,1)
{
cT Σˆ−11 PnB1
[
(|HT2,1(Vn + γ)− |HT2,1γ|)×
(21(T (H2,1,Vn + γ, Σˆ21,21) > χ)− 1)
+(|HT2,1γ| −HT2,1γsign(HT2,1(Vn + γ))1(T (H2,1,Vn + γ, Σˆ21,21) > χ)
]
×1(T (H2,1,
√
nθˆ2,1, Σˆ21,21) ≤ λn)
}
(3.13)
where λn is a sequence of deterministic numbers satisfying limn→∞ λn = +∞ and
limn→∞ λn/n = 0. If the sample size n is so small that λn < χ, we force λn = χ.
The lower bound L(c) is defined in a similar way, with “sup” replaced by “inf”.
To see where U(c) comes from, notice that Σˆ−11 PnB1(Un + On), the second term
in (3.9), is equal to
Σˆ−11 PnB1
[√
n(|HT2,1θˆ2,1| − |HT2,1θ∗2,1|)(21(T (H2,1,
√
nθˆ2,1, Σˆ21,21) > χ)− 1)
+
√
n(|HT2,1θ∗2,1| −HT2,1θ∗2,1sign(HT2,1θˆ2,1))1(T (H2,1,
√
nθˆ2,1, Σˆ21,21) > χ)
]
×1(T (H2,1,
√
nθˆ2,1, Σˆ21,21) > λn) +
Σˆ−11 PnB1
[√
n(|HT2,1θˆ2,1| − |HT2,1θ∗2,1|)(21(T (H2,1,
√
nθˆ2,1, Σˆ21,21) > χ)− 1)
+
√
n(|HT2,1θ∗2,1| −HT2,1θ∗2,1sign(HT2,1θˆ2,1))1(T (H2,1,
√
nθˆ2,1, Σˆ21,21) > χ)
]
×1(T (H2,1,
√
nθˆ2,1, Σˆ21,21) ≤ λn)
In the first of the two terms, if 1(T (H2,1,
√
nθˆ2,1, Σˆ21,21) > λn) = 1 we must have
that 1(T (H2,1,
√
nθˆ2,1, Σˆ21,21) > χ) = 1 since λn ≥ χ. Therefore, the above term can
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be simplified to
Σˆ−11 PnB1
[√
n(|HT2,1θˆ2,1| − |HT2,1θ∗2,1|) +
√
n(|HT2,1θ∗2,1| −HT2,1θ∗2,1sign(HT2,1θˆ2,1))
]
×1(T (H2,1,
√
nθˆ2,1, Σˆ21,21) > λn) +
Σˆ−11 PnB1
[√
n(|HT2,1θˆ2,1| − |HT2,1θ∗2,1|)(21(T (H2,1,
√
nθˆ2,1, Σˆ21,21) > χ)− 1)
+
√
n(|HT2,1θ∗2,1| −HT2,1θ∗2,1sign(HT2,1θˆ2,1))1(T (H2,1,
√
nθˆ2,1, Σˆ21,21) > χ)
]
×1(T (H2,1,
√
nθˆ2,1, Σˆ21,21) ≤ λn)
= Σˆ−11 PnB1
[√
n(|HT2,1θˆ2,1| − |HT2,1θ∗2,1|) +
√
n(|HT2,1θ∗2,1| −HT2,1θ∗2,1sign(HT2,1θˆ2,1))
]
×1(T (H2,1,
√
nθˆ2,1, Σˆ21,21) > λn) +
Σˆ−11 PnB1
[
(|HT2,1(Vn +
√
nθ∗2,1)| − |HT2,1
√
nθ∗2,1|)×
(21(T (H2,1,Vn +
√
nθ∗2,1, Σˆ21,21) > χ)− 1)
+(|HT2,1
√
nθ∗2,1| −HT2,1
√
nθ∗2,1sign(H
T
2,1(Vn +
√
nθ∗2,1)))×
1(T (H2,1,Vn +
√
nθ∗2,1, Σˆ21,21) > χ)
]
×1(T (H2,1,
√
nθˆ2,1, Σˆ21,21) ≤ λn)
Notice that in the second term we have re-expressed
√
nHT2,1θˆ2,1 as the sum of
HT2,1Vn = HT2,1
√
n(θˆ2,1 − θ∗2,1) and HT2,1
√
nθ∗2,1. The quantity H
T
2,1
√
nθ∗2,1 characterizes
the degree of non-regularity of HT2,1
√
n(θˆ1 − θˆ∗1). One way to make the second term
insensitive to local perturbation of θ∗2,1 is to replace
√
nθ∗2,1 with γ and take the
supremum over all γ ∈ Rdim(θ∗2,1). (After making this replacement and taking the
supremum, we have the form of U(c) in (3.13).) Doing this would give a regular
upper bound. The reason we do not apply this trick to the first term is that those
H2,1 with 1(T (H2,1,
√
nθˆ2,1, Σˆ21,21) > λn) = 1 are highly likely to be regular: non-
regularity occurs only when HT2,1θ
∗
2,1 is close to zero, which is unlikely the case when
we have 1(T (H2,1,
√
nθˆ2,1, Σˆ21,21) > λn) = 1, i.e., H
T
2,1θˆ2,1 has very large absolute
value.
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We remark that we use the function T both for estimation of θˆ∗1 (those with
comparison between T and χ) and for separation of data (those with comparison
between T and λn). For the former the second input of T is also allowed to vary as a
function of γ since in this situation T is a part of θˆ2,1 while for the latter we just use
√
nθˆ2,1 as the second input of T .
Before we formulate our result, we define
g2(B2, Y ; θ
∗
2) := B2(Y −BT2 θ∗2).
g1(B1, H2; θ
∗
1, θ
∗
2, θˆ2, Σˆ21,21) := B1
[
HT2,0θ
∗
2,0 − |HT2,1θ∗2,1|1(T (H2,1,
√
nθˆ2,1, Σˆ21,21) ≤ χ)
+HT2,1θ
∗
2,1sign(H
T
2,1θˆ2,1)|1(T (H2,1,
√
nθˆ2,1, Σˆ21,21) > χ)
−BT1 θˆ∗1
]
Assume the following:
(A1) The histories H2, features B1 and outcomes Y , satisfy the moment inequalities
P ||H2||2||B1||2 <∞ and PY 2||B2||2 <∞.
(A2) The matrices Σt,∞ and Cov(g1, g2) are strictly positive definite.
(A3) For any s ∈ Rdim(θ∗2,1), there exists a sequence of local alternatives Pn such that
(i) the Pn converge to P in the sense that
∫
[
√
n(dP 1/2n − dP 1/2)−
1
2
vsdP
1/2]2 → 0
for some real-valued measurable function vs,
(ii) if θ∗2,n := arg minθ Pn(Y − Q2(H2, A2; θ)2, then θ∗2,1,n := θ∗2,1 + s/
√
n + o(1/
√
n),
and
(iii) Pn||H2||2||B1||2 and PnY 22 ||B2||2 are bounded sequences.
(A4) limn→∞ λn = +∞ and limn→∞ λn/n = 0.
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Define
Yˆ ∗1,n := Y1 +H
T
2,0θ
∗
2,0,n − |HT2,1θ∗2,1,n|1(T (H2,1,
√
nθˆ2,1, Σˆ21,21) ≤ χ)
+HT2,1θ
∗
2,1,nsign(H
T
2,1θˆ2,1)|1(T (H2,1,
√
nθˆ2,1, Σˆ21,21) > χ)
θˆ∗1,n := arg min
θ
Pn(Yˆ
∗
1,n −Q1(H1, A1; θ))2. (3.14)
Because in our proof we are using indicator functions, which are discontinuous at
certain points, we make the mild assumption that P is absolutely continuous with
respect to the Lebesgue measure m, i.e., we assume P (A) = 0 for all A with m(A) = 0.
We call this the absolute continuity assumption. This assumption will be useful for
the proof.
Now we show the limiting behavior. We define Σ21,21,∞ to be the limit of Σˆ21,21.
Theorem III.5.
1.
cT
√
n(θˆ1 − θˆ∗1) d−→
cTS∞ + P (cTΣ−11,∞B1HT2,1V11HT2,1θ∗2,1>0)− P (cTΣ−11,∞B1HT2,1V11HT2,1θ∗2,1<0)
+cTΣ−11,∞PB1|HT2,1V1|(21(T (H2,1,V1,Σ21,21,∞) > χ)− 1)1HT2,1θ∗2,1=0
2. If, for each n, the underlying generative distribution is Pn which satisfying (A3),
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then
cT
√
n(θˆ1 − θˆ∗1,n) d−→
cTS∞ + cTΣ−11,∞P (B1HT2,1V11HT2,1θ∗2,1>0)− cTΣ−11,∞P (B1HT2,1V11HT2,1θ∗2,1<0)
+cTΣ−11,∞PB1
[
|HT2,1(V1 + s)| − |HT2,1s|
]
×
(21(T (H2,1,V1 + s,Σ21,21,∞) > χ)− 1)1HT2,1θ∗2,1=0
−cTΣ−11,∞PB1
[
(HT2,1s · sign(HT2,1(V1 + s))− |HT2,1s|)×
1(T (H2,1,V1 + s,Σ21,21,∞) > χ)
]
1HT2,1θ
∗
2,1=0
3. The limiting distribution of U(c) under both P and Pn is equal to
U(c) d−→
cTS∞ + cTΣ−11,∞P (B1H2,1V11HT2,1θ∗2,1>0)− cTΣ−11,∞P (B1H2,1V11HT2,1θ∗2,1<0) +
sup
γ∈Rdim(θ
∗
2,1)
[
cTΣ−11,∞P (B1(|HT2,1(V1 + γ)| − |HT2,1γ|))
×(21(T (H2,1,V1 + γ,Σ21,21,∞) > χ)− 1)1HT2,1θ∗2,1=0
−cTΣ−11,∞PB1(HT2,1γsign(HT2,1(V1 + γ))− |HT2,1γ|)×
1(χ < T (H2,1,V1 + γ,Σ21,21,∞) ≤ λn)1HT2,1θ∗2,1=0
]
where
S∞ = G∞
[
cTΣ−11,∞B1[Y1 +H
T
2,0θ
∗
2,0 − |HT2,1θ∗2,1|1(T (H2,1,
√
nθˆ2,1, Σˆ21,21) ≤ χ)
+HT2,1θ
∗
2,1sign(H
T
2,1θˆ2,1)1(T (H2,1,
√
nθˆ2,1, Σˆ21,21) > χ)−BT1 θˆ∗1
]
+ cTΣ−11,∞Σ12V0
Here G∞ is a tight Gaussian process in l∞(F2) with covariance function
Cov(G∞f1,G∞f2) = P (f1 − Pf1)(f2 − Pf2), and V∞ = (V0,V1) is the limiting
distribution of
√
n(θˆ2 − θ∗2). Further, χ is the square of z1−α the 1 − α quantile of a
standard normal distribution.
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The limiting distribution of L(c) is similar, with “sup” replaced by “inf”.
Note that the limiting distributions of cT
√
n(θˆ1− θˆ∗1), U(c), and L(c) are the same
in the case where HT2,1θ
∗
2,1 6= 0 with probability one. That is, when there is a large
treatment effect for almost all patients then the upper (or lower) bound is tight.
However, when there is a non-null subset of patients for whom there is no treatment
effect, then the limiting distribution of the upper bound is stochastically larger than
that of the limiting distribution of cT
√
n(θˆ1− θˆ∗1). Thus, the ACI adapts to the setting
in which all patients experience a treatment effect.
To form confidence intervals for cT
√
n(θˆ1 − θˆ∗1), the bootstrap distributions of
U(c) and L(c) are used. The next result concerns the consistency of these bootstrap
distributions. Let Pˆ(b)n denote the empirical measure, that is, Pˆ(b)n := n−1
∑n
i=1 Mn,iδTi
for
(Mn,1, . . . ,Mn,n) ∼ Multinomial(n, (1/n, . . . , 1/n)).
We use the superscript (b) to signify that a functional has been replaced by its
bootstrap analog, so that if ω := f(Pn) then ω(b) := f(Pˆ(b)n ). Denote the space
of bounded Lipschitz-1 functions on R2 by BL1(R2). Furthermore, let EM and
PM denote the expectation and probability with respect to the bootstrap weights.
The proofs of the following results appear after the proof of the limit results for
cT
√
n(θˆ1 − θˆ∗1) and U(c) :
Theorem III.6. Assume (A1)-(A2), and fix c ∈ Rdim(θ∗1). Then U(c) and U (b)(c)
converge to the same limiting distribution in probability. That is,
sup
v∈BL1(R2)
|EvU(c)− EMvU (b)(c)|
converges in probability to zero.
Corollary III.7. Assume (A1) (A2), fix c ∈ Rdim(θˆ∗1), and let uˆ and lˆ denote the
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1− α lower and upper quantile of U (b)(c). Then
PM(c
T θˆ1 − uˆ/
√
n ≤ cT θˆ∗1) ≥ 1− α + oP (1)
PM(c
T θˆ1 − lˆ/
√
n ≥ cT θˆ∗1) ≥ 1− α + oP (1)
Furthermore, if P (HT2,1θ
∗
2,1 = 0) = 0, then the above inequality can be strengthened to
an equality.
3.4 Simulation study
In this section we examine the small sample performance of the ACI method.
We will compare the result with that from the naive bootstrap method, called the
centered percentile bootstrap.
The naive bootstrap method, instead of getting bootstrap samples of U(c) defined
in (3.13) to obtain U(c)(b) in the paragraph above theorem III.6, bootstraps cT√n(θˆ1−
θˆ∗1) directly to obtain c
T
√
n(θˆ
(b)
1 − θˆ1). Specifically, naive bootstrap method uses uˆnaive
and lˆnaive, the 1−α lower and upper quantiles of cT
√
n(θˆ
(b)
1 − θˆ1) to construct two one-
sided confidence interval for cT θˆ∗1: (c
T θˆ1−uˆnaive/
√
n,+∞) and (−∞, cT θˆ1−lˆnaive/
√
n).
In our simulation for the ACI method, we let λn = log(n). (Recall that λn is
the critical value to determine whether we can distinguish the better second-stage
treatment. More details can be found in the construction of U(c) in section 3.3.)
We use the same set of generative models as in Laber et al. (2010). The setting
can be described as follows:
• Xt ∈ {−1, 1}, At ∈ {−1, 1} for t ∈ {1, 2}
• P (At = 1) = P (At = −1) = 0.5 for t ∈ {1, 2}
• X1 ∼ Bernoulli(0.5), X2|X1, A1 ∼ Bernoulli(expit(δ1X1 + δ2A1))
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• Y = γ1 + γ2X1 + γ3A1 + γ4X1A1 + γ5A2 + γ6X2A2 + γ7A1A2 + ,  ∼ N(0, 1)
Here expit(x) = exp(x)/(1 + exp(x)). This class is parametrized by nine values,
γ1, . . . , γ7, δ1, δ2. The analysis model uses feature vectors defined by
H2,0 = (1, X1, A1, X1A1, X2)
T ,
H2,1 = (1, X2, A1)
T .
H1,0 = H1,1 = (1, X1)
T
Recall that our models are
Q2(H2, A2; θ2) = H
T
2,0θ2,0 +H
T
2,1θ2,1A2
Q1(H1, A1; θ1) = H
T
1,0θ1,0 +H
T
1,1θ1,1A1
For both simulations, we use n = 300 samples. The number of bootstrap iteration is
taken to be B = 1000. The significance level is set at 0.05. i.e., we want to include
the better first-stage treatment with probability at least 95%.
Recall that in Q-learning, non-regularity occurs when two or more second stage
treatments have almost the same expected final outcome. In our model class above,
this occurs if the model generates histories for which γ5A2+γ6X2A2+γ7A1A2 ≈ 0. By
manipulating the values of γi and δi, we can control (i) the probability of generating
a patient history such that γ5A2 + γ6X2A2 + γ7A1A2 = 0, (ii) the standardized effect
size φ = E(γ5A2 + γ6X2A2 + γ7A1A2)/
√
V ar(γ5A2 + γ6X2A2 + γ7A1A2) and (iii) the
difference between the effects of A1 = 1 and A1 = −1. Note that (iii) is usually
not a fixed quantity: recall that our definition of the effect of a first-stage treatment
depends on the second-stage recommended set, which itself depends on the samples.
For each generative model, we list the simulated difference between the effects of
A1 = 1 and A1 = −1. The descriptions of the models are listed in table 3.1.
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Table 3.1: Description of the simulation models using ACI
Index γ δ p φ 2H1,1θˆ
∗
1,1
One (0, 0, 0, 0, 0, 0, 0)T (0.5, 0.5)T 1 0/0 0
Two (0, 0, 0, 0, 0.01, 0, 0)T (0.5, 0.5)T 0 ∞ [−0.02, 0.02]
Three (0, 0,−0.5, 0, 0.5, 0, 0.5)T (0.5, 0.5)T 1/2 1.0 0
Four (0, 0,−0.5, 0, 0.5, 0, 0.49)T (0.5, 0.5)T 0 1.02 [−0.02, 0]
Five (0, 0,−0.5, 0, 1, 0.5, 0.5)T (0, 0)T 1/4 1.41 0
Six (0, 0,−0.505, 0, 1, 0.49, 0.5)T (0, 0)T 0 1.43 [−0.01, 0]
Seven (0, 0,−0.495, 0, 1, 0.5, 0.49)T (0, 0)T 0 1.43 [−0.01, 0]
We compare the empirical performance of the ACI with the centered percentile
bootstrap, the naive bootstrap method discussed before. Our primary interest is the
probability of including the true better first-stage treatment in the recommended set.
If the two first-stage treatments have the same effect, we consider the minimum of
the two probabilities of including each of them. Recall that 2H1,1θˆ
∗
1,1 is the difference
between the effect of A1 = 1 and the effect of A1 = −1.
Also, we want to compare the width of the confidence intervals from two methods.
Since we are constructing one-sided confidence intervals, we must make clear what
we mean by the width of a one-sided confidence interval: this is defined to be the
distance between the upper (or lower) bound and the point estimator. Recall that we
are constructing upper and lower 1− α confidence intervals for half of the difference
between the effects of A1 = 1 and A1 = −1, and the two one-sided confidence
intervals have the forms (−∞, u) and (l,+∞). We use the subscripts of ACI and
BCI to indicate the corresponding u and l from ACI method and centered bootstrap
method. We denote the common point estimator of this difference by θˆ. Then we are
interested in the comparison between uACI − θˆ and uBCI − θˆ, as well as that between
θˆ− lACI and θˆ− lBCI . We are also interested in r the average ratio of the length of the
confidence interval coming from the ACI method to the corresponding quantity for
the centered bootstrap method: r = E(uACI − lACI)/(uBCI − lBCI). The results are
listed in table 3.2. More simulations can be found in the supplementary materials.
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Table 3.2: Simulation results of the ACI
Index PACI PBCI l1,ACI l1,BCI l2,ACI l2,BCI r
1 0.9760 0.9230∗ 0.2385 0.1748 0.2366 0.1716 1.3719
2 0.9905 0.9455 0.2386 0.1746 0.2369 0.1723 1.3707
3 0.9460 0.8820∗ 0.2190 0.1965 0.1895 0.1475 1.1906
4 0.9560 0.8880∗ 0.2188 0.1955 0.1896 0.1476 1.1903
5 0.9400 0.9110∗ 0.2019 0.1904 0.1892 0.1674 1.0930
6 0.9440 0.9120∗ 0.2023 0.1885 0.1909 0.1667 1.0929
7 0.9440 0.9110∗ 0.2028 0.1890 0.1914 0.1672 1.0927
P=Probability of choosing the true better first stage treatment.
∗: Significantly smaller than 0.95 at 0.05 level.
l1,ACI=E(uACI − θˆ), l2,ACI=E(θˆ − lACI)
l1,BCI=E(uBCI − θˆ), l2,BCI=E(θˆ − lBCI)
r = E(uACI − lACI)/(uBCI − lBCI)
We can see that, in all seven settings, the first-stage recommended sets from
ACI method satisfy the goal: the true better first stage treatment is included with
probability no smaller than 95%. By contrast, the naive bootstrap method fails in
several settings especially in setting 3. This is the case where for patients who start
with A1 = 1, one second-stage treatment has much better effect than the other, so
no non-regularity occurs. For patients who start with A1 = −1, the two second-stage
treatments have the same effect, so the second-stage recommended set will include
both treatments with high probability; therefore, the method tends to underestimate
the final expected outcome Y that a patient take the worse of the two treatments
(their effects are the same so they are both the worse one). Thus naive bootstrap
method underestimates the effect of A1 = −1 and consequently includes it with small
probability.
3.5 Analysis of the ADHD study
In this section we will illustrate our method by applying it to the data from the
ADHD study by Pelham et al. For more information on this study, please refer to
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Nahum-Shani et al. (2012b).
Attention-Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental psy-
chiatric disorder treated mostly through counseling, lifestyle choices, and medication.
Here we consider two particular approaches to treating ADHD at the first stage:
(i) offering low-intensity behavioral intervention, and (ii) giving low-dosage medica-
tion. Our primary goal is to test the effectiveness of each of the two approaches as a
first-stage treatment.
The design of the study is as follows. At the beginning of the study, half of the
children were randomly assigned (with probability 0.5) to low-intensity behavioral in-
tervention (coded as A1 = 1) or low-dosage medication (coded as A1 = −1). Starting
at the eighth week, each child’s response to the first-stage intervention was evaluated
monthly until the end of the school year. A monthly rating from the Impairment
Rating Scale (IRS) was used, along with an individualized list of target behaviors
(ITB), to determine whether a child was a responder. A child was defined to be
a non-responder if his/her average performance on the ITB was less than 75% and
he/she was rated by teachers as impaired on the IRS in at least one domain. If the
child was classified as a responder, he/she would remain in the first stage treatment
and continue the assigned treatment. If the child was a non-responder, he/she would
enter the second stage. Each of these children was re-randomized (with probabil-
ity 0.5) to either augmenting the first-stage treatment option with the other type of
treatment (i.e., adding medication if started with behavior intervention, and adding
behavior intervention if started with medication, coded as A2 = 1), or continuing the
same treatment but with increasing dose/intensity (coded as A2 = −1). The graph
of the structure of this study is shown in figure 3.1.
The first step in using Q-learning is to estimate a regression model for the second
stage. In this study, only non-responders have second stage treatment options. Two
tailoring variables are used here: one is the first-stage treatment A1, and the other
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Figure 3.1: The design of the ADHD study.
Table 3.3: Descriptions of variables in ADHD
Covariate Description
X1,1 Medication prior to the first stage treatment.
Binary: 1 for received and 0 for not received.
X1,2 ADHD symptoms at the end of the previous school year. Continuous.
X1,3 ODD. Binary: 1 for had ODD before and 0 otherwise.
X2,1 The month during the school year at which the child showed
inadequate response to the first stage treatment. Continuous.
X2,2 Adherence. Binary: 1 for adherence and 0 otherwise.
ODD=Oppositional Defiant Disorder.
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Table 3.4: Second-stage results for ADHD
A1 X2,2 CI1 CI2 Sˆ2
1 0 (−∞,−0.2282) (−0.9783,+∞) {-1}
1 1 (−∞, 0.7041) (−0.0427,+∞) {1,-1}
-1 0 (−∞,−0.1909) (−1.2138,+∞) {-1}
-1 1 (−∞, 0.6624) (−0.1992,+∞) {1,-1}
is the adherence to the first-stage treatment. The adherence is binary and can take
either values 1 (for high adherence) or the value 0 (for low adherence). The meaning
of low adherence depends on the type of treatment the child is started on: it means
the treatment is received on fewer than 75% (respectively, 100%) of the days in the
case of behavioral intervention (respectively, medication). The feature vectors we
use for the second stage are H2,0 = (1, X1,1, X1,2, X1,3, A1, A1X1,1, X2,1, X2,2)
T and
H2,1 = (1, A1, X2,2)
T . The descriptions of the variables are given in table 3.3.
There are only four possible values for H2,1. For each, we construct the upper
and lower 95% one-sided confidence intervals of HT2,1θ
∗
2,1 (i.e., half of the difference
between the effects of A2 = 1 and A2 = −1). The results are listed in table 3.4.
Recall that for each hT2,1θ
∗
2,1 we construct two one-sided confidence intervals with
forms (−∞, u) and (l,+∞). We include A2 = 1 in the second-stage recommended
set Sˆ2 if u ≥ 0 (i.e., we fail to reject the hypothesis that the difference between the
effect of A2 = 1 and that of A2 = −1 is positive, meaning that we fail to reject that
A2 = 1 is better than A2 = −1). Similarly we include A2 = −1 in the second-stage
recommended set Sˆ2 if l ≤ 0.
We can see from table 3.4 that for children started with either of the first-stage
treatments, if he/she adhered to it, we cannot distinguish the two second-stage treat-
ments at the 95% confidence level; meanwhile for children started with either first
stage treatment, if he/she didn’t adhere to it an intensified first-stage treatment would
be significantly better than adding the other first-stage treatment.
Our results are the same as those in Nahum-Shani et al. (2012b), in the sense of
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Table 3.5: First-stage result for AHDH
X1,1 CI1 CI2 BCI1 BCI2 Sˆ1
1 (−∞, 0.2090) (−0.7275,+∞) (−∞, 0.0662) (−0.6477,+∞) {1,-1}
0 (−∞, 0.3799) (−0.2387,+∞) (−∞, 0.3057) (−0.1591,+∞) {1,-1}
whether we can distinguish the two second-stage treatments for a given H2,1. But
the picture changes if we set the confidence level at 90% instead of 95%. In this
case, for children who were started with behavioral intervention and adhered to it,
our method shows that adding the other first-stage treatment is significantly better
than intensification. By contrast, we found that the method used in Nahum-Shani
et al. (2012b) is unable to distinguish these two second-stage options even at the
90% confidence level. The advantage in our method comes mainly from the use of
one-sided confidence intervals instead of a two-sided confidence interval.
The second step in using the Q-learning is to construct the first-stage recom-
mended set. At this stage we are interested in whether having a medication before
entering the study will effect the recommended set. The feature vectors used here are
H1,0 = (1, X1,1, X1,2, X1,3)
T and H1,1 = (1, X1,1)
T . The results are listed in table 3.5.
In this table, CI means confidence interval from our method, while BCI means
confidence interval from naive bootstrap method.
We can see that the confidence intervals from both methods inform no significant
difference between the two first-stage treatments. This conclusion is the same as that
in Nahum-Shani et al. (2012b). However, note that the “width” (i.e., the distance
between the bound and the point estimator) of the confidence intervals from our
method is larger than that from naive bootstrap method.
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3.6 Conclusion and future work
In this chapter we discussed the non-regularity problem that occurs in the pa-
rameter estimation and one way of solving it. We demonstrated that the Adaptive
Confidence Interval (ACI) method can handle the cases where non-regularities occur.
However, as mentioned by Laber et al. (2010), the confidence interval of the first-
stage-parameters estimation is conservative and therefore leads to the conservation of
the recommended set. That is, when the effects of two first-stage treatments are the
same, the probability of them being included in the recommended set is larger than
the value we set. This is a natural result of the construction of the upper and lower
bounds of the confidence intervals of the first-stage parameters. We can use a data
dependent critical value for λn instead of always setting it to be log(n). We can also
adopt the m-out-of-n bootstrap idea of Chakraborty et al. (2013) to decide the value
of λn according to the data.
All sections in this chapter but the last one consider the scenario where there
are two stages and two treatments at each stage. There are two directions in which
to extend this scenario. One is to consider the case where there are three or more
stages, possibly following the idea in Laber et al. (2010). The other direction is to
consider the case where there are more than two available treatments at each stage.
Suppose at stage t we have patient’s history Ht and Nt available treatments, coded
as {1, . . . , Nt}. Our Q-function at each stage can be written as
Qt(Ht, At; θt) :=
Nt∑
i=1
HTt θt,i1(At = i) (3.15)
So for a patient with Ht = ht, the treatment effects are θ = (θ1, · · · , θNt) where
θi = h
T
t θt,i. Following the idea of Hsu (1996), for each treatment i, we are interested
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in the (Nt − 1)-dimensional difference vector
δ(i) = (
θi − θ1
σi,1
, · · · , θi − θi−1
σi,i−1
,
θi − θi+1
σi,i+1
, · · · , θi − θNt
σi,Nt
) (3.16)
where σi,j is the variance of θˆi − θˆj, the point estimator for the true difference in
treatment effects between treatments i and j. The ith treatment is the best if and
only if all the components of δ(i) are non-negative. So we need to form a simultaneous
confidence interval for each component of δ(i).
In practice, we seldom know σi,j, and we have to use an estimator σˆi,j for it. The
challenge is that at the first stage, the point estimator θˆi is a non-smooth function of
the data, so σˆi,j needs to be carefully designed.
3.7 Three treatment per stage case
3.7.1 Introduction
In practice, we often face the situation when there are more than two treatments at
each stage. The reason and idea of constructing the recommended sets for each stage
are the same as what have been discussed in the earlier sections. The key difference
from the two-treatments-per-stage and hence the hard point, as will be discussed in
detail in the following sub-sections, is that now we are comparing three treatments at
a time as opposed to two. When there are only two treatments at hand, all we need
to do is to construct the confidence interval for the difference of effects between these
two treatments. Now for the situation where there are three, following the MCB idea
we need to construct simultaneous confidence intervals for a two-dimensional vector,
i.e., the differences of the effects between one of the three and the other two. Thus,
how to “distribute” the “length ratio” of the two confidence intervals becomes a big
issue. Again we will discuss it in detail when mentioning this issue.
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3.7.2 Formulation of the problem
We start from the most simple model. Now we have two stages denoted as stage
one and two. For stage one there are three available treatments, and for stage two,
there are also three available treatments (for simplicity we assume no matter what
you take at stage one, the number of available treatments in stage two are the same,
i.e., three.)
Assume that we have patients’ history Ht before we make the tth stage treatment
recommendation and the three available treatments are denoted as 0,1 and 2. Below
are our Q-learning model for stage two and its parametric form:
Q2(H2, A2) := E(U |H2 = h2, A2 = a2) (3.17)
Q2(H2, A2; β2) := H
T
2,0β2,0 +H
T
2,1β2,11(A2 = 1) +H
T
2,2β2,21(A2 = 2) (3.18)
Remark:
1. We denote β2 = (β
T
2,0, β
T
2,1, β
T
2,2)
T .
2. Another choice of parametrization for (3.18) is
Q2(H2, A2; β2) := H
T
2,0β2,01(A2 = 0) +H
T
2,1β2,11(A2 = 1) +H
T
2,2β2,21(A2 = 2)(3.19)
which looks more “symmetric”. But there is a potential problem with this form. In
the form of (3.18), H2,0 can include variables that do not interact with the treatments
but in the form of (3.19) there is no such option. So throughout this section we will
use (3.18).
3. In order to use the expression in (3.18), we need to put some constrain to make it
“invariant” under different coding of the three treatments. To be specific, the general
for of (3.18) is
Q2(H2, A2; β2) := H
T
2,0β2,0 +H
T
2,1β2,1f1(A2) +H
T
2,2β2,2f2(A2) (3.20)
68
where the matrix
VF =

1 f1(0) f2(0)
1 f1(1) f2(1)
1 f1(2) f2(2)

has full rank. We need that for two investigators using two different choices of (f1, f2)
will have the same conclusion (i.e., the estimator of Q2(H2, A2) should be the same
from the two choices for all values of A2, as well as the covariance matrix of this
estimator). A necessary and and sufficient condition for this is given in the following
lemma.
Lemma III.8. Invariance to the coding of the treatments For any fixed dataset satis-
fying: H2,1 is a sub-vector of H2,0 and H2,1 = H2,2, then for any f = (f1, f2) satisfying
that VF defined above is of full rank, from (3.22) and (3.23) we get βˆ2,f and Σˆ2,f . Then
neither
HT2,0βˆ2,0 +H
T
2,1βˆ2,1f1(A2) +H
T
2,2βˆ2,2f2(A2)
nor
(HT2,0, H
T
2,1f1(A2), H
T
2,2f2(A2))
T Σˆ2,f (H
T
2,0, H
T
2,1f1(A2), H
T
2,2f2(A2))
depend on f , for all A2 = 0, 1, 2.
The proof of this lemma can be found in the appendix. So throughout this section
we will assume that H2,1 is a sub-vector of H2,0 and H2,1 = H2,2. And we will use the
coding of (3.18), which means we use f1(A2) = 1(A2 = 1) and f2(A2) = 1(A2 = 2).
4. Although we only consider the case of three treatments per stage, the scenario of
more than three treatments can be dealt with similarly, although as we will see, the
deduction will be more complicated.
We have two goals. First, for a patient at the second stage with H2 = h2, among
three available treatments, we would like to provide a non-empty set of treatments
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that is a subset of {0, 1, 2}, such that the true best second stage treatment will be
included in this subset with probability no less than a pre-specified level, say, 1− α.
Our second goal is that for a patient at the first stage with H1 = h1, among three
available treatments we would like to provide a non-empty set of treatments that is
a subset of {0, 1, 2} such that the true best first stage treatment will be included in
this subset with probability no less than 1 − α. To compare treatments in order to
define the “best” one we need to define the “effect” of a treatment. We will make
this definition later.
The second stage estimand is defined as
β∗2 := arg min
β2
P (Y −Q2(H2, A2; β2))2 (3.21)
Here β∗2 can be interpreted as the true second-stage regression coefficient. At stage
two we are interested in vector (HT2,1β
∗
2,1, H
T
2,2β
∗
2,2). The first component is the true
difference of effect between A2 = 1 and A2 = 0 while the second component is the
true difference of effect between A2 = 2 and A2 = 0. If we have H
T
2,1β
∗
2,1 ≤ 0 and
HT2,2β
∗
2,2 ≤ 0, then for this patient A2 = 0 is the best. If we have HT2,1β∗2,1 ≥ 0 and
HT2,1β
∗
2,1 − HT2,2β∗2,2 ≥ 0, then for this patient A2 = 1 is the best. Finally if we have
HT2,2β
∗
2,2 ≥ 0 and HT2,1β∗2,1 −HT2,2β∗2,2 ≤ 0, then for this patient A2 = 2 is the best.
The estimator of β∗2 is
βˆ2 := arg min
β2
Pn(Y −Q2(H2, A2; β2))2 (3.22)
where Pn is the empirical measure. And the estimated variance matrix of βˆ2 is
[
(Y −BT2 βˆ2)T (Y −BT2 βˆ2)/n
]
(B2B
T
2 )
−1 (3.23)
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where BT2 is an n by n2 second stage design matrix, with n being the number of
observations and n2 the dimension of H2.
The procedure of constructing Sˆ2 is as follows. First we fix our significance level α.
For each individual with H2 = h2, first we do the hypothesis test with the null being
A2 = 0 being the best, i.e., H0 is −hT2,1β∗2,1 ≥ 0 and −hT2,2β∗2,2 ≥ 0, with significance
level α (From now on every hypothesis test without specifying the significance level
will have a default significance level α). If we fail to reject this hypothesis, we include
A2 = 0 in Sˆ2, otherwise we do not include it. The test statistic is (−hT2,1βˆ2,1,−hT2,2βˆ2,2).
We fail to reject the null when both of these two elements are greater than some
negative quantities. Details will be provided later. Similar procedures are performed
for deciding whether to include A2 = 1 and A2 = 2.
Next we show the detail of testing whether A2 = 0 is the best for patients with
H2 = h2. Let σˆ
2
2,1(h2) = h
T
2,1Σˆ21,21h2,1 be the estimated variance of
√
nhT2,1βˆ2,1,
where Σˆ21,21 is the estimated variance matrix of
√
nβˆ2,1. Similarly define σˆ
2
2,2(h2) =
hT2,2Σˆ22,22h2,2. We also define σˆ2,12(h2) = h
T
2,1Σˆ21,22h2,2 where Σˆ21,22 is the estimated co-
variance matrix of
√
nhT2,1βˆ2,1 and
√
nhT2,2βˆ2,2. Finally we let σˆ
2
2,1−2 = σˆ
2
2,1+σˆ
2
2,2−2σˆ2,12
be the estimated variance of
√
n(hT2,1βˆ2,1 − hT2,2βˆ2,2).
We fail to reject the null of A2 = 0 being the best if −
√
nhT2,1βˆ2,1 ≥ −d2,0σˆ2,1 and
−√nhT2,1βˆ2,2 ≥ −d2,0σˆ2,2 where d2,0 = d2(σˆ2,12/σˆ2,1σˆ2,2, α) is a data dependent critical
value.
To explain d2 function in detail, d2(ρ, α) is a deterministic function that takes a
scalar ρ satisfying |ρ| ≤ 1 and another scalar α with 0 ≤ α ≤ 1 as inputs and outputs
a scalar d. This d satisfies
P (max{X1, X2} ≤ d) = α (3.24)
where X1 and X2 both follow a N(0, 1) distribution and their correlation coefficient
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is ρ.dˆ2,0 is equal to the d satisfying the above relationship when ρ = σˆ2,12/σˆ2,1σˆ2,2.
We also provide the procedure of testing whether A2 = 1 and A2 = 2 are the
best, respectively. Next we consider treatment A2 = 1. We let 1 into Sˆ2 if and
only if
√
nhT2,1βˆ2,1 ≥ −dˆ2,1σˆ2,1 and
√
nhT2,1βˆ2,1 −
√
nhT2,2βˆ2,2 ≥ −dˆ2,1σˆ2,1−2 where
dˆ2,1 = d2((σˆ
2
2,1 − σˆ2,12)/σˆ2,1σˆ2,1−2, α) is a data dependent critical value. Finally we
consider treatment A2 = 2. We let 2 into Sˆ2 if and only if
√
nhT2,2βˆ2 ≥ −dˆ2,2σˆ2,2 and
√
nhT2,2βˆ2,2 −
√
nhT2,1βˆ1,1 ≥ −dˆ2,2σˆ2,1−2, where dˆ2,2 = d2((σˆ22,2 − σˆ12)/σˆ2,2σˆ2,1−2, α) is a
data dependent critical value.
Remark:
The idea behind this is MCB. Intuitively a treatment cannot be rejected to be the
best, if the normalized difference between the estimated effect of this treatment and
any other treatment is not too small (here a number is too small means it has large
absolute value and a negative sign, not having small absolute value with a positive
sign).
Note that σˆ22,1(h2), σˆ
2
2,2(h2) and σˆ2,12(h2) are all functions of h2,1, h2,2 and Σˆ2,A,
where Σˆ2,A is the estimated variance matrix of
√
n(βˆT2,1, βˆ
T
2,2)
T and independent of h2.
As dˆ2,0, dˆ2,1, dˆ2,2 are function of those σˆs they are all functions of h2,1, h2,2 and Σˆ2,A.
So for H2 = h2, we would write Sˆ2(h2) as
Sˆ2(h2) = s2(h2,1, h2,2,
√
nβˆ2,1,
√
nβˆ2,2, Σˆ2,A, d2) (3.25)
for any H2 = h2. Here s2(·) is a deterministic function with range Power(A2), which
is the collection of all subsets of the domain of A2 except the null set. In our setting
for A2 ∈ {0, 1, 2}, Power(A2) = {{0}, {1}, {2}, {0, 1}, {1, 2}, {0, 2}, {0, 1, 2}}. This
notation will be used later.
One note is that Sˆ2 depends on n only through
√
nβˆ2,1,
√
nβˆ2,2 and Σˆ2,A. Further
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more, Sˆ2 is random only due to the dependence on βˆ2 and Σˆ2,A.
As for each second stage treatment, we have probability of including it (in other
words, fail to reject the null of it’s the best stage-two treatment) if the null is true,
no matter which treatment is the true best one, the probability of including it in Sˆ2
is always no smaller than 1− α. To be specific, for each H2 = h2, let
[2] = [2](h2) = arg max{0, hT2,1β∗2,1, hT2,2β∗2,2}
denote the index of the best second stage treatment for patients with H2 = h2. Let
Sˆ2 be the second stage recommended set constructed following the instruction above,
then we have
P ([2] ∈ Sˆ2) ≥ 1− α
for any true β∗2 . This is a immediate result from theorem 1 of Edwards and Hsu (1983).
Next we consider the first stage. As has been discussed in the previous sections,
as we are providing a set of treatments at the second stage, it is unrealistic to assume
a patient will take the true best corresponding second-stage treatment, which is the
assumption of the definition using dynamic programming idea. We will allow the
patient take the true worst treatment among treatments in his/her recommended set.
To describe this in detail, first we need to define the Q-function for stage one. For
any deterministic function s2 that that maps the domain of H2 to the power set of
{0, 1, 2}, we define
Q1(h1, a1; s2) := E
[
min
a2∈s2(H2)
Q2(H2, a2)|H1 = h1, A1 = a1
]
(3.26)
This expectation is taken over H2. Recall that s2 is a subset of {0, 1, 2}.
One note is that here H2 is the only input of s2 while the s2 we defined earlier has
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many inputs. Later we will show that the s2 we will use for Q1 mentioned above is
s2(h2) = s2(h2,1, h2,2,
√
nβˆ2,1,
√
nβˆ2,2, Σˆ2,A, d2). i.e., other inputs are considered fixed.
The s2 mentioned below all mean the s2 wth H2 as the only input.
For a given s2, the parametric form of Q1 is defined as
Q1(h1, a1; β1(s2), s2) := h
T
1,0β1,0(s2) + h
T
1,1β1,1(s2)1(a1 = 1) + h
T
1,2β1,2(s2)1(a1 = 2)
(3.27)
where β1(s2) := (β
T
1,0(s2), β
T
1,1(s2), β
T
1,2(s2))
T .
y(s2, h2) := min
a2∈s2(h2)
Q2(h2, a2; β
∗
2) (3.28)
for a patient with h2. And we denote Yˆ
∗(s2) := y(s2, H2). Finally, for any second
stage treatment regime Sˆ2(h2) = s2(h2,1, h2,2,
√
nβˆ2,1,
√
nβˆ2,2, Σˆ2,A, d2), we define our
estimand as
βˆ∗1(Sˆ2) = β1(Sˆ2) :=
{
arg min
β1
P (Yˆ ∗(s2)−Q1(H1, A1; β1, s2))2
} |
s2=Sˆ2
(3.29)
Remark III.9. y(s2, h2) can be interpreted as the expected final outcome for a patient
with H2 = h2 if he or she had taken the worst treatment in s2(h2) at the second stage.
Remark III.10. We can see in (3.29) that the estimand, βˆ∗1(Sˆ2) depends on Sˆ2, which
is a random quantity. This follows the idea of Robins et al. (2014). We need to
consider the case where decision makers might choose the true worse treatment in
the recommended set (if the set contains more than one treatment); we also need to
consider the randomness of the recommended set. For notational convenience, we will
denote βˆ∗1(Sˆ2) by βˆ
∗
1 .
Remark III.11. We can interpret βˆ∗1 as the true first-stage regression coefficient if the
second-stage recommended set is Sˆ2. At stage one for a new patient with H1 = h1,
under the assumption that the second-stage recommended set is Sˆ2, the patient’s
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expected final outcome is hT1,0βˆ
∗
1,0 + h
T
1,1βˆ
∗
1,11(A1 = 1) + h
T
1,2βˆ
∗
1,21(A1 = 2). Thus we
are interested in the vector (hT1,1βˆ
∗
1,1, h
T
1,2βˆ
∗
1,2).
Remark III.12. To help understand our procedure, we are using one data set to mimic
the following procedure based on data sets from TWO clinical trials: from the first
trial Sˆ2 is constructed. Next consider the second trial, in which we use the mapping
Sˆ2 to offer treatment at each patient’s second stage. Then for a patient with H1 = h1,
this patient’s expected final outcome is hT1,0βˆ
∗
1,0+h
T
1,1βˆ
∗
1,11(A1 = 1)+h
T
1,2βˆ
∗
1,21(A1 = 2).
Note that this expected final outcome is conditional on the Sˆ2 from the first data set.
But of course we only have one data set, so our procedure mimics the above but with
only one data set.
Remark III.13. In stage one, we construct the first stage recommended set Sˆ1 similar
to how we do in stage two. First, for every patient, construct their hypothetical final
outcome
Y˜ (Sˆ2;H2) := min
a2∈Sˆ2
(HT2,0βˆ2,0 +H
T
2,1βˆ2,11(a2 = 1) +H
T
2,2βˆ2,21(a2 = 2)). (3.30)
as an estimator of y(s2, h2) in (3.28) with s2 = Sˆ2. Next we get the estimator of βˆ
∗
1
in (3.29) by
βˆ1 := arg min
β1
Pn(Y˜ − (HT1,0β1,0 +HT1,1β1,11(A1 = 1) +HT1,2β1,21(A1 = 2)))2 (3.31)
Before we move on to discuss in detail how to construct Sˆ1 we introduce some
notation. For s ⊂ {0, 1, 2}, we denote
F (s, a, b, c) := min
A∈s
(a+ b1(A = 1) + c1(A = 2)) (3.32)
Thus (3.30) can be expressed as Y˜ = HT2,0βˆ2,0 + F (Sˆ2, 0, H
T
2,1βˆ2,1, H
T
2,2βˆ2,2) and
(3.28) can be expressed as Yˆ ∗ = HT2,0β
∗
2,0 + F (Sˆ2, 0, H
T
2,1β
∗
2,1, H
T
2,2β
∗
2,2).
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For stage one, we consider the three first stage treatments one by one. For
A1 = 0, we are interested in a two dimensional vector, each component of which
is the difference between the effect of A1 = 0 and A1 = 1, 2. To be specific we
are interested in (−HT1,1βˆ∗1,1,−HT1,2βˆ∗1,2)T . Similarly for A1 = 1 and A1 = 2 we are
interested in (HT1,1βˆ
∗
1,1, H
T
1,1βˆ
∗
1,1 − HT1,2βˆ∗1,2)T and (HT1,2βˆ∗1,2, HT1,2βˆ∗1,2 − HT1,1βˆ∗1,1)T . We
include an index in our first stage recommended set Sˆ1 if and only if we fail to
reject the null that both components of the vector of interested are non-negative.
Thus, for A1 = 0, we would like to construct a simultaneous one sided 1-α level
confidence intervals for (−HT1,1βˆ∗1,1,−HT1,2βˆ∗1,2)T , say ((−∞, u1), (−∞, u2))T , (meaning
P (−HT1,1βˆ∗1,1 ≤ u1,−HT1,2βˆ∗1,2 ≤ u2) ≥ 1− α), then if both u1 and u2 are non-negative
we fail to reject the null at 1− α level and we would let 0 into Sˆ1. The test statistic
here is naturally (−HT1,1βˆ1,1,−HT1,2βˆ1,2). The procedure of whether letting A1 = 1, 2
into Sˆ1 are similar.
To make the problem more general, we are interested in constructing one sided
simultaneous confidence intervals for (c1βˆ
∗
1 , c2βˆ
∗
1)
T where c1 and c2 are two row vectors
with length equal to the length of β1. We are interested in the vector (
√
nc1(βˆ1 −
βˆ∗1),
√
nc2(βˆ1 − βˆ∗1))T . Let B1 be the first stage covariate B1 = (HT1,0, HT1,11(A1 =
1), HT1,21(A1 = 2))
T and Σˆ1 := PnB1BT1 then we have βˆ1 = Σˆ−11 PnB1Y˜ , similarly
define βˆ∗1 = Σ
−1
1,∞PB1Yˆ
∗ where Σ1,∞ := PB1BT1 . Thus, we can show that
√
nc1(βˆ1−
βˆ∗1) = c1(Sn + Un) where
Sn =
√
nΣˆ−11 PnB1
[
HT2,0β
∗
2,0 + F (Sˆ2, 0, H
T
2,1β
∗
2,1, H
T
2,2β
∗
2,2)−B1βˆ∗1 +HT2,0(βˆ2,0 − β∗2,0)
]
Un =
√
nΣˆ−11 PnB1
[
F (Sˆ2, 0, H
T
2,1βˆ2,1, H
T
2,2βˆ2,2)− F (Sˆ2, 0, HT2,1β∗2,1, HT2,2β∗2,2)
]
Below are some remarks:
1. Term Sn is always asymptotically normal. (proof will be included in the
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appendix)
2. Term Un, on the other hand, is not asymptotically normal when there are some
equally best second stage treatments for a certain kind of patients. For example for
some h2,1 and h2,2 that satisfy both P (H2,1 = h2,1, H2,2 = h2,2) > 0 and h
T
2,1β
∗
2,1 = 0 >
hT2,2β
∗
2,2 (this is the case that at the second stage for some patients treatment 0 and
1 have the same effect while treatment 2 is the worst, other scenarios are similar),
when n is large with probability converging to one we will not include A2 = 2 into
Sˆ2. Thus we have
√
n(F (Sˆ2, 0, H
T
2,1βˆ2,1, H
T
2,2βˆ2,2)− F (Sˆ2, 0, HT2,1β∗2,1, HT2,2β∗2,2))
=
√
nF (Sˆ2, 0, H
T
2,1βˆ2,1, H
T
2,2βˆ2,2)
=
√
n(min(0, HT2,1βˆ2,1)1(Sˆ2 = {0, 1}) +HT2,1βˆ2,11(Sˆ2 = {1}))
=
√
n(−[HT2,1βˆ2,1]−1(Sˆ2 = {0, 1}) +HT2,1βˆ2,11(Sˆ2 = {1}))
where [x]− equals to 0 if x ≥ 0 and −x if x < 0. We can see that this term is not
asymptotically normal. Thus the distribution of Un and its bootstrap analog U(b)n will
have different limiting distribution. Thus the confidence interval constructed from
bootstrap method will have poor coverage rate.
Now we discuss the lower bound of (c1
√
n(βˆ1 − βˆ∗1), c2
√
n(βˆ1 − βˆ∗1))T (Note that
then we can use this lower bound to form the upper bound of (c1βˆ
∗
1 , c2βˆ
∗
1)) . From
the above discussion, we already have that
 c1√n(βˆ1 − βˆ∗1)
c2
√
n(βˆ1 − βˆ∗1)
 =
 c1(Sn + Un)
c2(Sn + Un)
 (3.33)
What we want is an lower bound for the two dimensional vector (3.33), which
means we would like a data dependent value l such that the probability of both
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components of (3.33) above l is no smaller than 1− α, i.e.,
P (c1
√
n(βˆ1 − βˆ∗1) ≥ l, c2
√
n(βˆ1 − βˆ∗1) ≥ l) ≥ 1− α (3.34)
then after some algebra we have P (c1βˆ
∗
1 ≤ c1βˆ1− l/
√
n, c2βˆ
∗
1 ≤ c2βˆ1− l/
√
n) ≥ 1−α.
The idea of ACI (Adaptive Confidence Interval) is that we split our data into
two parts, those we determine the unique best second stage treatment and those
we cannot. For the former part, we just use normal bootstrap method since we are
quite sure that there is no “non-regularity” (details of how the bootstrap method is
applied is introduced in Tianshuang’s former paper); while for the latter part, we use
γ1 and γ2 to replace
√
nβ∗2,1 and
√
nβ∗2,2 and let them vary in their domain. Before
we introduce the explicit form of the lower bound we denote Vn =
√
n((βˆT2,1, βˆ
T
2,2)
T −
(β∗T2,1, β
∗T
2,2)
T ), Vn,1 =
√
n(βˆ2,1 − β∗2,1) and Vn,2 =
√
n(βˆ2,2 − β∗2,2). We also define
S˜2(λn) = Sˆ2(H2,1, H2,2,
√
nβˆ2,1,
√
nβˆ2,2, λn). Note that λn is not a function like d2 but
a constant (we can also treat λn as a constant function). As we will see we will let λn
go to infinity with rate slower than
√
n to ensure that the indices included in S˜2 are
eventually all the indices of the true best second stage treatments. Finally, note that
we can write the left hand side of (3.34) in one dimension form as P (min
(
c1
√
n(βˆ1−
βˆ∗1), c2
√
n(βˆ1 − βˆ∗1)
) ≥ l). A lower bound of min (c1√n(βˆ1 − βˆ∗1), c2√n(βˆ1 − βˆ∗1)) is
given by
L(c1, c2) = inf
γ1,γ2
(
min{F(c1, γ1, γ2),F(c2, γ1, γ2)}
)
(3.35)
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where
F(c, γ1, γ2)
= cTSn + cTUn1(|S˜2(λn)| = 1)
+
[
cT Σˆ−11 PnB1
[
F
(
Sˆ2(H2,1, H2,2, γ1 + Vn,1, γ2 + Vn,2, d2), 0, HT2,1(γ1 + Vn,1),
HT2,2(γ2 + Vn,2)
)
−F(Sˆ2(H2,1, H2,2, γ1 + Vn,1, γ2 + Vn,2, d2), 0, HT2,1γ1, HT2,2γ2)]]1(|S˜2(λn)| > 1)
Here |S| means the number of components of the set S.
Similarly, although we will not use it in this paper, an upper bound of
max
(
c1
√
n(βˆ1 − βˆ∗1), c2
√
n(βˆ1 − βˆ∗1)
)
is given by
U(c1, c2) = sup
γ1,γ2
(
max{F(c1, γ1, γ2),F(c2, γ1, γ2)}
)
(3.36)
As we have ci
√
n(βˆ1 − βˆ∗1) = F(ci,
√
nβ∗2,1,
√
nβ∗2,2) for i = 1, 2, so we have
L(c1, c2) ≤ min
(
c1
√
n(βˆ1 − βˆ∗1), c2
√
n(βˆ1 − βˆ∗1)
)
and max
(
c1
√
n(βˆ1 − βˆ∗1), c2
√
n(βˆ1 −
βˆ∗1)
) ≤ U(c1, c2) from the following lemma
Lemma III.14. Let γ be a vector and F1, F2 two functions of γ, we have
min{inf
γ
F1(γ), inf
γ
F2(γ)} = inf
γ
min{F1(γ), F2(γ)}
Proof. ∀γ, min{F1(γ), F2(γ)} ≥ LHS. Take infimum of γ we have RHS ≥ LHS.
infγ F1(γ) ≥ RHS and infγ F2(γ) ≥ RHS together imply LHS ≥ RHS. So we
finish our proof.
Remark III.15. In standard MCB procedure, instead of finding lower bound of
min
(
c1
√
n(βˆ1 − βˆ∗1), c2
√
n(βˆ1 − βˆ∗1)
)
, we would like to find a lower bound of
min
(
c1
√
n(βˆ1 − βˆ∗1)/std(c1
√
n(βˆ1 − βˆ∗1)), c2
√
n(βˆ1 − βˆ∗1)/std(c2
√
n(βˆ1 − βˆ∗1))
)
where
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std mean the standard deviation. We don’t do it here because it is very hard to
estimate std(c
√
n(βˆ1 − βˆ∗1)). Our procedure is still valid, in the sense that we would
still include the true best first stage treatment in the recommended set if we use this
form. Proof can be found in the later section. And if we assume that the variance of
each treatment effect estimator are close then our procedure is the same as standard
MCB.
Define
W∞ = (3.37)
Σ−11,∞GB1
[
HT2,0β
∗
2,0 +
F (Sˆ2(H2,1, H2,2,
√
nβ∗2,1 + V1,
√
nβ∗2,2 + V2,Σ2,A,∞, d2), 0, HT2,1β∗2,1, HT2,2β∗2,2)
−BT1 Σ−11,∞PB1
[
HT2,0β
∗
2,0 +
F (Sˆ2(H2,1, H2,2,
√
nβ∗2,1 + V1,
√
nβ∗2,2 + V2,Σ2,A,∞, d2), 0, HT2,1β∗2,1, HT2,2β∗2,2)
]
+HT2,0V0
]
We denote Vn,i =
√
n(βˆ2,i − β∗2,i) for i = 0.1, 2, and Vi the limiting distribution
correspondingly. We have
√
ncT (βˆ1 − βˆ∗1)
→ cTWn + cTΣ−11,∞PB1
[
F (Sˆ2(H2,1, H2,2,
√
nβ∗2,1 + V1,
√
nβ∗2,2 + V2,Σ2,A,∞, d2), 0, HT2,1(
√
nβ∗2,1 + V1),
HT2,2(
√
nβ∗2,2 + V2))
−F (Sˆ2(H2,1, H2,2,
√
nβ∗2,1 + V1,
√
nβ∗2,2 + V2,Σ2,A,∞, d2), 0,
√
nHT2,1β
∗
2,1,
√
nHT2,2β
∗
2,2)
]
Denote S∗ = S∗(H2) = {i ∈ {0, 1, 2}|i = arg maxiHT2,1β∗2,11(i = 1) +HT2,2β∗2,21(i =
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2)} be the set of indices of the best second stage treatment for patient with H2.
The limiting distribution of infγ1,γ2 F(c, γ1, γ2) is given by
cTW∞ + cTΣ1,∞PB1
[
HT2,0V0 +HT2,1V11(H∗2,1β∗2,1 > max{0, HT2,2β∗2,2})
+HT2,2V21(H∗2,2β∗2,2 > max{0, HT2,1β∗2,1})
]
1(|S∗| = 1)
+ inf
γ1,γ2
{
cTΣ−11,∞PB1
[
F (Sˆ2(H2,1, H2,2, γ1 + V1, γ2 + V2, d2), 0, HT2,1(γ1 + V1), HT2,2(γ2 + V2))
−F (Sˆ2(H2,1, H2,2, γ1 + V1, γ2 + V2, d2), 0, HT2,1γ1, HT2,2γ2)
]
1(|S∗| > 1)
}
Thus we can guarantee the probability of including min
(
c1
√
n(βˆ1−βˆ∗1), c2
√
n(βˆ1−βˆ∗1)
)
in the one-sided confidence interval.
3.7.3 Simulation Study
Similar to section 3.4, we would like to examine the performance of our methods.
Again we propose some generative models with different “degrees of non-regularity”.
We use the following generative model
Y = γ1 + γ2X1 + γ31(A1 = 1) + γ41(A1 = 2) + γ5X11(A1 = 1) + γ6X11(A1 = 2)
+
(
γ7 + γ8X1 + γ91(A1 = 1) + γ101(A1 = 2)
)
1(A2 = 1)
+
(
γ11 + γ12X1 + γ131(A1 = 1) + γ141(A1 = 2)
)
1(A2 = 2) + 
Below are some information about the simulation.
• Each trajectory has the form (X1, A1, X2, A2, Y ).
• For each sample, its A1 and A2 are assigned with probability 1/3 to be one of
0,1,2.
• X1 is the initial condition, with 1/2 probability of being -1 and 1.
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• X2 is the second stage covariate, as we will not use it for analyzing we will
assign the value of it with the same distribution as X1. It is here only to make
the trajectory similar to the two-treatments=per-stage case.
•  follows iid N(0, 1) distribution.
• H2,0 = (1, X1,1(A1 = 1),1(A1 = 2), X11(A1 = 1), X11(A1 = 2))
• H2,1 = H2,2 = (1, X1,1(A1 = 1),1(A1 = 2))
• H1,0 = H1,1 = H1,2 = (1, X1).
• α = 0.05. i.e., we want to include the best first stage treatment with probability
no smaller than 0.95.
We will focus on the case where γ9 = γ10 = γ13 = γ14, in this case if patients starts
with A1 = 0, all the three second stage treatments will be equally the best for them.
On the other hand, if they start with A1 = 1 or A1 = 2, only one of the three second
stage treatment is the best, and the effect is equal to the effects starting with A1 = 0.
In this case the effect of A1 = 0 will be highly underestimated. In this case, the ACI
method can cover the best treatment A1 = 0 with probability 0.951 while the naive
bootstrap method’s probability is only 0.83.
3.7.4 Discussion
We want to further examine if there is any less conservative method, since when
all the treatments have equal effect, the ACI method will include the true best first
stage treatment with probability very closed to one.
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CHAPTER IV
Identifying a set that contains the best DTR
The work presented in this chapter (except that in section 4.8) is joint work with
Ashkan Ertefaie who was a postdoc in our group when working on this, Kevin Lynch
who is a researcher in Pennsylvania, and Inbal Nahum-Shani who is an assistant
professor in the Institute for Social Research of University of Michigan.
The work in section 4.8 is a joint with Rong Zhou who is an undergrad student
in the department of Statistics.
4.1 Introduction
A dynamic treatment regime (DTR) is a treatment design that seeks to accommo-
date patient heterogeneity in response to treatments (Murphy et al., 2001; Murphy ,
2003; Robins , 2004). In DTRs the type and/or dose of the treatment is adapted over
time according to the patient’s characteristics and progress in treatment. At each
decision point (i.e., specific point in time in which a treatment is to be considered or
altered), decision rules are used to map individual characteristics to a specific type
of treatment or dosage. Recently, there has been an increased interest in sequential,
multiple assignment, randomized trials (SMARTs), which were developed specifically
to provide empirical evidence that informs the construction of optimal DTRs (Lavori
and Dawson, 2000; Laber et al., 2014b; Nahum-Shani et al., 2012a; Chakraborty and
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Moodie, 2013; Chakraborty and Murphy , 2014).
One scientific question motivating a SMART concerns the comparison of DTRs
that are embedded in the design. It aims to identify the best DTR or the set that
contains the best DTRs among those that are embedded in the design. In other
words, the goal is to screen out ineffective DTRs. This question can be framed as a
special case of the general multiple comparison problem.
Methods for multiple comparisons can be used to group sample means, such that
within each group, population means are not significantly different (Tukey , 1953;
Scheffe, 1953). Current approaches for identifying the set of best DTRs perform all
possible comparisons among embedded DTRs. In such a setting, standard multiple
comparison approaches used to control for Type I error result in a loss of statistical
power (Hsu et al., 1984; Hsu, 1996). Consequently, important differences between
DTRs might go undetected (Saville, 1990; Keselman et al., 1999). Here, we propose
a more efficient approach for identifying the set of best DTRs. This approach builds
on the work of Hsu et al. (1981), which identifies the best set of means by conducting
multiple comparisons with the best (MCB), namely by comparing the best mean with
others. Applying this approach will result in fewer comparisons relative to standard
approaches, and hence improved power.
The current manuscript will extend the MCB toolbox for analyzing data from
SMART studies. The contribution of this paper is twofold. First, we provide and
illustrate, for the first time, a method that can be used to efficiently address an impor-
tant scientific question that motivates many SMART studies. This question concerns
the need to identify the optimal DTR, or several optimal DTRs from a list of DTRs
embedded in a SMART study. Enabling researchers to address this scientific question
can support clinical decision making, offering clinicians a set of efficacious DTRs to
choose from based on other considerations such as cost and patient preferences. The
second contribution concerns the correlation structure of the estimators derived from
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SMART data. The method proposed by Hsu requires a known correlation structure
(up to a constant). In SMART, the correlation structure of estimators are not known
a priori. Therefore, generalization of the method os warranted.
We briefly introduce SMART designs and explain the structure of SMART data
in Section 4.2. We then present two methods to estimate the mean outcome under
each DTR in Section 4.3. The framework of MCB in SMART settings is introduced in
Section 4.4. We conduct a simulation study in Section 4.5 to examine the performance
of our method. We illustrate the method with analyses of the Extending Treatment
Effectiveness of Naltrexone (EXTEND) study in Section 4.6. The last section contains
some concluding remarks. Proofs are given in an online supplementary document.
4.2 Preliminaries
4.2.1 Sequential, Multiple Assignment, Randomized Trials
The SMART is a clinical trial design in which each individual proceeds through
stages of treatments (Lavori et al., 2000; Murphy , 2005a; Lei et al., 2012; Nahum-
Shani et al., 2012a). At each treatment stage, individuals are randomized to one
of the available treatment options at that stage, where the subsequent treatment
options may depend on an embedded tailoring variable observed at current stage.
For example, in the EXTEND study, at stage 1, patients were randomized to one
of two definitions of non-response while receiving naltrexone (NTX): 1) Stringent
criterion– a patient is a non-responder if (s)he has two or more heavy drinking days
in the first eight weeks; 2) Lenient criterion– a patient is a non-responder if (s)he has
five or more heavy drinking days in the first eight weeks. At stage 2, non-responders
were re-randomized to combined behavioral intervention (CBI) +NTX or CBI alone.
Individuals who did not meet their non-response criterion were re-randomized to
telephone disease management (TDM)+NTX or NTX alone. Thus, in this two-stage
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design, the embedded tailoring variable is the response/non-response status to initial
NTX.
4.2.2 Data Structure
For simplicity, we focus on SMARTs with two stages. The observed data on each
individual are given by a trajectory (O1, A1, O2, S, A2, Y ). Oj, for j = 1, 2 is a set of
covariates available at the beginning of stage j. Aj denotes the treatment options at
the beginning of stage j. S is a binary variable that is coded 1 if an individual has
been re-randomized at stage 2, and coded 0 otherwise. Finally, Y is the continuos
primary outcome. The treatment and the covariate history through j are denoted by
A¯j and O¯j, respectively. We use lowercase letters to refer to the possible values of
the corresponding capital letter random variable.
In SMART settings, the stage-2 treatment options may depend on embedded tai-
loring variables, which are part or all of the observed history up to and including
time 2, and we denote them as V . In the EXTEND study, V is the response(R)/non-
response(NR) status to stage-1 treatment (i.e., V ∈ {R,NR}). Hence, for each indi-
vidual, we conceptualize a v-treatment trajectory T = (A1, AR2 , ANR2 ). For responders
and non-responders, we set ANR2 = 0 and A
R
2 = 0, respectively, with probability 1.
This basically means that for responders ANR2 does not apply and vice versa. We
use the v-treatment trajectory to model the marginal structural model discussed in
Section 3. Note, the v-treatment trajectory and treatment history are not necessarily
the same. In fact, in this example, the treatment history is two-dimensional, while
the v-treatment trajectory is three-dimensional.
4.2.3 Embedded Dynamic Treatment Regimes
An embedded dynamic treatment regime (EDTR) is one DTR that participants
can follow as part of the study design. In the EXTEND study, there are 8 EDTRs:
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1) Start with lenient definition. If the patient is non-responsive, offer NTX+CBI; if
the patient is responsive, offer NTX+TDM. 2) Start with lenient definition. If the
patient is non-responsive, offer NTX+CBI; if the patient is responsive, offer NTX. 3)
Start with lenient definition. If the patient is non-responsive, offer CBI; if the patient
is responsive, offer NTX+TDM. 4) Start with lenient definition. If the patient is
non-responsive, offer CBI; if the patient is responsive, offer NTX. The other four
EDTRs are similar except that they start with stringent definition. Note that a
given v-treatment trajectory T can be consistent with more than one EDTR. For
example, a responder to the lenient definition with T = (A1 = lenient, AR2 = NTX +
TDM,ANR2 = 0) is following both EDTRs (1) and (3).
4.3 Estimation
Let θk be the population outcome mean under the kth EDTR for k = 1, 2, ..., K
where K is the number of EDTRs in a SMART. Here, we provide two methods that
are based on weighted least squares minimizations and used throughout this paper as
tools to estimate the mean outcome under each EDTR. The first approach would be
to postulate a marginal structural model (MSM) m(T ; βp×1) for the outcome given
the observed v-treatment trajectory T and define θk as a known function of β for all
k. Let Pn be the empirical average. The parameters of the MSM can be estimated
using the following estimating equation:
Pn
K∑
k=1
m˙(T ; β)w2(V, A¯2, k)(Y −m(T ; β)) = 0, (4.1)
where m˙(T ; β) = ∂m(T ; β)/∂β, and
w2(v, a¯2, k) =
IEDTRk,1(a1)IEDTRvk,2(a2)
p(A1 = a1)p(A2 = a2|A1 = a1, V = v) , for V = v and A¯2 = a¯2,
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where EDTRVk,2 is the treatment option determined by EDTRk at stage 2 given V ,
and EDTRk,1 is the treatment option determined by EDTRk at stage 1. The indicator
function selects individuals whose treatment history is consistent with the kth EDTR
given V . This method is referred to as inverse probability weighting (IPW) (Robins ,
1999; Robins et al., 2000; Herna´n et al., 2000). The treatment trajectory is used
to define the MSM function. For example, in the EXTEND study, the MSM would
be m(T ; β) = β0 + β1A1 + β2AR2 + β3ANR2 + β4A1AR2 + β5A1ANR2 . We denote the
solutions of this equation as βˆIPW . Hence, the mean outcome under each EDTR can
be estimated as (θˆIPW1 , ..., θˆ
IPW
K ) = Dβˆ
IPW , where D is a K× p matrix. The kth row
of D is the contrast corresponding to EDTRk (see Section 4.5).
The second approach is based on the augmented IPW (AIPW), which is a more
efficient version of IPW developed by Robins et al. (2008) and Orellana et al. (2010).
Let EDTRVk = (EDTRk,1, EDTR
V
k,2). The corresponding estimating equation for a
two-stage design is given by
Pn
K∑
k=1
m˙(T ; β)
[
w2(V, A¯2, k)(Y −m(T ; β))
− (w2(V, A¯2, k)− w1(A1, k))(ϕk2(O¯2)−m(T ; β))
− (w1(A1, k)− 1)(ϕk1(O1)−m(T ; β))] = 0, (4.2)
where ϕk2(O¯2) = E[Y |A¯2 = EDTRVk , O¯2], ϕk1(O1) = E[ϕk2(O¯2)|A1 = EDTRk,1, O1],
and
w1(a1, k) =
IEDTRk,1(a1)
p(A1 = a1)
, for A1 = a1.
To obtain estimators of β, we postulate parametric models for the unknown functions
ϕk1(.) and ϕ
k
2(.) parametrized by γ and replace them with their estimated values
ϕk1(., γˆ) and ϕ
k
2(., γˆ). The estimates may be obtained by fitting two least squares
models. We denote the solutions of (4.2) as βˆAIPW and, similar to the first approach,
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we define (θˆAIPW1 , ..., θˆ
AIPW
K ) = Dβˆ
AIPW .
Estimator (4.2) is double robust in the sense that it results in an unbiased esti-
mate of β if either ϕk(., γ) or the treatment assignment probabilities are correctly
specified (van der Laan and Robins , 2003; Davidian et al., 2005; Bang and Robins ,
2005; Orellana et al., 2010). Although we are focusing on randomized trials and
treatment assignment probabilities are known by design, for efficiency we estimate
these probabilities nonparametrically using the available data (Robins et al., 1995;
Hirano et al., 2003). One may also postulate a parametric model to estimate these
probabilities given the observed covariate/treatment history.
The following proposition provides the asymptotic behaviours of estimators θˆIPW
and θˆAIPW obtained by (4.1) and (4.2), respectively, which is an immediate conse-
quence of Lemma 3 in Orellana et al. (2010). In the proposition, the superscript 
denotes IPW or AIPW.
Proposition IV.1. Let θˆ = Dβˆ, where D is a K × p matrix with the kth row
of D being the contrast corresponding to the kth EDTR. Then under the stan-
dard regularity assumptions,
√
n(θˆ − θ)→ N (0,Σ = D′[Γ′−1ΛΓ−1]D), where Γ =
−E
[∑K
i=1 m˙
′(T ; β)m˙(T ; β)
]
, and Λ = E[U ′U] with
UAIPW =
K∑
k=1
m˙(T ; β)
[
w2(V, A¯2, k)(y −m(T ; β))
− (w2(V, A¯2, k)− w1(A1, k))(ϕk2(O¯2)−m(T ; β))
− (w1(A1, k)− 1)(ϕk1(O1)−m(T ; β))],
U IPW =
K∑
k=1
m˙(T ; β)
[
w2(V, A¯2, k)(y −m(T ; β))
]
.
The asymptotic variance Σ may be estimated consistently by replacing the ex-
pectations with expectations with respect to the empirical measure and (β, γ) with
its estimate (βˆ, γˆ) and denoted as Σˆ = D[Γˆ−1ΛˆΓˆ−1]D.
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4.4 Multiple Comparison with the Best
Let B be the true set of best EDTRs and Bˆ be a set of EDTRs that cannot be
differentiated from the best EDTR using the available data. In the previous section,
we discussed our procedures to estimate the mean outcome under each EDTR, θˆIPWk
and θˆAIPWk for k = 1, 2, ..., K. Since our methodology holds for both IPW and AIPW
approaches to estimation, for simplicity of notation, we drop the superscripts IPW
and AIPW and refer to the estimator of θk as θˆk. In this section, we generalize the
MCB method introduced by Hsu et al. (1981) to SMART settings. The goal is to
find EDTRs that are not significantly different from the EDTR with the maximum
outcome, say θ[K] = max1≤k≤Kθk. Hence, a natural criterion would be to include
index i in the set Bˆ if the standardized difference (θˆi − θˆj)/σij is greater than a
constant for all j 6= i. This can be written as
θˆi ≥ maxj 6=i[θˆj − ciσij], (4.3)
where ci is a constant and σij =
√
var(θˆi − θˆj), which can be estimated using the
variance formula in Proposition IV.1. The challenge is to find ci such that Bˆ includes
the true best EDTR with probability at least (1− α); that is, Pθ(arg maxi θi ∈ Bˆ) ≥
1−α for any θ. In cases where there are more than one best EDTR, Bˆ includes each
index k ∈ B with at least (1 − α) probability. This condition will be satisfied if we
find ci such that under the null hypothesis (i.e., all EDTRs are equally good), the set
Bˆ includes each index k with probability (1−α). In other words, when σij is known,
ci must satisfy
p(Zi ≥ Zj − ciσij for j = 1, 2, i− 1, i+ 1, ..., K) = 1− α, (4.4)
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where Z1, ..., ZK are multivariate normal random variables with mean 0 and covariance
matrix Σ such that
√
var(Zi − Zj) = σij. The above equality can be written as
∫
p(Z1 ≤ z+ciσij, ..., Zi−1 ≤ z+ciσij, Zi+1 ≤ z+ciσij, ..., ZK ≤ z+ciσij)dφ(z) = 1−α,
where φ(z) is the marginal cdf of Zi. Note that for α ≤ 0.5, the constant ci > 0 for
i = 1, ...K. Hence, in our setting where α represents the Type I error rate, we can
assume that ci is a positive constant.
Hsu et al. (1981) present an equation that can be used to find the constant ci
when the structure of the covariance matrix Σ is known up to a constant. This is the
case in a standard regression where Σ = σ(X ′X)−1. Note that in this case, given the
design matrix, Σ is known up to a constant σ. In Hsu’s setting, the constant ci is a
function of the correlation matrix and thus it is not a function of σ. In the marginal
structural model, however, the structure of the design matrix is random because it
depends on intermediate outcomes (i.e., variables observed before stage 2 and after
stage 1 treatment assignment) that are not included in the design matrix, such as
response or non-response status (i.e., embedded tailoring variables). In such setting,
the constant ci will be a function of an unknown Σ which is estimated by Σˆ using the
observed data. Theorem IV.2 generalizes the idea in Hsu to cases where the structure
of the design matrix is unknown. We use the notation cˆi to reflect the dependence of
ci to Σˆ.
Theorem IV.2. Define the estimated set of best EDTRs as Bˆ = {i|θˆi ≥ maxj 6=i[θˆj −
cˆiσˆij]}, where σˆij =
√
vˆar(θˆi − θˆj), and cˆi satisfies
∫
p(Z1 ≤ z + cˆiσˆi1, ..., Zi−1 ≤ z + cˆiσˆi(i−1),
Zi+1 ≤ z + cˆiσˆi(i+1), ..., ZK ≤ z + cˆiσˆiK)dφ(z) = 1− α,
with Z1, ..., ZK being multivariate normal random variables with mean 0 and unknown
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covariance matrix Σ, which is estimated by Σˆ. Then, asymptotically, Bˆ contains the
true best EDTR with probability at least (1− α).
Let δij = θi − θj be the difference between the ith and the jth EDTR. The
probability of including an EDTRi in the estimated set of best EDTRs for any given
ci is
p(EDTRi ∈ Bˆ)
= p
(
θˆi ≥ θˆ1 − ciσˆi1, ..., θˆi ≥ θˆi−1 − ciσˆi(i−1), θˆi ≥ θˆi+1 − ciσˆi(i+1), ..., θˆi ≥ θˆK − ciσˆi(K)
)
= p
(
Wi1 ≤ ci σˆi1
σi1
+
δi1
σi1
, ...,Wi(i−1) ≤ ci
σˆi(i−1)
σi(i−1)
+
δi(i−1)
σi(i−1)
,Wi(i+1) ≤ ci
σˆi(i+1)
σi(i+1)
+
δi(i+1)
σi(i+1)
, ...,WiK ≤ ci σˆiK
σiK
+
δiK
σiK
)
, (4.5)
where Wij = −(θˆi − θˆj − δij)/σij and is distributed as a standard normal random
variable. Accordingly, the estimated set size (ESS) of Bˆ is defined as∑Ki=1 p(EDTRi ∈
Bˆ). Note, under the null hypothesis, where all EDTRs are equally good, ESS =
K(1− α). The following theorem shows that the probability of including an inferior
EDTRi in the estimated set Bˆ decays to zero exponentially for i = 1, ..., K as the
difference between the best and the ith EDTR increases.
Theorem IV.3. For any fixed index i, let Wi = (Wi1, · · · ,WiK) follow a multivariate
normal distribution with mean zero and unknown variance matrix. Define Yj = ci
σˆij
σij
for j = 1, ..., i − 1, i + 1, ..., K as non-negative random variables. (Note that Yj also
depends on i but as we are fixing i, for notation convenience we omit i here). Let
K = argmax1≤i≤Kθi, ∀δKi ≥ 0; we have
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P(
Wi1 ≤ Y1,Wi2 ≤ Y2, · · · ,WiK ≤ YK − δKi
σiK
)
≤ P (Wi1 ≤ Y1,Wi2 ≤ Y2, · · · ,WiK ≤ YK) exp (−ζδKi/σiK) ,
(4.6)
where ζ > 0 is a constant that depends on cov(Wi) and Y1, · · · , YK but is independent
of δKi.
Note that σiK =
√
var(θˆi − θˆK), which decays to zero with rate 1/
√
n. This
implies that for a fixed δKi, as n increases the probability of including an inferior
EDTRi to Bˆ decreases with rate exp(−
√
n). Also, in the statement of Theorem IV.3,
replacing Yi with Yi +
δi1
σi1
, for i = 1, ..., K − 1, shows the exponential decay rate in
(4.5).
Remark. Let ΣAIPW and ΣIPW be the covariance matrix of cov(θˆAIPW ) and
cov(θˆIPW ), respectively. Since ΣAIPW  ΣIPW , for any fixed sample size and a set of
δijs, the efficient estimator AIPW results in an ESS which is less than or equal to the
one obtained by the inefficient estimator IPW (see Figures A.1 and A.2).
4.5 Simulation Study
This section provides empirical evidence for the theoretical results presented in the
manuscript. We compare the estimated sets of best obtained by the IPW and AIPW
methods and show that the latter method screens out the ineffective EDTRs more
efficiently. We examine the performance of the proposed method using two different
types of SMART designs. We describe that the form of the marginal structural
model m(., β) may vary based on the design structure. We also discuss the effect that
misspecifying the function ϕk. (.) has on estimating the parameters of the marginal
structural model and the mean outcome under each EDTR.
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In all simulation scenarios, baseline variables O11 and O12 are generated from stan-
dard normal, and A1 ∈ {−1,+1} is based on a Bernoulli distribution with probability
0.5. The intermediate outcomes are O21 ∼ N(0.5O11, 1) and O22 ∼ N(0.5O12, 1). The
estimator IPW and AIPW refer to (4.1) and (4.2), respectively, while AIPWm refers
to an AIPW estimator where ϕk. (.) functions are misspecified. All the Web tables
and figures corresponding to this section are presented in Appendix A.4 of the sup-
plementary material available at Biometrics online.
4.5.1 SMART Design: Example 1
This is a type of SMART design in which just a subset of individuals are rerandom-
ized at stage 2. In our simulation, this subset is non-responders to stage-1 treatment
(see Web Figure 1). Thus, the embedded tailoring variable V ∈ {R,NR} is the indi-
cator of responder or non-responder status, respectively. Four DTRs are embedded
in this design depending on v-treatment trajectory T = (A1, ANR2 ); these are listed
in Web Table 1. Note that because there is only one treatment option for responders,
the v-treatment trajectory does not include AR2 . We generate these SMART data
with sample sizes 100, 200, 300 and 400 from the following generative model. The
stage-2 treatment option ANR2 ∈ {−1,+1} is generated from a Bernoulli distribution
with probability 0.5. The outcome is generated from normal distribution with mean
1 + O11 − O12 + O21 + O22 + A1(δ + O11) + Sδ/2ANR2 , with variance σ2 = 1, where
S = I(O21 > 0). The main effect of treatment options are parametrized with δ. The
true ϕk. s are given by
ϕk2(o¯2, a¯2 ∈ EDTRVk , γ) = γ0 + γ1o11 + γ2o12 + γ3o21 + γ4o22 + a1(γ5 + γ6o11) + γ7sa2,
ϕk1(o1, a1 ∈ EDTRVk , γ) = γ8 + γ9o11 + γ10o12 + γ11a1 + γ12a1o11.
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We also consider a misspecified scenario where ϕk2(o¯2, a¯2 = EDTR
V
k , γ
†) = γ†0+γ
†
1o11+
γ†2o21 + γ
†
3o22 and ϕ
k
1(o1, a1 = EDTRk,1, γ
†) = γ†4 + γ
†
5o11 are assumed to be working
models. Moreover, the marginal structural model is
m(T ; β) = β0 + β1A1 + β2ANR2 .
Hence, the true parameter value β∗ = (1.00, δ, δ/4), which means, for δ > 0, (A1 =
+1, ANR2 = +1) is the true best EDTR and, for δ < 0, (A1 = −1, ANR2 = −1) is the
true best EDTR. Table A.1 presents the point estimate and standard errors of the
parameters β3×1 and θ4×1 = Dβ estimated using IPW, AIPW and AIPWm, where
D =

1 1 1
1 −1 1
1 1 −1
1 −1 −1

.
The rows of this matrix represent EDTR1, ..., EDTR4 listed in Web Table 1. In
Table A.1, we set δ = 0.1 and generated 1000 datasets of sizes 100 and 400. Our
results show that AIPW reduces the standard error by up to 60% compared to IPW,
and even when ϕk. (.) functions are misspecified AIPWm maintains unbiasedness, but
some of the standard errors increase. In fact, under our misspecification scenario
AIPW still has better performance than IPW. We see a similar pattern in estimation
of the mean outcome under different EDTRs.
Figure A.1 shows how fast the size of the set of best Bˆ converges to 1 as δ increases
when the parameters of each EDTR is estimated using IPW and AIPW. Note that
for δ 6= 0, the true set size B is 1. For each δ, we generated 500 data sets and defined
the ESS as the empirical average of the set sizes for each data set. This figure shows
that when the parameters β of the marginal structural model are estimated using
AIPW, the ESS decreases to 1 faster than when using IPW. This is due to the more
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efficient estimation of βs.
4.5.2 SMART Design: Example 2
In some SMART designs, stage-2 randomization depends on prior treatment and
an intermediate outcome such as response indicator (see Web Figure 2). We generate
datasets of sizes 100, 200, 300 and 400 from the following generative model. The stage-
2 treatment options are generated from a multinomial distribution with probability
0.25 coded as 1,2,3, and 4. Let R ∈ {0, 1} be the non-response and response indicator,
respectively. Then, if V = I(A1 = +1) + I(A1 = −1)I(R = 1) = 1 (i.e., V satisfies
condition A), there is no randomization; while individuals with V = 0 (i.e., V satisfies
condition B) will be randomized to one of the four stage-2 treatment options. Hence
the v-treatment trajectory in this example is T = (A1, AB2 ). Five DTRs are embedded
in this design depending on the treatment trajectory (A1, A
B
2 ); these are listed in Web
Table 2.
The outcome is generated from a normal distribution with mean 1 +O11 −O12 +
O21 + O22 + I(A1 = −1)(δ + O11) + SI(A1 = −1)[−δ/4I(A2 = 1) + δ/2I(A2 =
2) + 0I(A2 = 3) + δ/2O21I(A2 = 2)] with variance σ
2 = 1, where S = I(O21 > 0).
Thus the true ϕk. (.)s are
ϕk2(o¯2, a¯2 = EDTR
V
k , γ)
= γ0 + γ1o11 + γ2o12 + γ3o21 + γ4o22 + I(a1 = −1)(γ5 + γ6o11)
+ sI(a1 = −1)[γ7I(a2 = 1) + γ8I(a2 = 2) + γ9I(a2 = 3) + γ10o21I(a2 = 2)],
ϕk1(o1, a1 ∈ EDTRk,1, γ) = γ11 + γ12o11 + γ13o12 + γ14I(a1 = −1) + γ15I(a1 = −1)o11.
We also consider a misspecified scenario where ϕk2(o¯2, a¯2 = EDTR
V
k , γ
†) = γ†0 +
γ†1o11 + γ
†
2o21 + γ
†
3o22 + γ
†
4a1 + sI(a1 = −1)[γ†5I(a2 = 1) + γ†6I(a2 = 2) + γ†7I(a2 = 3)]
and ϕk1(o1, a1 = EDTRk,1, γ
†) = γ†8 +γ
†
9o11 +γ
†
10a1 are assumed to be working models.
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The MSM is
m(T ;β) = β0 + β1I(A1 = −1) + I(A1 = −1)[β2I(AB2 = 1) + β3I(AB2 = 2) + β4I(AB2 = 3)].
Hence, the true parameter value β∗ = (1.00, δ,−δ/8, δ/4, 0), which means that for
positive and negative δs, (A1 = −1, AB2 = 2) and (A1 = −1, AB2 = 1) are the best
EDTRs, respectively. Table A.2 presents the bias and standard errors of the param-
eters β5×1 and θ5×1 = Dβ estimated using IPW, AIPW and AIPWm, where
D =

1 0 0 0 0
1 1 0 0 0
1 1 1 0 0
1 1 0 1 0
1 1 0 0 1

.
The rows of this matrix represent EDTR1, ..., EDTR5 listed in Web Table 2. In
Table A.2, we set δ = 0.4 and generated 1000 datasets of sizes 100 and 400. Our results
show that AIPW reduces the standard error of θs and βs by up to 55% compared to
IPW. The misspecified scenario, where the interaction terms in both ϕk. (.) functions
are ignored, results in estimators with slightly larger standard errors compared to
AIPW .
Figure A.2 shows how fast the size of the set of best converges to 1 as δ grows
when the parameters of each EDTR are estimated using IPW and AIPW. Note that
for δ 6= 0 the true set size B is 1. For each δ, we generated 500 datasets and defined
the ESS as the empirical average of the set sizes for each data set. This figure shows
that when the parameters β of the marginal model are estimated using AIPW, the
estimated set size decreases to 1 faster than when using IPW. This is due to more
efficient estimation of βs. The plot of ESS when estimated using AIPWm is omitted
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since it is similar to IPW in this simulation.
4.6 Illustrative data analysis
The EXTEND study was a 24-week, multistage clinical trial that enrolled alcohol
dependent patients (Lei et al., 2012). At stage 1, patients are randomized with
probability 0.5 to either the stringent or lenient definitions of non-response while
receiving naltrexone (NTX). Participants were assessed weekly for drinking behavior,
and starting at week 3, as soon as the participant met his/her assigned criterion
for early non-response, he/she was immediately re-randomized to one of two rescue
tactics: (1) offering CBI in addition to NTX (i.e., NTX+CBI); or (2) offering CBI
alone (i.e., CBI). Participants who did not meet their assigned criterion for early non-
response by the end of week 8 (i.e., responders to NTX) were re-randomized at that
point (i.e., end of week 8) to one of two maintenance tactics: either (1) adding TDM
to NTX (i.e., NTX+TDM) or offering NTX alone (NTX). Web Figure 3 (Appendix
A.4 of the supplementary material) depicts this two-stage SMART design.
For illustration we focus on a simplified version of this trial. Let the primary
outcome Y denote the Penn Alcohol Craving Scale (PACS) score over 24 weeks.
Lower PACSs are preferable. Let A1 denote the non-response criterion coded as -1
for stringent and +1 for lenient. The embedded tailoring variable V in this design
is the response/non-response status. The stage-2 treatment options for responders
are NTX (AR2 = −1) and NTX+TDM (AR2 = +1) and for non-responders the rescue
treatment options are CBI (ANR2 = −1) and NTX+CBI (ANR2 = +1). Additionally,
let R denote the indicator for whether (R=1) or not (R=0) the patient was a responder
to the initial NTX treatment. Web Figure 3 in Appendix A.4 of the supplementary
material available at Biometrics online shows the number of patients assigned to each
treatment option. By design, there are 23 EDTRs in this SMART based on different
combinations of (A1, A
R
2 , A
NR
2 ), which are listed in Web Table 3.
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Baseline variables include PACS before stage 1 (O11) and gender (O12). The
intermediate outcomes are the average PACS during stage 1 (O21) and the standard
error of the measured PACS during stage 1 (O22). We consider the following marginal
structural model: m(T , β) = β0+β1A1+β2AR2 +β3ANR2 . One may add the interaction
terms A1A
R
2 and A1A
NR
2 to this model. Also, we consider ϕ
k
2(o¯2, a¯2 = EDTR
V
k , γ) =
γ0 +γ1o11 +γ2o12 +γ3o21 +γ4o22 +a1(γ5 +γ6o11)+ra2(γ7 +γ8o21)+(1−r)a2(γ9 +γ10o21)
and ϕk1(o1, a1 = EDTRk,1, γ) = γ11 + γ12o11 + γ13o12 + γ14a1 + γ15a1o11 + γ16a1o12.
We estimated the parameter vector β4×1 and θ8×1 = Dβ using both the IPW (4.1)
and AIPW (4.2) estimators and the results are presented in Table A.3, where
D =

1 1 1 1
1 1 1 −1
1 1 −1 1
1 1 −1 −1
1 −1 1 1
1 −1 1 −1
1 −1 −1 1
1 −1 −1 −1

.
The rows of this matrix represent EDTR1, ..., EDTR8 listed in Web Table 3. The
point estimate and standard errors for β0 and β1 are very close using both estima-
tors. However, the parameters corresponding to AR2 and A
NR
2 have smaller standard
errors when estimated using AIPW. Moreover, our procedure screens out EDTR6
and EDTR8 when the parameter vector β is estimated using AIPW, but using IPW
results in keeping all eight EDTRs in the set of best. In other words, when using
MCB with the AIPW approach to estimate the mean outcome under each EDTR, re-
sults indicated that DTRs that begin with NTX, classifies patients as non-responders
by using a stringent criterion, and offers CBI alone to non-responders and NTX or
NTX+TDM to responders, do not belong to the set of best EDTRs.
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4.7 Discussion
An important research question motivating many SMART studies concern the
selection of the best (i.e., most efficacious) DTR among a set of DTRs that are
embedded in a SMART. However, this is often not possible due to small sample size.
In this manuscript, we propose a method that can be used to identify the set that
contains the best DTR. We frame the problem as a special case of multiple comparison
and show that the constructed set of best contains the true best DTR with at least
a given probability. We use the AIPW estimator to estimate the mean under each
DTR, and our simulation results show that for any given sample size the cardinality
of the constructed set of best is less than the cardinality obtained by IPW estimators,
while maintaining the Type I error rate. Moreover, we prove that the probability of
inclusion of an inferior DTR in the constructed set of best decays exponentially as
the difference between the best and the inferior DTR grows.
Currently most SMART designs are sized such that an investigator can detect
either a given stage-1 or stage-2 treatment effect or a given difference between two
DTRs with a given probability. One important extension of this work would be
to devise a method that can be used to plan SMART sample sizes such that the
constructed set of best includes at most m DTRs, for a fixed difference between the
best and the worst DTRs, with a given probability. This will be more consistent with
the goal of SMART designs in many applications.
4.8 Comparison with the modified version of ACI method
The work presented in this section is a joint work with undergrad student Rong
Zhou.
Another way of constructing a set that contains the best DTR is the modified
version of the ACI method discussed in chapter III. But there are two aspects that
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are different from that method. Below we will introduce this modified method in
detail.
First, we will adapt the dynamic programming idea discussed in Laber et al.
(2010), which is different from our idea in chapter III. Recall that we argue that we
assume that patients will choose the true worst treatment in the future while Laber
et al. (2010) assumes that patients will choose the true best treatment in the future.
The second difference is that instead of treating each treatment as a unit, we will
treat a DTR as a unit. Thus the we will try to evaluate the “effect” of a DTR.
Below is the detailed procedure of the modified ACI method. One remark is that this
modified ACI method can only be applied to embedded DTRs.
1. For the second stage treatments, if we have more than one options, form the
recommended set Sˆ2(A1, R) where A1 is the first stage treatment and R is the response
indicator. The procedure of forming the set is the same as that in chapter III
2. Define the hypothetical outcome Y˜ and form the confidence interval for the “effect”
of a first stage treatment as in Laber et al. (2010).
3. Use the adaptive confidence interval to construct the first stage recommended set
Sˆ1.
4. A DTR is included in the recommended set of DTR if and only if each of its
compartment is in the corresponding recommended set of treatments.
As an example of the last step, consider a set of eight DTRs where at the first
stage, at the second stage for responders and at the second stage for non-responders,
there are two available treatments. We use a triplet (A1, A2R, A2NR) to denote a DTR
where each of the three can take values 1 and -1. For a particular DTR (a1, a2R, a2NR)
to be included in the recommended set of DTRs, we need all a1 ∈ Sˆ1, a2R ∈ Sˆ2(A1 =
a1, R = 1) and a2NR ∈ Sˆ2(A1 = a1, R = 0) to be true.
Another remark is that since we are doing three hypothesis testing for one DTR,
for now we use Bonferroni correction to control the overall error rate. This means if
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we want to include the true best DTR with probability 1− α, then for each test we
will use 1− α/3 as the significance level.
We would like to check the performance of these two methods: the one introduced
in this chapter and denoted as MCB method, and the modified ACI method which
is denoted as ACI method for short. We will use the same generative model as in
chapter III as follows:
Y = γ1 + γ2X1 + γ3A1 + γ4X1A1 + γ5A2 + γ6X2A2 + γ7A1A2 + ,  ∼ N(0, 1)
For details of how A1, R and A2 are generated please refer to the simulation section
in chapter III.
We will compare the two methods in four scenarios. Each scenario represents
a case where a certain “degree of non-regularity” is obtained. We will compare the
probability of containing the true best DTR as well as the average set size. The latter
is a measure of how conservative a method is. On average, subjective to containing
the true best DTR with at least the given probability, a more conservative method
will end up in a set with larger average set size. Naturally the size of a set is the
number of DTRs it contains.
Intuitively, MCB method will perform better when the degree of non-regularity if
high, as in this case all DTRs are close and this is the least conservative scenario for
MCB, while in this case ACI will be the most conservative because the second stage
recommended set of treatments will contain both treatments with high probability,
ending up with a conservative confidence interval for the difference of effects of the two
first stage treatments. On the other hand, when the model is “regular”, i.e., there is a
significant difference between each pair of second stage treatments, ACI method will
be the least conservative while MCB method will be conservative since the number
of DTRs to be compared is unnecessarily large, resulting in an unnecessarily large
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recommended set of DTRs.
The detailed description and discussion are included in Appendix A.5
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CHAPTER V
Discussion and future work
5.1 Discussion
In this thesis we discussed several techniques and application of DTRs. The main
focus is to construct a recommended set of DTRs or treatments at a certain stage.
This technique allows clinicians and patients to have more choices according to their
own preferences. The treatments or DTRs contained in the recommended set are
those we cannot differentiate from the best while those we excluded are what we
believe to be inferior. The goal of constructing the set is not to pin down the sole
best treatment or DTR, but to exclude inferior options.
In order to construct the recommended set, we need to compare treatments or
DTRs, thus we review and develop many comparisons methods in this thesis. Each
of the methods discussed has its own advantages and disadvantages, and researchers
will choose among them according to their preference and the scientific questions they
are trying to answer.
The main part of this thesis is chapter III, where we introduce a new definition of
the effect of a non-final stage treatment. Following this definition, we construct the
recommended set of non-final stage treatments using ACI technique to overcome the
non-regularity problems. A consistency theorem is proved as well. Simulation studies
shows both the poor behavior of the naive bootstrap method under some certain
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scenario and the power of our new method. This method is generalized to the case
where we have more than two treatments per stage.
5.2 Future work
There is a long way along the set valued policy setting. First, we have not proved
the consistency result for the case where there are more than two treatments per
stage. This will be a main focus after my graduation. Also, we are using the “un-
standardized” vector in the hypothesis test. This will be fine if the true variances of
the estimator of the effects of the treatments are close, which should be the common
case in reality. However we need to examine the behavior of our method under the
scenario that the variances differ by a considerably large amount.
Another direction, as has been discussed at the end of chapter III, is that we
will try to extend our procedure to the case where there are more than three stages.
Laber et al. (2010) discussed this situation but they assumed that the covariance of the
estimated difference between a certain treatment and the true best treatment, is the
covariance of the estimated difference between this treatment and the treatment with
the larges point estimator. Mathematically they assumed v̂ar(θˆi − θˆ[N ]) = v̂ar(θˆi −
θˆ(N)) where [N ] = arg maxi θi and (N) = arg maxi θˆi. In our future work we will try
to examine how bad it can be if this is violated.
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APPENDIX
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APPENDIX A
Related Proof and other supplements
A.1 The proof of theorem III.5
This section provides the proof of all the theorems in section 3. The proof of these
theorems requests several lemmas. First, we state some results without proving.
They are results for the second stage estimation and the proofs are exactly the same
as those in Laber et al. (2010).
Theorem A.1. Assume (A1) and (A2) and fix a ∈ Rp2, then
1. aT
√
n(θˆ2 − θ∗2) d−→P aZ∞,
2. aT
√
n(θˆ
(b)
2 − θˆ2) d−→PM aZ∞ in P-probability; and
3. if in addition (A3) holds, aT
√
n(θˆ2 − θ∗2,n) d−→PM aZ∞
where Z∞ is a mean zero normal random vector with covariance matrix Σ−12,∞P [B2BT2 (Y2−
BT2 θ
∗
2)
2]Σ−12,∞.
Theorem A.2. Assume (A1),(A2), then Σˆ2 →P Σ2,∞, and Σˆ(b)2 →PM Σ2,∞ in P-
probability as n→∞. Furthermore if (A3) holds then Σˆ2 →Pn Σ2,∞ as n→∞.
Now we prove the main theorem. First we define a sequence of functions to have a
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decomposition of U(c).
1. ω11 : Dp1×Dp1×p20×Dp21× l∞(F11)× l∞(F11)×Rp2×Rp21×Rp1+p2 → R is defined
as
ω11(Σ1,Σ12,Σ21,21µ, ω, ν, η, θ)
:= µ(cTΣ−11 B1(Y1 +H
T
2,1θ2,0 − |HT2,1θ2,1|1(T (H2,1, η + ν1,Σ21,21) ≤ χ)
+HT2,1θ2,1sign(H
T
2,1(η + ν1))1(T (H2,1, η + ν1,Σ21,21) > χ)−B1θ1)
+cTΣ−11 Σ12ν0 + ω(c
TΣ−11 B1H
T
2,1ν11HT2,1θ∗2,1>0)− ω(cTΣ−11 B1HT2,1ν11HT2,1θ∗2,1<0)
where F11 = {f(b1, y1, h2,0, h2,1) = aT1 b1(y1+hT2,0θ2,0−|hT2,1θ2,1|1(T (h2,1, η+ν1,Σ21,21) ≤
χ)+hT2,1θ2,1sign(h
T
2,1(η+ν1))1(T (h2,1, η+ν1,Σ21,21) > χ)−bT1 θ1)+aT2 b1(hT2,1ν1)1hT2,1θ∗2,1>0−
aT2 b1(h
T
2,1ν1)1hT2,1θ∗2,1<0 : θ = (θ
T
1 , θ
T
2,0, θ
T
2,1)
T ∈ Rp1+p2 , ν = (νT0 , νT1 )T ∈ Rp2 , η ∈
Rp21 .a1.a2 ∈ Rp1 , max{||a1||, ||a2||, ||θ||, ||ν||, ||η||} ≤ K}.
2. ω12 : Dp1 ×Dp21 × l∞(F12)× Rp21 × Rp21 → R is defined as
ω12(Σ1,Σ21,21, µ, ν, γ) := µ
[
cTΣ−11 B1(|HT2,1ν +HT2,1γ| − |HT2,1γ|)
×(21(T (H2,1, ν + γ,Σ21,21) > χ)− 1))1HT2,1θ∗2,1=0
]
where F12 = {f(b1, h2,1) = aT b1(|hT2,1(ν + γ)| − |hT2,1γ|)(21(T (h2,1, ν + γ,Σ21,21) >
χ)− 1))1hT2,1θ∗2,1=0) : a ∈ Rp1 , ν, γ ∈ Rp1 ,max{||a||, ||ν||, ||γ||} ≤ K}
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3. ω13 : Dp1 ×Dp21 × l∞(F13)× Rp21 × Rp21 → R is defined as
ω13(Σ1,Σ21,21, µ, ν, γ)
:= 2µ
[
cTΣ−11 B1|HT2,1γ|1(T (H2,1, ν + γ,Σ21,21) > χ)×
1(HT2,1γ ×HT2,1(ν + γ) < 0)1HT2,1θ∗2,1=0
]
where F13 = {f(b1, h2,1) = aT b1|hT2,1γ|1(T (h2,1, ν + γ,Σ21,21) > χ)1(hT2,1γ × hT2,1(ν +
γ) < 0)1hT2,1θ∗2,1=0) : a ∈ Rp1 , ν, γ ∈ Rp1 ,max{||a||, ||ν||, ||γ||} ≤ K}
4.ρ11 : Dp1 ×Dp21 × l∞(F˜11)× Rp21 × Rp21 × Rp21 × R→ R is defined as
ρ11(Σ1,Σ21,21, µ, ν, η, γ, λ)
= µ
[
cTΣ−11 B1(|HT2,1(ν + γ)| − |HT2,1γ|)(21(T (H2,1, ν + γ,Σ21,21) > χ)− 1)
×(1(T (H2,1, ν + η,Σ21,21) ≤ λ)− 1HT2,1θ∗2,1=0)
]
where F˜11 = f(b1, h2,1) = aT b1(|hT2,1(ν + γ)| − |hT2,1γ|)(21(T (h2,1, ν + γ,Σ21,21) >
χ)− 1)(1(T (h2,1, ν + η,Σ21,21) ≤ λ)− 1hT2,1θ∗2,1=0) : a ∈ Rp1 , ν, η ∈ Rp21 ,Σ21,21 ∈ Dp21 ,
max{||a||, ||ν||, ||η||, ||γ||} ≤ K}
5.ρ12 : Dp1 ×Dp21 × l∞(F˜12)× Rp21 × Rp21 → R is defined as
ρ12(Σ1,Σ21,21, µ, ν, η)
:= µ(cTΣ−11 B1(|HT2,1(ν + η)− |HT2,1η|)(21(T (H2,1, ν + η,Σ21,21) > χ)− 1)
−HT2,1ν)1HT2,1θ∗2,1>0
]
+µ(cTΣ−11 B1(|HT2,1(ν + η)− |HT2,1η|))(21(T (H2,1, ν + η,Σ21,21) > χ)− 1)
+HT2,1ν)1HT2,1θ∗2,1<0
]
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where F˜12 = {f(b1, h2,1) = aT b1((|hT2,1(ν + η)| − |hT2,1η|)(21(T (h2,1, ν + η,Σ21,21) >
χ) − 1) − hT2,1ν)1HT2,1θ∗2,1>0 + aT b1((|hT2,1(ν + η)| − |hT2,1η|)(21(T (h2,1, ν + η,Σ21,21) >
χ) − 1) + hT2,1ν)1HT2,1θ∗2,1<0 : a ∈ Rp1 , ν, η ∈ Rp21 ,Σ21,21 ∈ Dp21 ,max{||a||, ||ν||, ||η||} ≤
K}
6.ρ13 : Dp1 ×Dp21 × l∞(F˜13)× Rp21 × Rp21 → R is defined as
ρ13(Σ1,Σ21,21, µ, ν, γ)
:= 2µ
[
(cTΣ−11 B1(|HT2,1γ|1(T (H2,1, ν + γ,Σ21,21) > χ)×
1(HT2,1γ ×HT2,1(ν + γ) < 0)1HT2,1θ∗2,1 6=0
]
where F˜13 = {f(b1, h2,1) = aT b1(|hT2,1γ|1(T (h2,1, ν + γ,Σ21,21) > χ)1(hT2,1γ × hT2,1(ν +
γ) < 0)1hT2,1θ∗2,1 6=0 : a ∈ Rp1 , ν, γ ∈ Rp21 ,Σ21,21 ∈ Dp21 ,max{||a||, ||ν||, ||γ||} ≤ K}
7.ρ14 : Dp1 ×Dp21 × l∞(F˜14)× Rp21 × Rp21 × Rp21 × R→ R is defined as
ρ14(Σ1,Σ21,21, µ, ν, η, γ, λ)
:= 2µ
[
(cTΣ−11 B1(|HT2,1γ|1(T (H2,1, ν + γ,Σ21,21) > χ)1(HT2,1γ ×HT2,1(ν + γ) < 0)
×(1(T (H2,1, ν + η,Σ21,21) ≤ λ)− 1HT2,1β∗2,1=0)
]
where F˜13 = {f(b1, h2,1) = aT b1(|hT2,1γ|1(T (h2,1, ν + γ,Σ21,21) > χ)1(hT2,1γ × hT2,1(ν +
γ) < 0)(1(T (h2,1, ν + η,Σ21,21) ≤ λ) − 1hT2,1β∗2,1=0) : a ∈ Rp1 , ν, γ, η ∈ Rp21 ,Σ21,21 ∈
Dp21 ,max{||a||, ||ν||, ||γ||, ||η||} ≤ K}
Using the following functions we have the following expressions for the first stage
parameters:
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cT
√
n(θˆ1 − θˆ∗1) = ω11(Σˆ1, Σˆ12, Σˆ21,21,Gn,Pn,
√
n(θˆ2 − θ∗2),
√
nθ∗2,1, (θˆ
∗T
1 , θ
∗T
2 )
T )
+ω12(Σˆ1, Σˆ21,21,Pn,
√
n(θˆ2,1 − θ∗2,1),
√
nθ∗2,1)
+ω13(Σˆ1, Σˆ21,21,Pn,
√
n(θˆ2,1 − θ∗2,1),
√
nθ∗2,1)
+ρ12(Σˆ1, Σˆ21,21,Pn,
√
n(θˆ2,1 − θ∗2,1),
√
nθ∗2,1)
+ρ13(Σˆ1, Σˆ21,21,Pn,
√
n(θˆ2,1 − θ∗2,1),
√
nθ∗2,1)
cT
√
n(θˆ1 − θˆ∗1,n) = ω11(Σˆ1, Σˆ12,
√
n(Pn − Pn),Pn,
√
n(θˆ2 − θ∗2,n), (θ∗T1,n, θ∗T2,n)T )
+ω12(Σˆ1, Σˆ21,21,Pn,
√
n(θˆ2,1 − θ∗2,1,n),
√
nθ∗2,1,n)
+ω13(Σˆ1, Σˆ21,21,Pn,
√
n(θˆ2,1 − θ∗2,1,n),
√
nθ∗2,1,n)
+ρ12(Σˆ1, Σˆ21,21,Pn,
√
n(θˆ2,1 − θ∗2,1,n),
√
nθ∗2,1,n)
+ρ13(Σˆ1, Σˆ21,21,Pn,
√
n(θˆ2,1 − θ∗2,1,n),
√
nθ∗2,1,n)
Similarly we can express the upper bound U(c) in terms of the above functions:
U(c) = ω11(Σˆ1, Σˆ12, Σˆ21,21,Gn,Pn,
√
n(θˆ2 − θ∗2),
√
nθ∗2,1, (θˆ
∗T
1 , θ
∗T
2 )
T )
−ρ11(Σˆ1, Σˆ21,21,Pn,
√
n(θˆ2,1 − θ∗2,1),
√
nθ∗2,1,
√
nθ∗2,1, λn)
+ρ12(Σˆ1,Pn,
√
n(θˆ2,1 − θ∗2,1),
√
nθ∗2,1)
+ρ13(Σˆ1, Σˆ21,21,Pn,
√
n(θˆ2,1 − θ∗2,1),
√
nθ∗2,1)
+ρ14(Σˆ1, Σˆ21,21,Pn,
√
n(θˆ2,1 − θ∗2,1),
√
nθ∗2,1,
√
nθ∗2,1, λn)
+ sup
γ∈Rdim(θ
∗
2,1)
[
ω12(Σˆ1, Σˆ21,21,Pn,
√
n(θˆ2,1 − θ∗2,1), γ)
ω13(Σˆ1, Σˆ21,21,Pn,
√
n(θˆ2,1 − θ∗2,1), γ)
+ρ11(Σˆ1, Σˆ21,21,Pn,
√
n(θˆ2,1 − θ∗2,1),
√
nθ∗2,1, γ, λn)
+ρ14(Σˆ1, Σˆ21,21,Pn,
√
n(θˆ2,1 − θ∗2,1),
√
nθ∗2,1, γ, λn)
]
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We will also make use of the following alternative expression for the upper bound
U(c) under Pn:
U(c) = ω11(Σˆ1, Σˆ12,
√
n(Pn − Pn),Pn,
√
n(θˆ2 − θ∗2,n),
√
nθ∗2,1,n, (θ
∗T
1,n, θ
∗T
2,n)
T )
−ρ10(Σˆ1, Σˆ21,21,Pn,
√
n(θˆ2,1 − θ∗2,1,n),
√
nθ∗2,1,n,
√
nθ∗2,1,n, λn)
+ρ12(Σˆ1,Pn,
√
n(θˆ2,1 − θ∗2,1,n),
√
nθ∗2,1,n)
+ρ13(Σˆ1, Σˆ21,21,Pn,
√
n(θˆ2,1 − θ∗2,1,n),
√
nθ∗2,1,n)
+ρ14(Σˆ1, Σˆ21,21,Pn,
√
n(θˆ2,1 − θ∗2,1,n),
√
nθ∗2,1,n,
√
nθ∗2,1,n, λn)
+ sup
γ∈Rdim(θ
∗
2,1)
[
ω12(Σˆ1, Σˆ21,21,Pn,
√
n(θˆ2,1 − θ∗2,1,n), γ)
ω13(Σˆ1, Σˆ21,21,Pn,
√
n(θˆ2,1 − θ∗2,1,n), γ)
+ρ11(Σˆ1, Σˆ21,21,Pn,
√
n(θˆ2,1 − θ∗2,1,n),
√
nθ∗2,1,n, γ, λn)
+ρ14(Σˆ1, Σˆ21,21,Pn,
√
n(θˆ2,1 − θ∗2,1,n),
√
nθ∗2,1,n, γ, λn)
]
Similarly we will make use of following expression for the bootstrap analog of the
upper bound
U (b)(c) = ω11(Σˆ(b)1 , Σˆ(b)12 ,
√
n(P(b)n − Pn),P(b)n ,
√
n(θˆ
(b)
2 − θˆ2),
√
nθˆ2,1, (θˆ
T
1 , θˆ
T
2 )
T )
−ρ10(Σˆ(b)1 , Σˆ(b)21,21,P(b)n ,
√
n(θˆ
(b)
2,1 − θˆ2,1),
√
nθˆ2,1,
√
nθˆ2,1, λn)
+ρ12(Σˆ
(b)
1 ,P(b)n ,
√
n(θˆ
(b)
2,1 − θˆ2,1),
√
nθˆ2,1)
+ρ13(Σˆ
(b)
1 , Σˆ
(b)
21,21,P(b)n ,
√
n(θˆ
(b)
2,1 − θˆ2,1),
√
nθˆ2,1)
+ρ14(Σˆ
(b)
1 , Σˆ
(b)
21,21,P(b)n ,
√
n(θˆ
(b)
2,1 − θˆ2,1),
√
nθˆ2,1,
√
nθˆ2,1, λn)
+ sup
γ∈Rdim(θ
∗
2,1)
[
ω12(Σˆ
(b)
1 , Σˆ
(b)
21,21,P(b)n ,
√
n(θˆ
(b)
2,1 − θˆ2,1), γ)
ω13(Σˆ
(b)
1 , Σˆ
(b)
21,21,P(b)n ,
√
n(θˆ
(b)
2,1 − θˆ2,1), γ)
+ρ11(Σˆ
(b)
1 , Σˆ
(b)
21,21,P(b)n ,
√
n(θˆ
(b)
2,1 − θˆ2,1),
√
nθˆ2,1, γ, λn)
+ρ14(Σˆ
(b)
1 , Σˆ
(b)
21,21,P(b)n ,
√
n(θˆ
(b)
2,1 − θˆ2,1),
√
nθˆ2,1, γ, λn)
]
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Below we argue that ρ11 through ρ14 are negligible and ω11 through ω13 are continuous
in such a fashion so as to facilitate the use of continuous mapping theorem.
First we show the negligibility of the ρs. The function ρ11 is the most difficult to
handle so we address it here and omit the proof of ρ12, ρ13 and ρ14.
Theorem A.3. Assume (A1)-(A4). Then
1. supγ∈Rp21 |ρ11(Σˆ1, Σˆ21,21,Pn,
√
n(θˆ2,1 − θ∗2,1),
√
nθ∗2,1, γ, λn)| →P 0.
2. supγ∈Rp21 |ρ11(Σˆ(b)1 , Σˆ(b)21,21, Pˆ(b)n ,
√
n(θˆ
(b)
2,1 − θˆ2,1),
√
nθˆ2,1, γ, λn)| →PM 0 almost surely
P .
3. supγ∈Rp21 |ρ11(Σˆ1, Σˆ21,21,Pn,
√
n(θˆ2,1 − θ∗2,1,n),
√
nθ∗2,1,n, γ, λn)| →Pn 0,
Proof. First, it’s easy to show that ||HT2,1ν−HT2,1γ|− |HT2,1γ|| ≤ |HT2,1ν|. Thus for any
probability measure µ in l∞(F˜11),
|ρ11(Σ1,Σ21,21, µ, ν, η, γ, λ)|
≤ K
{
µ(||B1|| ||H2,1||1H∗2,1θ∗2,1=0,HT2,1η/||H2,1||>√λk−K)
+µ(||B1|| ||H2,1||1H∗2,1θ∗2,1=0,HT2,1η/||H2,1||<√λk−K)
+µ(||B1|| ||H2,1||1H∗2,1θ∗2,1 6=0,√λk−K≤HT2,1η/||H2,1||≤√λk+K)
}
for a sufficiently large constant K > 0 and a sufficiently small constant k ∈ (0, 1).
The rest of the proof is exactly the same as those in Laber et al. (2010).
Next we would like to show that ω11 is continuous at points in
(Σ1,∞,Σ12,∞, Cb(F11), P,Rp2 , (θˆ∗T1 , θ∗T2 )T ), ω12(·, ·, ·, ·,
√
nθ∗2,1) ,ω12(·, ·, ·, ·,
√
nθ∗2,1,n),
ω13(·, ·, ·, ·,
√
nθ∗2,1) and ω13(·, ·, ·, ·,
√
nθ∗2,1,n) are continuous at points in
(Σ1,∞,Σ21,21,∞, P,Rp21), and ω′12 := supγ∈Rp21 ω12(Σ1,Σ21,21, µ, ν, γ),
ω′13 := supγ∈Rp21 ω13(Σ1,Σ21,21, µ, ν, γ) are continuous at points in (Σ1,∞,Σ21,21,∞, P,Rp21).
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To prove the desired continuity of ω12 and ω
′
12, we will establish the stronger result
that ω13 is continuous at points (Σ1,∞,Σ21,21,∞, P,Rp21 , γ,+∞) uniformly in γ. That
is, for any Σn → Σ1,∞,Σ21,21,n → Σ21,21,∞, probability measure µn → P and νn → ν
(where ν equals one of the following:
√
n(θˆ2,1−θ∗2,1),
√
n(θˆ2,1−θ∗2,1,n),
√
n(θˆ
(b)
2,1− θˆ2,1)),
we have
Theorem A.4. supγ |ω12(Σn,Σ21,21,n, µn, νn, γ)− ω12(Σ1,∞,Σ21,21,∞, P, ν, γ)| → 0
Proof.
|ω12(Σn,Σ21,21,n, µn, νn, γ)− ω12(Σ1,∞,Σ21,21,∞, P, ν, γ)|
≤ |ω12(Σn,Σ21,21,n, µn, νn, γ)− ω12(Σn,Σ21,21,n, µn, ν, γ)|
+|ω12(Σn,Σ21,21,n, µn, ν, γ)− ω12(Σn,Σ21,21,n, P, ν, γ)|
+|ω12(Σn,Σ21,21,n, P, ν, γ)− ω12(Σn,Σ21,21,∞, P, ν, γ)|
+|ω12(Σn,Σ21,21,∞, P, ν, γ)− ω12(Σ1,∞,Σ21,21,∞, P, ν, γ)|
= I + II + III + IV
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I= µn
[
cTΣ−1n B1(|HT2,1(νn + γ)| − |HT2,1γ|)(21(T (H2,1, νn + γ,Σ21,21,n) > χ)− 1)×
1HT2,1θ
∗
2,1=0
]
−µn
[
cTΣ−1n B1(|HT2,1(ν + γ)| − |HT2,1γ|)(21(T (H2,1, ν + γ,Σ21,21,n) > χ)− 1)×
1HT2,1θ
∗
2,1=0
]
= µn
[
cTΣ−1n B1(|HT2,1(νn + γ)| − |HT2,1(ν + γ)|)(21(T (H2,1, νn + γ,Σ21,21,n) > χ)
−1)1HT2,1θ∗2,1=0
]
+2µn
[
cTΣ−1n B1(|HT2,1(ν + γ)| − |HT2,1γ|)
×(1(T (H2,1, νn + γ,Σ21,21,n) > χ)− 1(T (H2,1, ν + γ,Σ21,21,n) > χ))1HT2,1θ∗2,1=0
]
= I1 + I2
We have I1 ≤ µn(|cTΣ−1n B1|HT2,1(νn − ν)||) ≤ ||c|| ||Σ−1n ||µn(||B1|| ||H2,1||)||νn − ν|| =
o(1) since we have ||Σ−1n || is bounded above for sufficiently large n.
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Let M := ||c|| ||Σ−1n || ||B1|| ||H2,1|| ||ν||, then
I2
≤ ||c|| ||Σ−1n ||µn
[
||B1|| ||H2,1|| ||ν||(1(T (H2,1, νn + γ,Σ21,21,n) > χ)
−1(T (H2,1, ν + γ,Σ21,21,n) > χ))
]
= µn
[
M |1(T (H2,1, νn + γ,Σ21,21,n) > χ)− 1(T (H2,1, ν + γ,Σ21,21,n) > χ)|
]
= µn
[
M |1(T (H2,1, νn + γ,Σ21,21,n) > χ)− 1(T (H2,1, ν + γ,Σ21,21,n) > χ)|
×1(T (H2,1, ν + γ,Σ21,21,∞) > χ+ δ)
]
= µn
[
M |1(T (H2,1, νn + γ,Σ21,21,n) > χ)− 1(T (H2,1, ν + γ,Σ21,21,n) > χ)|
×1(T (H2,1, ν + γ,Σ21,21,∞) < χ− δ)
]
= µn
[
M |1(T (H2,1, νn + γ,Σ21,21,n) > χ)− 1(T (H2,1, ν + γ,Σ21,21,n) > χ)|
×1(χ− δ ≤ T (H2,1, ν + γ,Σ21,21,∞) ≤ χ+ δ)
]
:= I21(δ) + I22(δ) + I23(δ)
For any positive number δ.
I23(δ) ≤ 2Mµn1(χ−δ ≤ T (H2,1, ν+γ,Σ21,21,∞) ≤ χ+δ) ≤ 2M ||µn−P ||+2MP1(χ−
δ ≤ T (H2,1, ν + γ,Σ21,21,∞) ≤ χ + δ). When δ → 0, the second term converges
to 2MP1((T (H2,1, ν + γ,Σ21,21,∞) = χ + δ) = 0 since we have m1((T (H2,1, ν +
γ,Σ21,21,∞) = χ + δ) = 0 and we have the absolute continuity assumption. The first
term goes to zero as n increases. So for any  > 0, there exists N1 sufficiently large
and δ > 0 sufficiently small such that I23(δ) < /3 for all n > N1.
For this fixed δ, as νn → ν and Σ21,21,n → Σ21,21,∞ and T is continuous with respect
to all its components we have both T (H2,1, νn +γ,Σ21,21,n) and T (H2,1, ν+γ,Σ21,21,n)
converge to T (H2,1, ν + γ,Σ21,21,∞) and the speed is independent of γ. So there
exists N2 such that P
(
|T (H2,1, νn + γ,Σ21,21,n) − T (H2,1, ν + γ,Σ21,21,∞)| < δ/2
)
≥
1 − /9 and P
(
|T (H2,1, ν + γ,Σ21,21,n) − T (H2,1, ν + γ,Σ21,21,∞)| < δ/2
)
≥ 1 −
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/9 for all n > N2. In such case, I23(δ) ≤ 2M ||µn − P || + MP
[
|1(T (H2,1, νn +
γ,Σ21,21,n) > χ)− 1(T (H2,1, ν + γ,Σ21,21,n) > χ)|1(T (H2,1, ν + γ,Σ21,21,∞) > χ+ δ)
]
.
The first term is no larger than /9 when n > N3 for some large N3, the second
term is no larger than MP
[
1(T (H2,1, νn+γ,Σ21,21,n) ≤ χ)1(T (H2,1, ν+γ,Σ21,21,∞) >
χ + δ)
]
+ MP
[
1(T (H2,1, ν + γ,Σ21,21,n) ≤ χ)1(T (H2,1, ν + γ,Σ21,21,∞) > χ + δ)
]
=
MP
(
|T (H2,1, νn + γ,Σ21,21,n) − T (H2,1, ν + γ,Σ21,21,∞)| < δ/2
)
+ MP
(
|T (H2,1, ν +
γ,Σ21,21,n)−T (H2,1, ν + γ,Σ21,21,∞)| < δ/2
)
≤ /9 + /9. So we have I21(δ) ≤ /3 for
all n > max(N2, N3). Similarly we have I22(δ) ≤ /3 for all n > max(N2, N3).
So for all n > max(N1, N2, N3) we have that I2 < . So we have I → 0.
II
= |(µn − P )((cTΣ−1n B1(|HT2,1ν +HT2,1γ| −
|HT2,1γ|)(21(T (H2,1, ν + γ,Σ21,21,n) > χ)− 1)1HT2,1θ∗2,1=0
≤ |(µ− P )|cTΣ−1n B1(|HT2,1ν +HT2,1γ| − |HT2,1γ|)||
If ||ν|| = 0 obviously II = 0. Otherwise, II ≤ |(µn − P )|((cTΣ−1n B1(|HT2,1ν +
HT2,1γ|/||ν|| − |HT2,1γ|/||ν||)| · ||ν|| ≤ ||µn − P || · ||ν|| → 0.
III
= 2P (cTΣ−1n B1(|HT2,1(ν + γ)| − |HT2,1γ|)
×(1(T (H2,1, ν + γ,Σ21,21,n) > χ)− 1(T (H2,1, ν + γ,Σ21,21,∞) > χ))1HT2,1θ∗2,1=0
Following similar proof for the convergence of I2 we have III → 0 uniformly over γ
as n→∞.
IV ≤ P(||Σ−1n − Σ−11,∞||(||cT || ||B1|| ||HT2,1|| ||ν||))→ 0.
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This established the continuity of ω12 and hence ω
′
12. The continuity of ω11 and
ω13 can be established through similar arguments and is therefore omitted.
A.2 The proof of lemma III.8
First we prove the lemma for the case where the treatment can take two values.
Lemma A.5. Suppose the treatment A can take two values 1 and -1. We are using
the linear model as
E(Y ) = h0β0 + h1β1 × f(A) (A.1)
where h1 ⊂ h0 and f is any function satisfying f(1) 6= f(−1). Denote the OLS
solution of (A.1) as
βˆ(f) = (βˆ
(f)
0 , βˆ
(f)
1 )
Then for any new observation c = (c0, c1f(A)), we have that both c0βˆ
(f)
0 +c1βˆ
(f)
1 ×f(1)
and c0βˆ
(f)
0 + c1βˆ
(f)
1 × f(−1) do not depend on f .
Proof. Let our observation have the form H0, H1 and Y . The proof of this lemma is
equivalent to prove that for every choice of f , the two terms above equal to the case
when f is identity function.
First without of loss we assume that the first n1 samples received A = 1 and the last
n2 samples received A = −1. (Thus n = n1 + n2) Denote p1 as the dimension of β1.
As we have H1 ⊂ H0, without loss we assume that the last p1 columns of H0 is H1
and rewrite H0 = (H0,0, H1). Let XI and Xf denote the design matrix when f equals
to identity function and general f , i.e.
XI =
 H0,0,1 H1,1 H1,1
H0,0,−1 H1,−1 −H1,−1
 Xf =
 H0,0,1 H1,1 H1,1f(1)
H0,0,−1 H1,−1 H1,−1f(−1)

where the last subscript of Hs means the treatment they receive. We denote the
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number of columns of H0,0,1 as p0. So the dimension of β is p = p0 + 2p1. It’s not
hard to show that we have Xf = XI ×Q where Q is a p by p matrix with the form
Q =

Ip0×p0 O O
O Ip1×p1 J1
O O J2
 J1 = f(1) + f(−1)2 Ip1×p1 , J2 = f(1)− f(−1)2 Ip1×p1 ,
Another thing to mention is Q is invertible.
Denote the estimator of β using f being identity matrix as βˆ(I), we will only show
that c0βˆ
(f)
0 + c1βˆ
(f)
1 × f(1) = c0βˆ(I)0 + c1βˆ(I)1 . The other equality can be proved using
exactly the same argument.
Denote cI = (c0, c1) and cf = (c0, c1f(1)), we also have cf = cIQ. Then
c0βˆ
(f)
0 + c1βˆ
(f)
1 × f(1) = cf βˆ(f)
= cf (X
T
f Xf )
−1XTf Y
= cIQ(Q
TXTI XIQ)
−1QTXIY
= cIQQ
−1(XTI XI)
−1Q−TQTXTI Y
= cI(X
T
I XI)
−1XTI Y
= cI βˆ
(I) = c0βˆ
(I)
0 + c1βˆ
(I)
1
And And
V ar(cf βˆ
(f))
= cf (X
T
f Xf )
−1cTf × (Y −Xf βˆ(f))T (Y −Xf βˆ(f))/n
= cIQ(Q
TXTI XIQ)
−1QT cTI × (Y −XI βˆ(I))T (Y −XI βˆ(I))/n
= cI(X
T
I XI)
−1cTI × (Y −XI βˆ(I))T (Y −XI βˆ(I))/n
= V ar(cI βˆ
(I))
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Now we prove lemma A.6
Similarly, we first make a special choice of f1 and f2. Here we use f1(A) = 1(A = 1)
and f2(A) = 1(A = 2). Denote the corresponding design matrix as X0, again without
loss we assume that the number of columns ofH2,1 = H2,2 as p1 and the last p1 columns
of H2,0 are H2,1. i.e., H2,0 = (H2,0,0, H2,1). Denote the number of columns of H2,0,0 as
p0. So the number of columns of H2 is p = p0 + 3p1. Again without loss we assume
that the first n0 rows of observations receive A2 = 0, the next n1 rows receive A2 = 1
and the last n3 rows receive A2 = 2. n = n1 + n2 + n3. We can rewrite X0 as
X0 =

H2,0,0,0 H2,1,0 O O
H2,0,0,1 H2,1,1 H2,1,1 O
H2,0,0,2 H2,1,2 O H2,1,2

where H2,0,0,i is ni by p0 matrix meaning the rows of H2,0,0 receiving A2 = i. Let Xf
be the design matrix when we use the general f1 and f2. Again all we need to prove
is that the estimated effect and variance will be equal to the case when we choose
f1(A) = 1(A = 1) and f2(A) = 1(A = 2). We have
Xf =

H2,0,0,0 H2,1,0 H2,1,0f1(0) H2,1,0f2(0)
H2,0,0,1 H2,1,1 H2,1,1f1(1) H2,1,1f2(1)
H2,0,0,2 H2,1,2 H2,1,2f1(2) H2,1,2f2(2)

We have Xf = X0Q where
Q =

Ip0×p0 O O O
O Ip1×p1 If1(0) If2(0)
O −I Ip1×p1(f1(1)− f1(0)) I(f2(1)− f2(0))
O −I I(f1(2)− f1(0)) Ip1×p1(f2(2)− f2(0))

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Again Q is invertible. For any new sample with c0 under the coding of which X0 is
the design matrix, it becomes cf = c0Q under the coding of which Xf is the design
matrix. So we have
cf βˆ
(f)
= cf (X
T
f Xf )
−1XTf Y
= cIQ(Q
TXT0 X0Q)
−1QTX0Y
= cIQQ
−1(XT0 X0)
−1Q−TQTXT0 Y
= cI(X
T
0 X0)
−1XT0 Y
= cI βˆ
(0)
And
V ar(cf βˆ
(f))
= cf (X
T
f Xf )
−1cTf × (Y −Xf βˆ(f))T (Y −Xf βˆ(f))/n
= c0Q(Q
TXT0 X0Q)
−1QT cT0 × (Y −X0βˆ(0))T (Y −X0βˆ(0))/n
= c0(X
T
0 X0)
−1cT0 × (Y −X0βˆ(0))T (Y −X0βˆ(0))/n
= V ar(c0βˆ
(0))
A.3 Proof of theorems in chapter IV
Lemma A.6. For any random variable X , x1, x2, let xmin := min{x1, x2}, xmax :=
max{x1, x2}, we have P (X ≥ x1) ≥ P (X ≥ x2)− P (xmin ≤ X ≤ xmax).
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Proof.
P (X ≥ x2) = P (X ≥ x2, x2 ≥ x1) + P (X ≥ x2, x2 < x1)
≤ P (X ≥ x1, x2 ≥ x1) + P (X ≥ x1, x2 < x1) + P (x2 ≤ X ≤ x1, x2 < x1)
= P (X ≥ x1) + P (x2 ≤ X ≤ x1, x2 < x1)
≤ P (X ≥ x1) + P (xmin ≤ X ≤ xmax)
Thus we have P (X ≥ x1) ≥ P (X ≥ x2)− P (xmin ≤ X ≤ xmax).
Proof of Theorem IV.2: For notation convenience we define K = arg maxi θi (i.e.
∀i, θK ≥ θi).
P (K ∈ Bˆ)
= P (
θˆK − θˆ1
σˆk1
≥ −cˆK , · · · , θˆK − θˆK−1
σˆK(K−1)
≥ −cˆK)
= P (wK1 ≥ −cˆK − θk − θ1
σˆK1
, · · · , wK(K−1) ≥ −cˆK − θk − θN
σˆK(K−1)
)
≥ P (wK1 ≥ −cˆK , · · · , wK(K−1) ≥ −cˆK)
≥ P (wK1 ≥ −cK , wK2 ≥ −cˆK , · · · , wK(K−1) ≥ −cˆK)
−P (min{cˆK , cK} ≤ wK1 ≤ max{cˆK , cK}, wK2 ≥ −cˆK , · · · , wK(K−1) ≥ −cˆK)
≥ P (wK1 ≥ −cK , wK2 ≥ −cˆK , · · · , wK(K−1) ≥ −cˆK)
−P (min{cˆK , cK} ≤ wK1 ≤ max{cˆK , cK})
· · ·
≥ P (wK1 ≥ −cK , · · · , wK(K−1) ≥ −cK)− P (min{cˆK , cK} ≤ wK1 ≤ max{cˆK , cK})
− · · · − P (min{cˆK , cK} ≤ wK(K1) ≤ max{cˆK , cK})
= 1− α + op(1).
The last equality follows from P (wK1 ≥ −cK , · · · , wK(K−1) ≥ −cK) = 1 − α and
cˆK →p cK (Lemma A.6).
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Proof of Theorem IV.3: We denote the pdf of Yi as fi(yi) for i = 1, · · · , N . Let
Φ(·) denote the cdf of standard normal distribution.
When δKi = −δiK is large, we have
lim
δKi→∞
P (Wi1 ≤ Y1,Wi2 ≤ Y2, · · · ,WiK ≤ YK − δKiσKi )
P (Wi1 ≤ Y1,Wi2 ≤ Y2, · · · ,WiK ≤ YK) exp(−δKi)
< lim
δKi→∞
P (WiK ≤ YK − δKiσKi )
P (Wi1 ≤ Y1,Wi2 ≤ Y2, · · · ,WiK ≤ YK) exp(−δKi)
=
1
P (Wi1 ≤ Y1,Wi2 ≤ Y2, · · · ,WiK ≤ YK) limδKi→∞
∞∫
0
Φ(yK − δKi/σKi)
exp(−δKi) fK(yK)dyK
=
1
P (Wi1 ≤ Y1,Wi2 ≤ Y2, · · · ,WiK ≤ YK)
∞∫
0
lim
δKi→∞
Φ(yK − δKi/σKi)
exp(−δKi) fK(yK)dyK
= 0.
From the third line to the fourth line we can validly change the order of integration
and limit because Φ(yK−δKi/σKi)
exp(−δKi) fK(yK) is bounded and thus absolutely continuous.
Thus, there exists M > 0 such that
P (Wi1 ≤ Y1,Wi2 ≤ Y2, · · · ,WiK ≤ YK − δKi
σKi
)
≤ P (Wi1 ≤ Y1,Wi2 ≤ Y2, · · · ,WiK ≤ YK) exp(−δKi) ∀δKi ≥M.
(A.2)
Define g(δKi) :=
d
dδKi
P (Wi1 ≤ Y1,Wi2 ≤ Y2, · · · ,WiK ≤ YK − δKiσKi ) < 0. Then,
normality of Wi implies that g(δKi) is a smooth function of δKi and g(δKi) < 0, for
all δKi ≥ 0. Thus, there exists a constant ζ0 > 0 independent of δKi, such that
g(δKi) ≤ −ζ0 for all δKi ∈ [0,M ].
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Table A.1: Simulation SMART design Example 1: Inference about the parameters β
using IPW, AIPW and AIPWm where the latter represents the misspeci-
fied scenario.
n=100 n=400
Parameter IPW AIPW AIPWm IPW AIPW AIPWm
Bias S.D. Bias S.D Bias S.D Bias S.D. Bias S.D Bias S.D
β0 0.010 0.24 0.002 0.23 0.007 0.24 0.004 0.12 0.000 0.12 0.007 0.12
β1 0.001 0.24 0.002 0.18 0.005 0.18 0.011 0.12 0.002 0.09 0.002 0.10
β2 0.002 0.17 0.003 0.07 0.002 0.10 0.000 0.08 0.002 0.04 0.004 0.05
θ1 0.013 0.41 0.007 0.32 0.014 0.39 0.015 0.21 0.004 0.16 0.013 0.20
θ2 0.011 0.33 0.003 0.27 0.004 0.31 0.007 0.17 0.000 0.14 0.009 0.15
θ3 0.009 0.41 0.003 0.32 0.010 0.39 0.015 0.21 0.000 0.16 0.005 0.20
θ4 0.007 0.33 0.003 0.27 0.000 0.31 0.007 0.17 0.004 0.14 0.001 0.15
For δKi ∈ [0,M ], we have
log P (Wi1≤Y1,Wi2≤Y2,··· ,WiK≤YK)
P (Wi1≤Y1,Wi2≤Y2,··· ,WiK≤YK− δKiσKi )
δKi
=
d
dδKi
logP (Wi1 ≤ Y1,Wi2 ≤ Y2, · · · ,WiK ≤ YK − δKi
σKi
)
∣∣∣∣
δKi=η∈[0,δKi]⊂[0,M ]
= −g(η)/P (Wi1 ≤ Y1,Wi2 ≤ Y2, · · · ,WiK ≤ YK)
> −g(η) > ζ0.
Thus,
P (Wi1 ≤ Y1,Wi2 ≤ Y2, · · · ,WiK ≤ YK − δKi
σKi
)
≤ P (Wi1 ≤ Y1,Wi2 ≤ Y2, · · · ,WiK ≤ YK) exp(−ζδKi), ∀δKi ∈ [0,M ],
(A.3)
where ζ = min{1, ζ0}. Combining (A.2) and (A.3) completes the proof.
A.4 Tables for chapter IV
Here, we present the supplementary Tables from Sections 4.5 and 4.6
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Table A.2: Simulation SMART design Example 2: Inference about the parameters β
using IPW, AIPW and AIPWm where the latter represents the misspeci-
fied scenario.
n=100 n=400
Parameter IPW AIPW AIPWm IPW AIPW AIPWm
Bias S.D. Bias S.D Bias S.D Bias S.D. Bias S.D Bias S.D
β0 0.004 0.35 0.001 0.30 0.005 0.30 0.003 0.18 0.001 0.15 0.002 0.15
β1 0.004 0.75 0.003 0.40 0.002 0.48 0.004 0.37 0.001 0.20 0.002 0.23
β2 0.010 0.81 0.005 0.30 0.003 0.47 0.000 0.40 0.002 0.14 0.004 0.23
β3 0.011 0.81 0.008 0.30 0.008 0.49 0.010 0.40 0.005 0.14 0.001 0.23
β4 0.013 0.81 0.006 0.31 0.001 0.47 0.005 0.40 0.006 0.14 0.003 0.24
θ1 0.004 0.35 0.001 0.30 0.005 0.30 0.003 0.18 0.001 0.15 0.002 0.15
θ2 0.008 0.66 0.004 0.37 0.007 0.46 0.007 0.32 0.002 0.18 0.004 0.21
θ3 0.018 0.66 0.009 0.38 0.010 0.45 0.007 0.33 0.004 0.19 0.008 0.21
θ4 0.019 0.66 0.012 0.38 0.015 0.48 0.017 0.33 0.007 0.19 0.005 0.22
θ5 0.021 0.66 0.010 0.38 0.006 0.45 0.012 0.33 0.008 0.18 0.007 0.21
A.5 Discussion and tables for the simulation results in sec-
tion 4.8
In this section we present the description and results in each of the four scenarios
in section 4.8. They are summarized by Rong Zhou.
For all the tables, we denote SACI as the expected set size for the ACI method,
SMCB as the expected set size for the MCB method, PACI as the probability of
containing the true best DTR for the ACI method, and PMCB as the probability of
containing the true best DTR for the MCB method
A.5.0.1 Scenario One
In scenario one, all eight DTRs are equally optimal. In this scenario, different
sample sizes in each setting are used. In addition, slightly altered γ3 values are as-
signed as well, and as γ3 changes from 0 to positive values, the optimal DTRs changes
to when the first stage treatment selection is A1 = 1. In Table 1, We find that the
MCB method performs better than the modified ACI method.
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Table A.3: Extend trial: Inference about the parameters β using IPW and AIPW.
Parameter IPW AIPW
Est. S.D. Est. S.D
β0 8.86 0.45 8.84 0.47
β1 -0.99 0.45 -0.90 0.44
β2 -0.24 0.34 -0.09 0.27
β3 -0.07 0.28 -0.21 0.13
θ1 7.56 0.76 7.65 0.67
θ2 7.71 0.74 8.06 0.67
θ3 8.05 0.71 7.83 0.70
θ4 8.19 0.69 8.24 0.70
θ5 9.53 0.81 9.44 0.76
θ6 9.68 0.80 9.85 0.77
θ7 10.02 0.83 9.62 0.70
θ8 10.17 0.82 10.03 0.72
Table A.4: Results of Scenario One
Number
of iter-
ation,
Sample
size
γ vector setting
Best
DTR
in-
dex
PACI PMCB SACI SMCB
10000
150
( 0,0,0,0,0,0,0) 1-8
0.96 0.97
0.96 0.96
0.96 0.96
0.96 0.96
0.96 0.94
0.94 0.94
0.94 0.98
0.97 0.94
7.70 7.52
10000
300
( 0,0,0,0,0,0,0) 1-8
0.96 0.96
0.96 0.97
0.97 0.96
0.96 0.96
0.94 0.95
0.95 0.95
0.94 0.94
0.94 0.95
7.70 7.56
10000
600
( 0,0,0,0,0,0,0) 1-8
0.96 0.96
0.96 0.97
0.97 0.96
0.96 0.96
0.94 0.95
0.95 0.95
0.95 0.95
0.95 0.95
7.71 7.57
2000
150
( 0,0,0.01,0,0,0,0) 1-4
0.97 0.97
0.96 0.96
0.94 0.95
0.95 0.94
7.70 7.47
2000
150
( 0,0,0.05,0,0,0,0) 1-4
0.97 0.97
0.96 0.96
0.95 0.96
0.96 0.96
7.69 7.37
2000
150
( 0,0,0.1,0,0,0,0) 1-4
0.97 0.97
0.96 0.96
0.96 0.97
0.97 0.97
7.65 7.03
2000
150
( 0,0,0.2,0,0,0,0) 1-4
0.97 0.97
0.96 0.96
0.97 0.97
0.97 0.97
7.33 5.76
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2000
150
( 0,0,0.3,0,0,0,0) 1-4
0.97 0.97
0.96 0.96
0.97 0.97
0.97 0.97
6.47 4.52
A.5.0.2 Scenario Two
In scenario two, the final outcomes are different by the second stage decision A2 if
the first stage decision A1 is 1, but are the same if the first stage decision A1 is -1. In
Table 2, we find that both methods have similar performance, with a slightly better
result from MCB.
Table A.5: Results of Scenario Two
Iteration,
Sample
size
γ vector setting
Best
DTR
in-
dex
PACI PMCB SACI SMCB
10000
150
( 0,0,-0.5,0,0.5,0,0.5)
1
5
6
7
8
0.98
0.96
0.96
0.96
0.96
0.97
0.96
0.96
0.96
0.96
4.83 4.82
10000
300
( 0,0,-0.5,0,0.5,0,0.5)
1
5
6
7
8
0.98
0.96
0.96
0.96
0.96
0.97
0.96
0.97
0.97
0.97
4.83 4.83
10000
600
( 0,0,-0.5,0,0.5,0,0.5)
1
5
6
7
8
0.99
0.97
0.96
0.96
0.96
0.97
0.97
0.97
0.97
0.97
4.84 4.83
2000
150
( 0,0,-0.49,0,0.51,0,0.51) 1 0.99 0.98 4.83 4.80
2000
150
( 0,0,-0.5,0,0.5,0,0.5)
1
4
0.99
0.97
0.97
0.97
4.82 4.81
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Figure A.1: Simulation SMART design Example 1: The vertical axes is the estimated set
(of best) size (ESS) and horizontal axes is the difference between the best and
the second best EDTR.
A.5.0.3 Scenario Three
In scenario three, responders to the first stage have the same final outcomes to
A2, but non-responders have different expected final outcomes to A2. In Table 3, we
find that the MCB method performs better than the modified ACI method.
Table A.6: Results of Scenario Three
Iteration,
Sample
size
γ vector setting
Best
DTR
in-
dex
PACI PMCB SACI SMCB
128
2000
150
( 0,0,0,0,0.5,-0.5,0)
1
3
5
7
0.98
0.97
0.97
0.97
0.97
0.97
0.96
0.96
3.89 3.88
2000
150
( 0,0,0.01,0,0.5,-0.5,0)
1
3
0.98
0.97
0.98
0.97
3.89 3.88
2000
150
( 0,0,0.05,0,0.5,-0.5,0)
1
3
0.99
0.98
0.98
0.98
3.88 3.85
2000
150
( 0,0,0.1,0,0.5,-0.5,0)
1
3
0.99
0.98
0.99
0.98
3.85 3.77
2000
150
( 0,0,0.2,0,0.5,-0.5,0)
1
3
0.99
0.98
0.99
0.99
3.60 3.35
2000
150
( 0,0,0.3,0,0.5,-0.5,0)
1
3
0.99
0.98
0.99
0.99
3.16 2.79
A.5.0.4 Scenario Four
In scenario four, we manipulated the γ vector such that only one or two optimal
DTRs will be obtained in this case, and there is no non-regularity. In Table 4, we find
that the modified ACI method performs better than the MCB method. Because there
is no non-regularity in this scenario, the modified ACI method will not be conservative
compared to its performance in the first three scenarios. Also, since there are only
two optimal DTRs in this scenario, and the MCB method still uses the critical value
for comparing all eight DTRs when it chooses a set in this case, the result of the
MCB method will be conservative.
Table A.7: Results of Scenario Four
Iteration,
Sample
size
γ vector setting
Best
DTR
in-
dex
PACI PMCB SACI SMCB
2000
150
( 0,0,-1,0,-1,0,-0.5)
4
8
0.98
0.98
0.99
0.99
1.96 1.98
2000
150
( 0,0,-0.99,0,-1,0,-0.5) 4 0.98 0.99 1.96 1.98
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2000
150
( 0,0,-0.45,0,-1,0,-0.5) 4 0.99 0.99 1.95 1.98
2000
150
( 0,0,-0.4,0,-1,0,-0.5) 4 1.00 1.00 1.93 1.96
2000
150
( 0,0,-0.51,0,-1,0,-0.5) 8 0.98 0.99 1.96 1.98
2000
150
( 0,0,-0.55,0,-1,0,-0.5) 8 0.99 1.00 1.95 1.98
2000
150
( 0,0,-0.6,0,-1,0,-0.5) 8 1.00 1.00 1.92 1.96
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Figure A.2: Simulation SMART design Example 2: The vertical axis are the estimated set
(of best) size (ESS) and horizontal axes are the difference between the best
and the second best EDTR.
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